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All the contents in chapter 1, 2, 3, 4, and 5 were written by the author of this dissertatio n
and revised by Dr. Ashutosh Tiwari. This dissertation is the collection of manuscr ipt
submitted to peer-review journal for publication and article under preparation. The initia l
ideas of all research projects in this dissertation were conceived by Dr. Ashutosh Tiwari.
Chapter 3 is based on multi-author article which is currently under preparation. The author
of this dissertation carried out the expression, purification and characterization of protein
and is responsible for all data collection, analysis and writing of the manuscript. The
cloning part was carried out by former postdoctoral fellow Dr. Jagadeesh Janjanam and Dr.
Ashutosh Tiwari. Dr. Colina Dutta contributed to this work by helping with initia l
expression of the TDP-43 protein. Dr. Ashutosh Tiwari revised the manuscript and is the
corresponding Author.
Chapter 4 is based on multi-author article that is submitted to Scientific Reports for
publication. This work is a shared authorship between author of this dissertation and Dr.
Mu Yang. The Tht fluorescence measurements were carried out by Dr. Yang and was
involved in preparation of the initial manuscript. The author of this dissertation carried out
ANS, Bis-ANS, SEM, MTS, LDH, DCFH-DA experiments. Primary neuronal cell cultures
were prepared by Dr. Zhiying Shan and Immunostaining experiments were conducted by
the author of this dissertation. Ms. Wafa FA Alharbi assisted in Immunostaining
experiment. Dr. Colina Dutta carried out the SEM imaging reported in submitted paper.
SEM images in this chapter are work of the author of this dissertation. All computatio na l
work and associated writing were carried out by Professor Ravindra Pandey and Dr.
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Nabanita Saikia. Dr. Ashutosh Tiwari wrote and revised the manuscript and is the
corresponding author.
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Abstract
Proteins are the biological macromolecules central to most cellular functions. The native
structure of protein determines its function and any perturbations such as mutation, changes
in pH, macromolecular crowding, oxidative stress, may promote protein misfolding and/or
aggregation. Protein misfolding or aggregation can contribute to diseases either through
loss of proteins’ critical function or by gain of toxic function. Among the various proteins
associated with neurodegeneration, trans-active response (TAR) DNA binding protein 43
(TDP-43) has sparked interest in researchers due to its diverse role in several
neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS), Frontotemporal
Lobar degeneration (FTLD), Alzheimer’s, Parkinson’s and Huntington’s disease. Most of
the reported work on TDP-43 protein have been carried out on truncated version of the
protein from prokaryotic source due to difficulty in expressing and purifying the full- le ngth
protein. Another protein, amyloid β peptides role in Alzheimer’s disease has been studied
in great detail. However, the role posttranslational modifications play in Aβ related toxicity
has not been fully explored. In this dissertation, I address these two major gaps as follows :
1) I have successfully purified full- length TDP-43 protein using a eukaryotic source and
carried out some physicochemical characterization. Now this full- length protein which is
from eukaryotic source can be used to better understand proteins role in health and disease.
2) I explored the physicochemical properties of acetylated Amyloid β peptides includ ing
its effects on modulating toxicity in SH-SY5Y cell lines (neuroblastoma) and primary
neuronal cultures. This work underscores the importance of posttranslational modifica tio n
such as acetylation of Aβ peptides on toxicity as well as aggregate morphology which will
lead to better drug designs in future.

x

Chapter 1 Background
1.1 Proteins
Proteins, this word is familiar to us, since our childhood we learnt that proteins are the
building block of our body. Made up of 20 different amino acids, proteins play role in
performing a wide variety of biological function. In order to be functionally active, protein
needs to fold into its native, three-dimensional structure. In addition, about 20-30% of
proteins in eukaryotic cells lack their three-dimensional structure and remains folded once
they interact with their binding partners. The newly synthesized proteins have a greater
chance of being misfolded leading to aggregation and forms a toxic species under the
cellular conditions1 . Cells have several quality control measures like molecular chaperones,
which guide the correct de novo folding or refolding of the protein, and help to prevent
aggregation of non-native proteins. Ubiquitin-proteasome system (UPS) and Phagosomelysosome system helps to degrade the misfolded proteins (Figure 1)2,3 . Despite having
cellular control measures, there is evidence showing the presence of misfolded and
aggregated proteins appearing at late stage of life in several neurological and systemic
diseases. The most likely cause of this is decline in the proteostasis capacity of a cell with
the aging of an individual. Studies have suggested the several genetic and environme nta l
factors can contribute to protein misfolding and aggregation. Change in conformation of
normal protein leads to protein destabilization, which eventually leads to disease condition.
Mutation, changes in metal ions, pH, macromolecular crowding, oxidative stress or high
concentration of misfolded protein might drive the process of protein misfolding and
aggregation3 .

In order to strengthen the understanding of protein folding, misfold ing,
1

aggregation and toxicity, I will discuss the different forces involved in protein folding,
posttranslational modifications, factors leading to misfolding and aggregation. In addition,
I will highlight how morphology/nature of aggregates of disease proteins along with key
proteins contribute to cytotoxicity leading to neurodegenerative diseases. This will help
underscore the importance of my two main body of work included as chapters in this
dissertation.

Figure 1: Representation of the Protein misfolding and fibrillization. Genetic and
environmental factors might play the role in the process of aggregation thus resulting into
the deposition of aggregated proteins in the nucleus, cytoplasm and extracellular space.
Several cellular quality control systems like molecular chaperones, the ubiquitin
2

proteasome system and the phagosome-lysosome system facilitate in the reduction of
accumulation of misfolded proteins. Reprinted with permission from Forman, S. et.al.
20042 .
1.2. Physical forces involved in protein folding
Protein folding is a complex process that has been studied for more than a century. As
every protein requires very unique set of parameters for its correct folding, protein folding
problem has intrigued researchers for a very long time. Researchers are interested in
understanding how native structure of proteins acquires its well folded 3D structure. A
protein starts as a sequence, like a chain of amino acids that rapidly folds, residues come
close (2 to 7 Å; short/medium-range distance) to each other held by non-covalent forces,
forming the native structure of a protein. Now, a substantial amount of information about
a protein can be obtained from Protein Databank (PDB), which has collection of more than
100,000 protein structures. Interestingly, proteins are only marginally stable at room
temperature and its stability can be affected by the weak non-covalent interactions. This
makes understanding of these different types of molecular interactions involved in protein
stability very important. The major non-covalent forces in a protein are: Hydrogen bonds,
Van der Waals interaction, Electrostatic interactions, and hydrophobic interactions that
contribute to protein folding and stability. In the following paragraphs, I will discuss briefly
about each of these forces.
1.2.1 Hydrogen bonds
During protein folding, due to contact with water 70% of the peptide groups and 65% of
polar side chains are buried in the interior of the protein4 . Hydrogen bonds are formed by
3

the interaction of the hydrogen atoms that are covalently bonded to the electronegative
atoms (usually N, O, S). Hydrogen bonding provides the rigidity to the protein structure.
Both polar side-chains as well as carbonyl oxygen and N-amide proton from peptide bond
can take part in H-bonding. H-bond also provides the structural integrity to the α-helix and
β-sheet conformations of proteins. The strength of the hydrogen bond is usually in the range
of 2-10 kcal/mol which depends on the orientation as well as electronegativity of the
bonding atoms. The concept of H-bonding as the dominant force in protein folding was
first suggested by Mirsky and Pauling (1936). They introduced the possibility of formatio n
of H-bond between carbonyl C=0 and amide NH groups of the peptide backbone5 .
1.2.2 Electrostatic interactions
The earliest known protein denaturants were acids and bases, hence researchers assumed
that electrostatic interactions are the forces responsible for protein folding. Any process
that is driven electrostatically is dependent on pH/ ionic strength. The total charge on the
protein is determined by the protein whereas salt determines the extent of interactio n.
Linderstrom-Lang was the first person to propose the quantitative model of electrostatic
interactions for native proteins in 19245 . Electrostatic interactions can affect protein
stability in different ways. One such way is due to the non-specific repulsion interactio n
which arises when the protein is extreme charged. The native protein can be destabilized
by increasing the charge of the solution either by increasing acidity or basicity of the
solution. This results in the increase in the charge density in the folded protein compared
to the unfolded one leading into its destabilization due to greater charge repulsion. For this
reason, when the protein is at its isoelectric point, there is no effect of electrostatic
4

interaction on protein stability. Another way that affect the protein stability includes
specific charge interactions. Ion pairing or the salt bridge is observed when the side chains
of two oppositely charged amino acids are in close proximity to each other. As the charge
in the protein increases, the destabilization of folded protein takes place but the ion pairing
can stabilize the protein. Earlier in 1930’s the dominant force in protein folding was
considered to be ion pairing. Studies shows that ion pairing affects the protein stability but
is not considered as the dominant force as much of the charges are centered on the surface
6,7 .

1.2.3 Hydrophobic interactions
Hydrophobic interactions occurs in a protein as a result of nonpolar side chain of amino
acids as well as other nonpolar solutes prefer to cluster in nonpolar environment rather than
a polar solvent. The formation of bond reduces the interaction of nonpolar residues with
water thus making the interaction highly favorable. During folding of the protein, the
hydrophobic side chains of amino acids are buried down in the interior of the protein core
and polar amino acids are not found in the interior of the protein8 . The case for importance
of hydrophobic interaction in protein folding was first made strong by Kauzmann.
1.2.4 Van der Waals Interactions
Van der Waals interactions are the weak interactions with the stabilization energies of 0.4
to 4.0 kJ/mol. Interactions with the fixed and induced dipoles results into Van der Waals
attractions.

These kinds of interactions occur largely in proteins and contribute

significantly to stability of protein.
5

1.2.5 Intrinsic propensities
Intrinsic propensities do not relate to single type of force but is related to preference of
certain confirmation by di-or tri-peptides, their size or sequence, which can arise from the
local interactions. The stability of the long polypeptides chains in aqueous solutions is due
to intrinsic propensities. For instance, As the length of the polypeptide chain increases the
stability of the helix is also increased. Although while considering the free energy from
individual residue is small but summing up the free energy over many residues results into
strong force that favors helix formation. The intrinsic propensities is also responsible for
protein confirmation when it folds.
1.3 Energy landscape of protein folding
Getting back into the history of protein folding, the researchers assumed that the folding of
the protein takes place in distinct pathways through particular intermediate states. Figure 2
shows the classical pathways for protein folding. The graphical representation of protein
folding in the funnel shape is the generic representation that is applicable not only to
proteins but also to RNA and compact polymers. It represents that protein folds through
several intermediate pathways. Studies by protein denaturation experiments suggested
protein exist as a two-state model, i.e. at equilibrium they either can exist as fully native or
fully unfolded structure4 . Later, Ptitsyn and coworkers found that several destabilizing
conditions such as low pH can lead to protein with expanded form, with loose tertiary
structure but still having the secondary structure in considerable amount which was called
as molten globule

4, 5-7, 9 .

6

The large polypeptide chain has complex folding pathways and different models have been
developed to describe the pathways. Among those model one describes that the folding
process is hierarchical in which the local secondary structures are formed first where the
amino acids sequence fold into α and β sheets. Next, the super secondary structures are
formed which occurs due to the long-range interactions, like two α-helices come together
and form stable structure. This process takes place until the folding process of a protein is
completed. In another model, the folding is mediated by the hydrophobic interactio ns
among non-polar residues where the polypeptide is collapsed spontaneously into compact
state. At this stage, there is a high content of secondary structures, however much of the
side-chain of amino acids are not fixed. The resultant from the hydrophobic collapse are
often termed as molten globule state. While considering how protein folds, most of the
proteins folds by incorporating the features of both models. Proteins may take a differe nt
route for folding that results into same end point with several folding intermediates.
The process of protein folding can be viewed as a free-energy funnel. The unfolded states
contain high degree of conformational entropy as well as free energy. The narrowing of
funnel takes place as the folding process proceeds where the decrease of entropy takes
place. The semistable intermediates are represented by the small depressions that are found
along the side of the funnel and they slow down the process of folding. At the end of the
funnel, a native confirmation is present where other folding intermediates are reduced10 .

7

Figure 2: Folding pathways of a protein A. Classic approach of a protein folding pathway
B. Funnel-shaped landscape of a protein folding9 . Reprinted with permission from
Englander and Mayne. Proc Natl Acad Sci U S A. 2014 Nov 11; 111(45): 15873–
15880201597.
1.4 Disulfide bonds
Disulfide bond is present in most proteins and it ensures the correct folding of proteins
under native conditions. Disulfide bonds occupy 15% of the human proteome and are
present mainly in secreted protein where it makes up to 65%. Next to peptide bond, the
common covalent link between the amino acids in the protein is the disulfide bond.
Disulfide bonds are known to decrease the entropy of the unfolded state thereby stabilizes
the protein thermodynamically. The presence of disulfide bonds are found in 55% of the
8

pathologic amyloid forming proteins underscoring the importance of disulfide bonds in
aggregation kinetics, nature of aggregates, as well as its role in cellular toxicity. For proper
folding of protein into its native structure, many proteins require the correct formation of
disulfide bonds. Protein misfolding results when there is abnormal reduction/formation of
disulfide bonds. Disulfide bonds are involved in proteins involved in neurodegeneratio n.
Until date, the role of disulfide bonds have been studied and found to be important in three
proteins involved in neurodegeneration: prion, SOD1 and Tau. The folding/misfold ing
pathway can thus be traced by determining the thiol-disulfide status in the protein. For
example, the folding/misfolding is regulated by thiol-disulfide status in case of SOD1 (Cu,
Zn-superoxide dismutase) . The stabilization of matured SOD1 is achieved by the
formation of intramolecular disulfide bonds whereas the reduction of these disulfide bonds
leads to the misfolding and aggregation of SOD1 due to a decrease in conformatio na l
stability of a protein. Therefore, the disulfide bonds play important role in familial form of
amyotrophic lateral sclerosis (fALS) .
1.5 Posttranslational modification (PTM) of proteins
Synthesis of the proteins occurs during a process of ‘translation.’ The chemical changes
that protein may have after the process of translation or concomitant with translation is
commonly known as posttranslational modifications. Posttranslational modifications is
present in both prokaryotes and eukaryotes. However, the modifications are present more
in eukaryotic cells where the enzyme constitutes 5% of the genome that carry out
posttranslational modification of protein. Post-translation modification can be enzymatic
and non-enzymatic depending on its attachment of the chemical group to amino-acid side
9

chain11 .The most common modifications includes the formation of disulfide bonds,
cleavage of the precursor proteins or the addition or removal of low molecular weight
groups covalently, which results into modifications like acetylation, biotinylatio n,
amidation, deamidation, farnesylation, formylation, cysteinylation, geranylgeranylatio n,
glutathionylation,
ribosylation,

glycation,

myristoylation,

glycosylation,
oxidation,

hydroxylation,

palmitoylation,

methylation,

phosphorylation,

mono-ADPpoly(ADP-

ribosyl)ation, stearoylation, or sulfation11-16 .
Table 1: Posttranslational modifications and their target amino acids with enzyme
involved.
Amino acid residue(s)

Tyrosine,

Protein/Enzyme involved

Serine, Kinases, phosphatases

Post-translation modification

Phosphorylation

Threonine

Lysine

Ubiquitin-activating

Ubiquitination

enzymes, Ubiquitin ligases

Lysine

Acetyltransferases,

Acetylation

deacetylases

Lysine, Arginine

Methyltransferases,
demethylases

10

Methylation

Lysine

Glycation

Lysine

Ubiquitin-activating

Sumoylation

enzymes, Ubiquitin ligases

Asparagine

Glycosyltransferases,

Glycosylation N-linked

deglycosylases

Serine/ Threonine

Glycosyltransferases,

Glycosylation O-linked

deglycosylases

Glycine

N-Myristoyltransferases

Myristoylation

Tyrosine

Sulfatases, sulfatases

Sulfation

Cysteine

Prenylation/Palmitoylation

Prenylation/Palmitoylation

Farnesyltransferases / DHHC
protein

acyltranaferases,

acyl- protein thioesterases

Lysine,

Carbonylation

Proline,

Arginine, Threonine

11

Cysteine, Methionine

S-nitrosylation

Post-translational modification alter protein’s structure and also affects its cellular and
physiological functions. This leads to change in protein’s size, charge, or conformatio n,
altering its hydrophobicity, binding affinity and enzyme activity. Some of the common
posttranslational modifications found in eukaryotes along with their target amino acids and
enzymes involved are highlighted in Table 1. Posttranslational modifications of the
proteins can be detected by various methods. The analytical methods like column
chromatography, thin-layer chromatography, radiolabeling of proteins and polyacryla mide
gel electrophoresis is used for the detection of PTM. Apart from that protein sequencing
and Western blot is also widely used. Currently, mass spectrometry and antibody based
detection is most commonly used. Antibody- based detection is based on the availability
of the polyclonal or monoclonal antibodies that can specifically recognize the modified
amino residue present in the peptide or the protein. This is accompanied by the detection
either by using the Chemiluminescence (Western blotting) or the Absorbance/Fluoresce nce
(ELISA) methods. On the other hand, detection of PTM by mass spectrometry is based on
the change in mass. Based on the type of the modification involved there occurs the specific
change in the mass of the peptide/ amino acid which is confirmed by the Mass
spectrometry. Tandem mass spectrometry is also used to identify the modification involved
at the specific site11-13 .
Among the various PTM, phosphorylation is the most common modification which
involves the reversible addition of the phosphoryl group to the three amino acids: serine,
12

threonine or tyrosine from the adenosine triphosphate (ATP). This modification leads to
change in conformation resulting into altered cellular function and signaling. The changes
involve activation or deactivation of an enzyme by affecting its catalytic activity and/or
increase a tendency of a protein to misfold and aggregate. Secondly, phosphorylation also
helps to bind other proteins by facilitating its recruitment. Likewise, considering
acetylation, about 80-90% of the eukaryotic proteins are acetylated. However, it is not clear
what the biological role of those acetylated proteins are. Acetylation leads to blockage of
positively charged lysine side chains by the neutral acetyl groups thereby altering the
protein’s charge distribution. Though, acetylation was first reported in histones, it is also
observed in cytoplasmic proteins. Lysine acetylation regulates gene transcription in histone
proteins. Histone acetylation is related to transcriptional activation whereas transcriptio na l
suppression is the result of deacetylation. Talking about ubiquitination, it involves addition
of 8 kDa polypeptide to the target proteins through the C-terminal glycine present in
ubiquitin. Ubiquitination also targets lysine residues like acetylation and methylatio n.
Ubiquitination acts as a signaling scaffold during biological responses. The proteins that
are targeted by ubiquitination are usually the ones that needs to relocated or degraded.
Posttranslational modification plays important role in protein folding and aggregatio n.
Among these modifications like phosphorylation, acetylation, ubiquitination are observed
in many diseases including neurological disorders. For example: In Parkinson’s disease,
which affects around 6.3 million worldwide, α-synuclein protein is involved in this disease
and posttranslational modifications like phosphorylation , ubiquitination or nitration are
known to be involved in the aggregation of α-synuclein protein and is known to possess
several impacts in its cellular neurotoxicity. Due to the role of PTMS, in a signaling
13

pathways, in many diseases they are used as a potential therapeutic target or as a biomarker.
Studying PTMs also helps to understand the disease pathology.
1.6 Protein aggregation
The key macromolecules of the living systems include proteins, lipids, carbohydrates and
nucleic acids. Among which protein plays a vital role in performing wide variety of
functions. About 100,000 types of proteins are involved in controlling the reactions
involved in life of the living organisms. How one protein is distinguished from another is
based on the constituents of amino acids

17 .

Failure of a polypeptide chain to maintain or reach its three-dimensional structure leads to
aggregation. Though protein aggregation is widely studied topic but there are some key
questions which some unanswered questions which includes: Mechanism underlying the
protein aggregation, nature and structure of the aggregates, reason behind same protein
leading to ordered and disordered aggregates, toxic species, specificity of intermolec ular
interactions, effect of environmental factors on aggregation rate and methods to prevent
those aggregation18 . In most of the cases, aggregation is usually irreversible which is due
to the equilibrium shifted towards favor of aggregate rather than soluble form. Some of the
aggregates like in vivo amyloid deposits are reversible

19,20 . However,

under the native like

conditions the process is irreversible once the insoluble aggregates are formed.
Protein misfolding diseases includes a broad range of diseases which occurs due to failure
of a specific protein /peptide to maintain its native conformational state. Many of these
misfolding diseases are associated with the formation of organized fibrillary structures rich
14

in β-sheet structures from its soluble form

21, 22 . Although

the work by Christian Anfinse n

showed that the proper folding of protein is directed by the amino acid sequence of it, now
it is acknowledged that the variations in the folding trajectory of a protein to its native form
including alternative states associated to pathogenesis is also governed by the same
sequence. Apart from these different environmental as well as metabolic stresses,
molecular crowding, aging, synthesis errors that are related to the cellular environment also
act in addition to sequence-based challenge.
1.6.1 Types of protein aggregates
Basically, there are two broad classification of protein aggregates. Protein aggregates are
classified as in vitro and in vivo aggregates, fibrillar and amorphous aggregates. Apart from
these, aggregates are also classified as physical and chemical, reversible and irreversib le,
soluble and insoluble. The amyloid fibrils are the ordered aggregates that are observed both
in vivo and in vitro whereas the disordered aggregates are the inclusion bodies that are
amorphous and are formed in vivo. The aggregates that are formed in vitro during refolding
of the proteins at high concentration are usually disordered aggregates. The physical
aggregates refers to the non-covalent and chemical aggregates refers to the covalent
aggregates. Similarly, the soluble oligomers include dimer to decamer22 .
Amyloid fibrils:
The term amyloid refers to extracellular proteinaceous deposits which are abnormal fibrous
and are found in tissues and organs. Initially, the word was coined by Schleiden and in
mid-19th century Virchow described the term in the deposits of iodine stained observed in
15

the autopsy of liver. Amyloid fibrils are formed from soluble proteins which turn into
insoluble structure rich in β-sheet structure and are resistant to degradation. Later on, the
properties of the amyloid like specifically binding to the Congo red was discovered
suggesting the structure of amyloid to be fibrillar. The use of transmission electron
microscopy and X-ray fiber diffraction pattern further confirmed the morphology and
cross-β structure of amyloid. Ranging from size of 7-12 nm in diameter, amyloid fibrils are
dissociated at high concentration of denaturant. Compared to other fibrous protein, the role
of amyloids in providing structural, motility or support is not known but is related to
number of the diseases which are known as amyloidosis. Some of these diseases includes
Alzheimer’s, type II diabetes, the spongiform encephalopathies23 . Understanding the
formation and physicochemical properties of amyloid is the highly studied area.

Figure 3: TEM images of Aβ1–42 aggregates in LMW (top) or HMW (bottom) incubatio n
at the indicated times24 . (Scale bars, 100 nm.). Reprinted with permission from Nakayama,
W.T. et.al. (2016)24 .
16

Amorphous aggregates
Amorphous aggregates are the disordered structures and are common to most proteins.
Formation of amorphous aggregates are observed during the process of protein expression
purification and even when amyloidogenic proteins fails to form amyloid fibrils. Evidence
suggests that amorphous aggregates are also observed in disease conditions

25, 26 .

Protein aggregation and understanding the mechanism underlying it is important to
researchers in academia as well as industry. Amyloidogenic aggregates are hallmark of
several diseases such as type II diabetes, systemic amyloidosis, Alzheimer’s, and
Parkinson’s diseases. However, role of amorphous aggregation in the disease process is
not understood very well and were thought not to be associated with any diseases.
Nevertheless, recent research shows that it is found in several diseases. For instance: Cause
of cataracts is due to aggregation of crystalline protein which are amorphous in nature

27.

In Parkinson’s disease, in addition to an amyloidogenic structures, formation of amorphous
aggregates by α-synuclein have been reported28 . Also, in TDP-43 protein associated
aggregates, both amorphous and amyloid fibrils have been reported by different groups.
Formation of amorphous aggregates is of greatest importance especially in the production
as well as storage of industrial enzymes and therapeutic proteins29 . Although importance
of amorphous aggregates in the disease process has been established, it is not clear which
form of aggregate is more toxic. Protein aggregates size can be characterized by differe nt
methods like Light Scattering method (LS), Dynamic Light Scattering (DLS), and Size
Exclusion Chromatography (SEC).
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Figure 4: SEM images of lysozyme insoluble aggregates. The insoluble aggregates of
lysozyme in presence of 10mM DTT incubated for 4h (left) and 7d (right) respectively.
Scale bar = 1µm for both images. Reprinted with permission from Yang et.al. (2015)30
Copyright © 2015 American Chemical Society.
The nature or morphology of the protein aggregates is governed by several factors. It is not
characterized by the sequence of amino acids alone as the same protein can form
amorphous or fibrillar structure depending on the environmental conditions it is exposed
to. Among these factors like pH, temperature, external environment, salt concentration etc.,
pH is known to play a key role in determining the nature of aggregates. This is because pH
affects the net charge on the proteins. It has been reported that the proteins preferably form
fibrillar structure when they have high net charge and when the pH favors low net charge
the result is amorphous like aggregates. This finding has been supported by a study done
on seven different proteins where effect of pH resulted different morphology of a protein .
Protein aggregation and toxicity is widely studied topic. Also, there has always been a
question regarding the nature of aggregates and its associated toxicity, i.e. which aggregate
form of the protein is most toxic. Until recently, the mature amyloid fibrils that are mostly
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detected in the pathological diseases were considered to be most toxic to the cells. A
number of experimental data now suggests that pre-fibrillar aggregates, which are close in
properties to amorphous aggregates, protofibrils or protein micelles are most-toxic to cells.
This has been reported in number of studies carried out with Aβ peptides, α-synucle in
indicating that the toxic species are the early aggregates. This suggests importance of
understanding the toxic nature of aggregates as all aggregates generated and rich in β- sheet
are not necessarily toxic in nature.
1.7 Protein aggregation in neurodegenerative diseases
Accumulation of protein aggregates in the neurons is a common feature observed in several
neurological disorders. Neurodegenerative disorders are a clinical condition that involves
the loss of neurons gradually leading to the cognitive, behavioral and physical defects31 . In
order to identify the neurological pathologies, the identification of protein involved in
neurodegenerative disease is essential31 . There are several neurodegenerative diseases like
Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD),
Amyotrophic lateral sclerosis (ALS), Lewy Body dementia, and Prion like disease
identified, and each disease has a unique protein and gene involved in it. Involvement of
different proteins leading to distinct clinical symptoms and diseases have complicated the
research focusing on identifying some major common properties shared by these disease
proteins.
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that causes axonal
degeneration leading to motor neuron dysfunction and cell death. ALS is a sporadic disease
but about 10% of the cases are found to be a familial33 . Copper /Zinc Superoxide dismutase
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1 (SOD1) is the major enzyme involved in ALS and mutations in SOD1 has resulted in
major progress in the identification of pathogenesis in the field of ALS. The pathogenesis
of SOD1 mutant is associated with the gain of toxic function and not with the loss of normal
function.
Among the various proteins identified

in neurodegenerative diseases, Trans-active

response (TAR) DNA binding protein 43 (TDP-43) is increasingly implicated in several
neurodegenerative diseases like Alzheimer’s disease, ALS, FTLD-U, Huntington and
Lewy body diseases. This explains TDP-43 as a high value target protein. Knowing the
involvement of a common protein in multiple neurodegenerative diseases has a greater
application in identifying the mechanism involved in all these disease conditions. In case
of neurodegenerative disorders, the common features seem to be the presence of insolub le
intracellular aggregates, that are often phosphorylated and ubiquitinated34-36 . Association
of TDP-43 is found to be in neurodegenerative diseases as the aggregates of this protein
are present in patients with ALS and FTLD. In cases of TDP-43, the pathology has
distinguishing features like mislocalization of TDP-43 to the cytoplasm, the loss of nuclear
localization, as well as truncation. Therefore, TDP-43 proteinopathies involves all the
characteristic features that are linked to neurodegenerative diseases having the TDP-43
pathology

34 .
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1.8. Proteins used in study
1.8.1 TDP-43
Trans-active response (TAR) DNA binding protein is a 43kDa protein, first identified in
1995 as transcriptional inactivators of HIV virus35-37 . This protein could bind with the TAR
DNA element of HIV virus, hence named TAR DNA binding protein. TDP-43 is a 414
amino-acid protein belonging to the family of heterogeneous nuclear ribonucleoprote ins
and share many features of this family35,38 . TDP-43 is highly conserved among
invertebrates and mammals, with its expression present in nearly all tissues39 . Structurally,
distinguished by two RNA recognition motifs (RRM) i.e. RRM1 and RRM2 along with Nterminal and C-terminal regions, this protein is best known as RNA and DNA binding
protein

34-35, 40-43 . TDP-43, being

a protein of nuclear origin is known to play various roles

in metabolism of RNA including mRNA stability, splicing, transport, miRNA processing,
transcriptional repression. Under the pathological conditions these functions are altered or
there is an abnormal function leading to neurotoxicity. Moreover, the actual cause of
neurotoxicity is still not clear. Some studies support toxicity due to gain of function and
others support the toxicity due to loss of functions First identified in 2006, in a
ubiquitinated aggregates of a FTLD and ALS associated patients, TDP-43 protein caught
attention of many researchers and since then about 18,200 papers have been published on
TDP-43 till date. Accumulation of TDP-43 aggregates is present in approximately 98%
ALS and 50% FTD. Apart from that 50% of Alzheimer’s disease is associated with TDP43 pathology.
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1.8.2 Amyloid–Beta
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and distinct Aβ
aggregates are observed as the disease progresses. Getting back into 1907, Alois Alzheimer
first reported the findings of an autopsy of 55-year women as presence of neurofibrillar y
tangles and neuritic plaques who died of progressive behavioral and cognitive disorder. In
1984, Glenner and Wong purified and found that these substances was a peptide of 4.2kDa, with amino acids of 40 or 42 in length, which was thought to be cleaved from some
large precursor. In 1987, Kang et.al. cloned the amyloid precursor protein which confir med
the prediction made by Glenner and Wong and the peptide isolated was known as Amylo id
β peptide in short Aβ peptide44 .
Amyloid beta is produced as a proteolytic product of the precursor protein known as APP
which results from the cleavage by proteases, β-and γ-secretases. The proteolytic
processing of APP results into two products of varying lengths especially at the carboxy
terminal of the peptide. The two different forms of Aβ are of 40 and 42 amino acids in
length known as Aβ40 and Aβ42 respectively. In normal individual, Aβ40 is the major
form of Aβ produced. In a pool of Aβ only 5-15% of total Aβ is occupied by Aβ4245.
Though Aβ40 is present in higher concentration in cerebrospinal fluid compared to Aβ42,
the amyloid plaques from Aβ42 comprises the major component in AD brains. Further,
Ratio of Aβ42 /Aβ40 plays a critical role in AD, where the increased ratio is associated
with the early onset of familial AD and lowered ratio leads to decreased deposition of Aβ
in transgenic mice. Also, the higher ratio correlates with the increased neurotoxicity. Aβ42
is more aggregation prone compared to Aβ40, hence results into early deposition than
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Aβ40. This leads to explanation that although both isoforms are present, Aβ42 and Aβ40
preferentially aggregates with their own species.
1.9 Motivation:
Protein misfolding and aggregation is at the core of many neurodegenerative diseases. The
common pathophysiological feature shared for several neurodegenerative diseases is
accumulation of distinctly misfolded and aggregated proteins in brains, in cytosol,
intranuclear,
Amyotrophic

or extracellular
Lateral

spaces.

Sclerosis,

Different

Frontotemporal

neurodegenerative
dementia,

diseases

Alzheimer’s

like

disease,

Parkinson’s diseases, Huntington diseases, Lewy body diseases etc. have characterized
distinct aggregates in distinct part of the neuron. The unique characteristic is that each of
these diseases has specific protein involved in its pathogenesis, e.g. SOD1 in ALS,
Amyloid β in Alzheimer’s, and α-synuclein in Parkinson’s disease. While the general
mechanism of toxicity in these diseases in understood, still the molecular level of
understanding for these diseases is a subject of intense debate. This is complicated further
by lack of information on distinct physicochemical properties of proteins including its
aggregated structures at a molecular level, making difficult to understand its role in the
disease processes.
The main focus of this research is expression and purification of full- length TDP-43
protein using eukaryotic expression system and understand its aggregation property using
reducing and non-reducing environment and test its toxicity which is covered in Chapter
3. A number of studies have been carried out in TDP-43 protein using the prokaryotic
expression system. However, having method for purification in eukaryotic system is
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lacking. Therefore, in this research we have explained the standardized methods for
purification and addressed some of the aggregation and toxicity properties of full length
aggregates. This will help to shed some light in the understanding the role of the protein in
the disease process.
Posttranslational modification is the common modifications that takes place in protein.
Among the various modifications, acetylation of protein is one of the major modifica tio n
that taking place in eukaryotes. Aβ is the protein which is involved in Alzheimer’s disease.
Study on the effect of the lysine acetylation on this protein is not reported in detail, though
information of acetylation on lysine 28 is available. Therefore, in chapter 4, the effect of
acetylation on lysine16 on Aβ (1-42) aggregation is discussed. For this purpose, the single
acetylated lysine residues at position 16, 28 or double acetylated KKAc was used and its
comparison with WT was performed. Understanding the effect of lysine acetylation on Aβ
(1-42) aggregation will help to develop the proper therapeutic targets for treatment of
Alzheimer’s disease.
As discussed in above sections, several factors like pH, temperature, reducing environme nt
also causes protein destabilization

that leads to protein aggregation.

Therefore,

understanding the role of protein either by changing the charge on the protein, or by
reducing the disulfide bonds in it helps in providing some clue on its pathogenesis. As
evident, same protein can generate different types of aggregates under the conditions it is
exposed, it is equally important to understand under what conditions the differe nt
aggregates are formed and what is the level of toxicity of those aggregates at cellular level.
Given that, not all aggregates generated are toxic, if we could investigate the toxicity of
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aggregates based on its morphology or biophysical properties would provide a big insight
in understanding the molecular mechanism in disease process as well as help in selecting
the targets for drug discoveries. This topics will also be discussed in chapter 3 and 4.
Explanation of techniques used in conducting experiments described in chapters 3, 4 will
be discussed in Chapter 2. Various techniques ranging from cell biology, biophysical and
biochemical and imaging will be covered. This provides details on each technique along
with its applications which helps to guide as we go through experimental details in Chapter
3 and 4.
Future applications of the projects are discussed in Chapter 5. In future, since we have
already standardized the method of purification of full- length protein, more TDP-43 fulllength protein can be generated to study in great detail of its biophysical and biochemica l
properties. Though, we have some preliminary data on disulfide status of protein by
treating with mal-PEG, more extensive study can be conducted using differe nt
concentration of reducing agent and mal-PEG. This will help us to understand the disulfide
status of the protein which is still ambiguous to all researchers. In addition, the role of pH
on protein stability, structure and toxicity can be studied by altering the pH of the protein
and observing its aggregation property, morphology and toxicity. Not only that the
protein’s biophysical properties like hydrophobicity, flexibility etc. can be studied in great
detail using biophysical techniques. Gathering all these, information’s together will
provide some useful answers on structure of this protein and its associated toxicity.
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Chapter 2: Methods
In this chapter, I will discuss about the different techniques used in accomplishing the work
explained in Chapter 3 and 4. This chapter serves as providing detailed information’s on
each techniques with its applications and limitations. The work in one of the chapter is
about the expression and purification of TDP-43 protein. And I also carried out biophys ica l
and biochemical characterization of protein. To better understand the methods involved I
have represented each project in flow-diagram along with its description.

Figure 1: Schematic representation of techniques used in Expression and purification of
TDP-43 protein.
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Figure 2. Schematic representation of techniques used in chapter 4.
2.1 Affinity chromatography
Expression and purification of protein is routinely employed in biochemical studies.
Among the different purification techniques, affinity chromatography is one of the
powerful technique which involves the use of affinity tags that fuses with protein of
interest. Immobilized metal-affinity chromatography (IMAC) is used for purification of
recombinant proteins which contains short affinity tag like polyhistidine residues.
Purification using polyhistidine tags has been used successfully in different expression
systems like E.coli, mammalian,

baculovirus infected insect cells, Saccharomyces

cerevisiae. These tags are generally employed on either N- or C- terminal of the protein.
IMAC chromatography results into high yield of protein purification with up to 95% of
purity. IMAC employs the interaction of the stationary phase which is the immobilized
matrix consisting of transition metal ion (Co2+, Ni2+, Cu2+, Zn2+) with the side chain of
amino acid. Histidine has the high affinity with the metal ions like nickel ion present in the
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column matrix and results into strong interaction due to the formation of the coordinatio n
bonds between imidazole ring on the histidine with the transition metal ion. As a result of
which, peptides that contain the histidine residues are retained in the column which can be
eluted from the column by increasing the concentration of imidazole in the buffer system1 ,
2.

In Chapter 3, we used Ni-NTA affinity chromatography to purify our proteins. The column
was was first packed with HisPur™ Ni-NTA resin. This resin has the capacity of binding
upto 60mg of 6XHis tag protein per ml of resin and is applicable under both native and
denaturing conditions. After packing the column, the column was equilibrated with
equilibration buffer containing 10mM imidazole. Then, the protein lysate/urea soluble
/detergent soluble fraction was loaded on the column and unbound fraction was collected.
The column was further washed with wash buffer containing increasing concentration of
imidazole to remove unbound fractions. Finally, the protein was eluted from column using
the elution buffer with high concentration of imidazole.
2.2 Polyacrylamide gel electrophoresis (PAGE)
Electrophoresis is a technique that involves the separation of proteins based on the
migration of a charged particles in an electrical field. Electrophoresis of proteins are
generally carried out in Polyacrylamide gel which is a cross linked polymer that acts as a
molecular sieve and slows the migration of proteins approximately in proportion to their
charge to mass ratio. SDS PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis) and Native PAGE are the most commonly used gel electrophoresis. SDS
PAGE employs SDS (sodium dodecyl sulfate), an anionic detergent that denatures
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secondary and non–disulfide–linked tertiary structures of a protein. One SDS molecule
binds to every two amino acid residues thus the SDS confers a large net negative charge
on the protein molecule that allows the migration of all proteins in the same direction. The
proteins migrate through the pores in the gel towards the positive electrode at the bottom.
By the end of electrophoresis, the smaller proteins will be closer to the bottom of the gel
and the larger proteins will be closer to the origin. After electrophoresis proteins in the gel
can be visualized by the use of Coomassie blue dye which binds to the proteins but not to
the gel. Selection of proper gel concentration is critical for separation of proteins. Lower
percentage gels are better for resolving high molecular weight proteins, while higher
percentages are needed to resolve smaller proteins. SDS PAGE has a wide application like
separating different proteins based on their molecular weight, monitoring the progress of
protein purification, identifying molecular weight of unknown proteins based on the
electrophoretic mobility with reference to standard marker, separating the differe nt
subunits of a protein.
Native or Non-denaturing PAGE is a type of gel electrophoresis which is carried out in the
absence of SDS so that the proteins are not denatured and are in well-folded structure. In
this method, proteins are separated based on the protein's charge and their hydrodyna mic
volume. The mobility of proteins is based on the intrinsic charge on the protein at the pH
of the running buffer. The proteins in the Native PAGE retain their folded conformation so
the migration is also affected by the conformation of proteins i.e: higher mobility is seen
for more compact conformations and lower for larger structures like oligomers. Native
page is used to identify changes in protein migration due to oligomers, unfolded or molten
globule or other modified conformation, changes in charge due to chemical modifica tio n
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like degradation and aggregation. Another advantage of native gels is that it is possible to
recover proteins in their native state after the separation. Therefore, Native PAGE is one
of the most powerful technique for studying the composition and structure of native
proteins, since both the conformation and biological activity of proteins remain intact
during this technique.
The electrophoresis gels are formulated in buffers such that it provides conduction of an
electrical current through the matrix. In order to obtain optimal resolution of proteins
stacking gel is casted over the top of the resolving gel. Also, the pH of Tris in stacking gel
is 6.8 whereas the pH of Tris in Resolving gel is 8.8 which allows the proteins in a loaded
sample to be concentrated into a tight band during the first few minutes of electrophores is
before entering the resolving gel. This process occurs as Glycine ions has isoelectric point
near pH 6 so at that pH glycine has net charge zero so it migrates slower in the gel and
chloride ions has negative charge so can migrate faster in gel and proteins remain in
between the Glycine and chloride ions forming a layer in the stacking gel. Selection of
proper gel concentration is critical for separation of proteins. The gel consists of
acrylamide, bisacrylamide initiator, TEMED, denaturant (SDS) and a buffer with an
adjusted pH. Acrylamide has a property of auto polymerization and bisacrylamide forms a
cross link with acrylamide and thus results into the gel. The concentration used will depend
on the size of the proteins to be separated adequately. Ammonium persulfate is a source
for free radical that initiate the process of polymerization. TEMED accelerate the rate of
formation of free radicals from persulfate which in turn accelerate the polymerization. APS
and TEMED should be prepared fresh as APS and TEMED are highly hygroscopic and
start to decompose rapidly in presence of water leading to rapid loss of their reactivity. The
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rate of polymerization and the properties of the resulting gel depend on the concentratio ns
of free radicals. Increasing the amount of free radicals results in a decrease in the average
polymer chain length, an increase in gel turbidity and a decrease in gel elastic ity.
Decreasing the amount shows the reverse effect. Glycerol increases the density of the
sample, and bromophenol blue which is a tracking dye that has the mobility higher than
other analytes and helps to track the progress of electrophoresis3 .
In Chapter 2, we used SDS-PAGE for testing our proteins as well as for running western
blot. The reduced samples were prepared by adding the 5% β-mercaptoethanol in sample
whereas non-reduced

samples

were prepared by incubating

the samples

with

Iodoacetamide for 2 hours in dark and the reaction was terminated by adding the sample
buffer without reducing agents. Samples were boiled for 5 minutes and samples were
loaded on 12% /15% SDS gels. The gel were run for 3 hours using Tris-Glycine- SDS
running buffer (25mM Tris, 192mM glycine, 0.1% SDS, pH 8.3). The gels after separation
were stained with Coomassie blue and after the destaining process the images were
captured on Epson Scanner.
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Figure 3: Schematic illustration of SDS-PAGE. Protein samples are loaded on the wells
and the samples run from cathode to anode under the application of an electric field.
Reprinted with permission of the publisher.
2.3 Western blot
Western blot is the most commonly used technique in the cell and molecular biology. It is
used to detect the protein in the blot separated by the gel. In this technique, first the
protein/mixture of proteins is separated on the basis of molecular weight using the Sodium
dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE). Using a proper
membrane which can be PVDF (polyvinylidene difluoride), Nylon, or nitrocellulose, the
gel is transferred into the membrane using the transfer buffer under the specific voltage.
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PVDF membrane is more stable compared to other membranes and also allows relabeling
and easy storage. PVDF membrane provides high protein binding capacity due to its
hydrophobic nature. Nitrocellulose membrane is not good for use of transfer of low
molecular weight proteins due to its large pore-size. However, it has the advantages of low
background. The membrane becomes brittle and difficult to handle when it’s dry. Nylon
membrane has lots of advantages but due to its high background binding and irrevers ib le
staining of some dyes, it’s less common than the other two. The protein band is detected
using the antibodies. The membrane after the transfer is blocked with blocking solution
which is basically 5% skimmed milk or 5% Bovine Serum Albumin. The blocking step is
carried out to remove any nonspecific binding. Blocking is followed by the incubation with
primary antibody that is specific to the protein of interest. The unbound proteins are washed
off and then incubated with the secondary antibody which is HRP conjugated is used to
detect the protein band using the chemiluminesence method. The band observed can be
quantified that is related with the amount of protein present. Detection method for the
western blot can be direct or indirect. In the direct method, only one antibody is required.
The primary antibody is conjugated to an enzyme or fluorophore which detects the antigen
that is present in the blot. The most commonly employed detection method is the indirect
detection method. In this method, the primary antibody is unlabeled, and this is added to
blot to bind with the antigen and the detection is facilitated by the secondary antibody that
is conjugated to the enzyme or fluorophore which may be biotin, fluorescent probes, HRP
or Alkaline phosphatase (ALP). The advantage of using indirect method is same secondary
antibody can be used for multiple primary antibodies4 .
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In chapter 2, we used Western blot to confirm the expression of our protein. After the run
of the gels, the gel was transferred into PVDF membrane using the transfer buffer for an
hour. The membrane was blocked with 5% skimmed milk for an hour and then incubated
with primary antibody (1:4000) for overnight at 40 C. Next day, the membrane was
incubated with secondary antibody (1:10000) for 2 hours and finally the image was
acquired using the GelDoc.
2.4 Scanning Electron Microscopy
Electron microscope uses the electrons instead of visible light used by light microscopes.
The electron beams are travelled through the instrument which is facilitated by the high
vacuum. Due to the smaller wavelength of the beam the electron microscope is superior to
light microscopes in distinguishing smaller details. For example, the wavelength for
electrons accelerate by 100kV is only 0.004 nm when compared to wavelength of green
light which is 550 nm. There are basically two types of electron microscopes: Scanning
electron microscopes (SEM) and Transmission electron Microscopes (TEM). Comparing
two instruments in terms of resolution, SEM can resolve 1-5nm whereas resolution of TEM
is 0.1nm. In TEM, image formation takes place by the electrons beam that is transmitted
through the sample, whereas in case of SEM, the beam is scanned across the sample and
signals are detected by the detectors which uses the electrons that are reflected from surface
of the sample to generate the image. The field of view is wider in SEM in comparison to
TEM. SEM is advantageous over TEM in detection of unstable biomolecules due to its
utilization of low voltage in the range of 1-10kV. TEM on the other hand uses high voltage
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in the range of 100-200kV which makes its use limited to stable biomolecules which is not
affected by high voltage.
When the incident electron beam strikes the sample, different types of electron emissio n
are generated depending upon the type of interaction and depth of penetration. These
signals can be backscattered electrons, secondary electrons, X-rays, transmitted electrons,
scattered electrons, Auger electrons etc. Some of the signals produced are depicted in figure
4.

Figure 4: Representation of the different signals that are produced when interaction of an
incident electron beam takes place with sample. SEM and TEM are used to detect most of
these signals 5 . Figure adapted from
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Scanning Electron Microscopy (SEM) is the most widely used technique for imaging the
morphology and composition of various materials. Although the use of SEM was described
in 1942, its commercial use became available only in 1965 when Oatley and co-workers
from Cambridge University reported their work. SEM has many applications apart from
characterizing the topographical, morphological, and compositional information. It is used
to detect, analyze or identify the crystalline structures, variations in compositions of
chemicals surface fractures analysis, surface contamination examination. In SEM, the
images are generated either by the backscattered electron (BSE) or the Secondary electrons
(SE). Backscattered electrons are produced when the interaction between beam and the
sample is elastic. The specimen’s atomic number greatly determines the production of
backscattered electrons. As a result of which, the specimen with higher atomic number
appears brighter compared to the one with lower atomic number making it’s uses in
understanding composition of specimen. Secondary electrons are produced when the
interaction between beam and the sample is inelastic. SE is the commonly used signal for
imaging and is mainly related to the topography and used to detect the morphology of
samples

6,7 .
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Figure 5: FESEM images of 40µM lysozyme incubated at 370 C for 24 hours. (A) Sample
with 1mM TCEP (B) Sample with 1mM TCEP and 1M Glycine. Scale bar =10 µm, 5 µm
and 1 µm from left to right respectively.
The working principle of SEM is depicted in Figure 6. The electron gun forms a stream of
electron under high vacuum. These electrons are then accelerated with upto dozens of Kev
energy and focused by the electromagnetic lens into a monochromatic beam. This thin
beam inject the sample and the interaction of beam with the sample is detected and
transformed into an image.
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Figure 6: Schematic representation of principle of SEM. Figure adapted from Goldstein,
J., et.al. Scanning Electron Microscopy and X-ray Microanalysis. Third Edition.
One of the important aspect that needs to be taken care of while taking images of
biomolecules, examples proteins using SEM is burning or degradation of the sample due
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to the high energy electron bombardment. Also, when the nonconducting specimens are
subjected to imaging, charge-up of specimen occurs and the secondary electrons are not
emitted. As a result of which, image shift, deformation and abnormal contrast occurs. In
order to prevent this, the specimens are first added into sputter and allowed to dry and then
coated with conducting materials like gold or platinum. The average range for the coating
varies from 1 to 20nm which depends on the samples’ stability.
In the following chapters 3 and 4, the morphology of the aggregates were confirmed using
a cold field emission high resolution scanning electron microscope (Hitachi S-4700
FESEM). Samples were first diluted in MilliQ water and washed to remove the salts and
buffer using Millipore Amicon® Ultra centrifugal filters (3 kDa cut off). For this, samples
were centrifuged at the speed of 7,000 × g at 4o C and repeated thrice. After the washing
step, samples were aliquoted on stubs and left to dry at room temperature. Before imaging,
samples were coated with platinum at the thickness of 10 nm using a sputter coater. Images
were acquired using the acceleration voltage of 10 kV and emission current of 5μA8 .
2.5 Cell based assays:
Cell proliferation or viability is the most commonly employed technique to test the health
of the cells. Cell metabolism and health can be affected by various physical and chemical
agents. These agents can lead to cellular toxicity either by preventing protein synthesis,
leading to cellular destruction, binding to receptors in irreversible manner, or inhibiting
enzymatic reactions. This makes need of effective, cheap and reliable method to test cell
viability as well as toxicity9 . Different methods are available for testing cell viability or
cytotoxicity like colorimetric, dye exclusion methods, fluorometric and luminometr ic
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assays. In the following sections two most commonly used assays for cell viability and cell
toxicity as well as measurement of free radical will be discussed.
2.5.1 MTS assay
MTS assay is a colorimetric method that is used for determining the number of viable cells.
This assay is commonly employed for testing cell proliferation, cytotoxicity and chemo
sensitivity assays. The principle lies on formation of colored formazan from the conversion
of a tetrazolium

salt

(5-(3-carboxymethoxyphenyl)-2-(4,5-dimethyl-thiazoly)-3-(4-

sulfophenyl) tetrazolium, inner salt by the activity of living cells. The quantity of formazan
product as measured by the amount of 490nm absorbance is directly proportional to the
number of living cells in culture. MTS assay has many advantages ranging from
convenient, rapid, sensitive, economical and precise method for measuring in vitro cell
proliferation assay. The disadvantages of this assay is the absorbance value measured at
490nm is affected by the length of incubation, cell type, cell density and the ratio of reagent
to cells in culture. Studies suggested that within the short time incubation i.e. upto 5 hours
the linear relationship was observed for incubation time and absorbance

46

9,10 .

Viable cell
NADH

NAD

H
N

N
N

PMS

N

O
O S O
O

SO3

HOOH2CO

N NH
N
N

SO3

S

N N
HOOH2CO

N

Formazan

N

N

S
N

MTS

Figure 7: Mechanism of MTS assay. Structures were drawn using ChemDraw Pro 17.1
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Figure 8: Representation of general scheme for MTS assay.
In the current thesis, MTS assay was employed to detect the cell viability in chapter 4. The
effect of aggregates amyloid beta protein was tested using SH-SY5Y human neuroblasto ma
cells (from ATCC). In brief, SH-SY5Y cells was cultured in DMEM/F-12 medium
containing 10% FBS and 100 U/ml penicillin-streptomycin. The cells were seeded at the
density of 2 x 104 cells/well on 96-well plates and incubated overnight at 37o C in 5% CO2
humidified environment. All cellular experiments were conducted within first 10 passage
of cells. Following day, the cells were washed twice with 1X PBS. Then, 100 µl of fresh
media containing samples at desired concentrations were prepared and added to cells in
replicates of six. The cells containing samples were incubated at 37o C in 5% CO2
humidified environment for 48h. Similarly, controls were prepared without adding any
samples and containing only cells. After the incubation, MTS reagent ( CellTiter 96®
AQueous One Solution Cell Proliferation (MTS) Assay kit (Promega)) was added to each
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well and incubated for 4 h at 37o C. Finally, the absorbance was measured at 490 nm using
a plate reader (BioTek Instruments, Inc.). Blanks were prepared for background subtraction
and contained only media with test samples but without any cells.
2.5.2 Lactate dehydrogenase (LDH) assay
LDH is commonly employed technique for detecting the cytotoxicity in the cells. A
cytosolic enzyme (LDH) is present in different types of cells and is released when there is
damage to plasma membrane. The amount of released LDH can be quantified by using a
coupled enzymatic reaction.

In the first step, the conversion of lactate to pyruvate is

catalyzed by the LDH through the reduction of NAD+ to NADH.

Secondly, the

tetrazolium salt (INT) is reduced by diaphorase using NAD+ leading to the formation of a
red formazan product. The amount of LDH released in the media is directly proportional
to the level of formazan formation which is measured by taking absorbance at 490nm. LDH
assays has several features ranging from its reliability, quick and easy evaluation of cell
death. On the other hand, when talking about the limitations, some of the compounds like
serum (e.g. fetal calf serum) have inherent LDH activity leading to high background
reading. So, serum free or low serum media is usually preferred for this assay

49

9,11,12 .

Figure 9: LDH assay principle.
LDH assay was employed to test the toxicity of aggregates to cells in chapter 4. The effect
of aggregates from amyloid

beta peptides were tested using SH-SY5Y human

neuroblastoma cells (from ATCC) and primary neuronal culture. In brief, SH-SY5Y cells
was cultured in DMEM/F-12 medium containing 10% FBS and 100 U/ml penicillinstreptomycin. The cells were seeded at the density of 2 x 104 cells/well on 96-well plates
and incubated overnight at 37o C in 5% CO2 humidified environment. All cellular
experiments were conducted within first 10 passage of cells. Following day, the cells were
washed twice with 1X PBS. Then, 100 µl of fresh media containing samples at desired
concentrations were prepared and added to cells in replicates of six. The cells containing
samples were incubated at 37o C in 5% CO2 humidified environment for 48h. Simila r ly,
controls were prepared without adding any samples and containing only cells. After the
end of incubation, 10 μl of lysis solution (CytoTox 96® Non-Radioactive Cytotoxic ity
Assay (LDH) Assay kit, Promega) was added to maximum LDH release control wells and
incubated for 45 minutes at 37 °C in 5% CO2 . Then, 50µl of supernatant from all the wells
were transferred into a new plate and to each of those wells 50µl of LDH reagent was
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added. The plate was further incubated in dark for 30 minutes. After incubation, 50µl of
stop solution was added to each well. Absorption at 490 nm were collected using a plate
reader (BioTek Instruments, Inc.). Blanks were prepared for background subtraction and
contained only media with test samples but without any cells.
2.5.3 ROS measurement
Reactive oxygen species (ROS) are formed by the reduction of oxygen molecules which
contains unpaired electron (one or more) and are highly reactive in nature. The most
commonly occurred ROS includes superoxide radical (O2−), hydroperoxyl radical
(HO2−), hydroxyl radical (HO−), peroxyl radical (ROO−), alkoxyl radical (RO−),
hydrogen peroxide (H2O2), singlet oxygen (1O2), nitric oxide (NO) and hypochlorous acid
(HOCl). ROS plays an important role in health and diseases like they are known for their
protective and functional role in immune system. On the other hand, they are thought to
play role in cancer, neurodegenerative diseases, atherosclerosis, and diabetes. Cells have
antioxidant defense mechanism to overcome the production of free radicals in the cells.
However, oxidative stress occurs when the balance of free radicals exceeds its defense
mechanism. Reactive Oxygen Species (ROS) can be easily measured using 2′, 7′–
dichlorofluorescin diacetate (DCFDA), where the nonfluorescent DCFDA is converted to
the fluorescent compound in presence of ROS. The scheme for this reaction is shown in
Figure 10. This assay is very sensitive to changes in redox state of the cell and is easy to
perform and is an inexpensive method which can be used to detect the changes in ROS
over the time

13,14,15 .
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Figure 10: Reaction showing the conversion of DCFDA to fluorescent compound by
ROS. Structures were drawn using ChemDraw Pro 17.1
In chapter 4, we used 2',7'-dichlorofluorescin diacetate (DCFH-DA) fluorescence assay to
measure the ROS in the cell. Like MTS and LDH assay, SH-SY5Y human neuroblasto ma
cells (from ATCC) were cultured and were plated at 2 × 104 cells/well on 96-well plates
and allowed to grow overnight. The next day, cells were washed with 1X PBS buffer (pH
7.4) twice. Then, cells were incubated with 20 µM DCFH-DA for 45 minutes at 37 °C in
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dark. After incubation, the cells were washed twice with 1X PBS (pH 7.4) and then 100µl
of fresh media containing peptide samples were added to DCFH-DA (Sigma) treated cells
in six replicates and incubated for 24 h at 37 °C in 5% CO2 humidified environment. Cells
without any treatment and blanks were also incubated under identical condition. For
positive control, cells after DCFH-DA treatment were incubated with 50 µM of t-butylhydroperoxide (tBHP) for 4 h at 37 °C. Finally, the fluorescence intensity was measured
using fluorescence plater reader (Fluoroskan Ascent, Thermo Scientific) at excitatio n
wavelength of 485 nm and emission wavelength of 538 nm.
2.6 UV-Vis spectroscopy
UV- Vis spectroscopy deals with the measurement of absorbance in the UV and visible
range ranging from 200-800nm. While fluorescence spectroscopy measures the transitio ns
from excited to ground state, absorption spectroscopy measures the transition from ground
to excited state.

The principle of UV-absorbance is based on the Lambert Beer’s Law.

According to the Beer-Lambert Law, the absorbance of a solution is directly proportional
to the concentration of the substance present in that solution and is expressed as,
A=

cl

Where, A = absorbance; l = optical path length expressed in cm;

= molar extinctio n

coefficient, expressed in M-1cm-1; c= molar concentration. The three aromatic amino
acids namely Phenylalanine, Tyrosine and Tryptophan are responsible for the absorption
of light in UV range. Protein shows the absorption maxima around the wavelength of
280nm due to the presence of these three aromatic amino acids. Among them phenylala nine
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contributes the least due to its lower absorptivity and is usually not accounted for protein
UV absorbance. UV-Vis spectroscopy is also used to measure the concentration of a
sample. It is widely used for the quantitative analysis and also for measurements of
conformational changes of proteins and nucleic acids, ligand-binding reactions. Since, the
absorbance not only depend on the structure but also only the local environment, this
method is also used to quantify the protein aggregation. This is basically accomplished by
measuring the turbidity of the solution. The increase in turbidity leads to increase in
absorbance which signifies the increase in protein aggregates.
2.7 Fluorescence spectroscopy
Fluorescence is a slow process which usually occurs in the order of 10-9 to 10-7 seconds.
When an molecule receives an energy of certain wavelength it is excited from ground state
to its excited state. Since, the excited electron is not stable in its excited state, it returns
back to the ground state emitting a light of certain energy which is measured as a
fluorescence. Fluorophores are the fluorescent compounds and are aromatic in nature.
Jablonski diagram best describes the phenomenon of absorption, fluorescence and
phosphorescence which is shown in Figure 11. As shown in the figure below, the radiative
transitions are represented by the solid arrows and the non-radiative transitions are
represented by the dashed arrows. The notation S0, S1 and S2 represents the differe nt
energy levels namely ground, first and second respectively. Internal conversion and
Intersystem crossing are an example of the non-radiative transitions. Intersystem crossing
occurs between the states of different spin multiplicity. Coupling of vibrational state of
higher electronic state to lower electronic states results into internal conversion. For
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Emission of photons leads to release of energy and is observed when electron return to
different vibrational level of S0 from S1. This emission is measured as fluoresce nce.
Phosphorescence is generally observed when the electron from triplet state return back to
ground state. Compared to S1, triplet state is lower energy level hence phosphorescence
has longer emission wavelengths than fluorescence.
Intrinsic and extrinsic fluorescence are the most commonly used fluorescence methods to
detect the changes in protein structure. Fluorescence spectroscopy is widely employed
technique in studying the protein folding due to its sensitive detection of emission spectra,
which is greatly affected by the change in local environment as well as the structure of the
fluorophore.

Figure

11. Jablonski

diagram

representing

the

absorption,

fluorescence

and

phosphorescence. The different electronic states are represented by S0 (ground), S1 (first),
S2 (second), and T1 (triplet) state. Fluorescence and Phosphorescence represents the
radiative transitions and internal conversion,
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intersystem crossing and vibratio na l

relaxation represents the non-radiative transitions. Figure Adapted from Alvaraz.V. et.al.
201221 .
Intrinsic fluorescence of a protein is the mainly contributed by two aromatic amino acids
tyrosine and tryptophan. Due to the highest absorption coefficient of tryptophan compared
to other two aromatic amino acids Phenylalanine and Tyrosine (Figure 2.9), intrins ic
fluorescence is measure of tryptophan residue. The fluorescence contributed by the
tryptophan is highly sensitive to local environment as a result of which, it can be blue
shifted which is towards shorter wavelength when the protein is under the native condition
and red shifted fluorescence is observed when the protein is unfolded. This characteristic
can be used to monitor the conformation change of a protein and measure the protein
unfolding phenomenon. During folding of the protein, the hydrophobic residues are buried
down in the protein core and is not exposed to the solvent. . The intrinsic fluorescence can
be used to study the protein denaturation in presence of denaturants like Guanidine HCl
(GdnHCl) at different pH. Figure 13, Shows the chemical denaturation of cytochrome C
protein at pH 4, 7 and 10. The protein cytochrome C in presence of denaturant guanid ine
HCl (GdnHCl), shows the increase in the fluorescence intensity with the increase in the
concentration of the guanidine HCl. This is due to exposure of the hydrophobic residue
especially Tryptophan to the aqueous environment during the process of protein unfold ing.
The peak fluorescence intensity thus observed can be used to plot the denaturation curve
which is in the sigmoidal shape (Figure 13). The native fit line, transition fit line and
denatured fit line obtained from the curve helps to calculate the different thermodyna mic
parameters like ΔG, ΔH, ΔS, Cm.
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Figure 12: Structure of three aromatic amino acids Phenylalanine (Phe), Tyrosine (Tyr)
and Tryptophan (Trp). Structures were drawn using ChemDraw Pro 17.1

Figure 13. Chemical denaturation curves of Cytochrome C at pH 4.0, 7.0, and 10.0 as a
function of guanidine HCl concentration. Fluorescence emission of proteins were collected
at 300-600 nm, with excitation at 280 nm. The peak intensities at 355 nm were normalized
as fraction of denatured. Concentration of protein was 0.3 mg/ml at all pH.
Extrinsic fluorophores are the compounds that are covalently linked to ligands or proteins
and associated with the transfer of fluorescence energy. Electrostatic and hydrophobic
interactions are the major non-covalent interactions that are involved during the interactio n
of extrinsic fluorophores with proteins. These dyes are very sensitive to the local
environment. Extrinsic fluorophores help in characterization of protein such as it can be
used to study the changes in conformation, structure, size, kinetics of a protein, surface
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hydrophobicity, probe active sites of enzyme, detect intermediates of molten globule,
monitor folding and unfolding of protein, and its species that are produced during the
process of aggregation

22 .

Table 2.1. Common extrinsic fluorescent dyes and their applications /
Dyes

Applications

Thioflavin T (ThT)

Detect the morphology of aggregates

ANS

Protein

folding,

Aggregation

Kinetics,

Surface

hydrophobicity

Bis-ANS

Protein conformation , Surface hydrophobicity, Protein
folding and unfolding kinetics

Congo Red

Amyloid fibril analysis

Nile Red

Detect

changes

in

protein

hydrophobicity unfolding/folding
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Figure 14: Some common extrinsic fluorescent dyes used in protein aggregation studies.
Structures were drawn using ChemDraw Pro 17.1
ANS (1-anilinonaphthalene-8-sulfonate) and Bis-ANS (dimeric analogon 4, 4′-bis-1
anilinonaphthalene-8-Sulfonate), are the fluorescent dyes that are used for the protein
characterization. The dye ANS is the most commonly used dye to measure the surface
hydrophobicity. ANS fluorescence is highly sensitive to the local environment and shows
increase in fluorescence in non-polar environment whereas in polar environment it is
weakly fluorescent. Also, the fluorescence depends on the polarity, viscosity and
temperature of dye’s environment. The increase in quantum yield with the blue shift of
emission maxima results from the decrease in dielectric constant of the solvent. The
mechanism for binding of ANS to protein is through the hydrophobic and electrostatic
interactions. However, the sulfonate group of ANS pairs with the positive amino acids on
the proteins like lysine, arginine and histidine through ion-pairing making it the
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predominant interactions. Apart from this the weak forces like van der Waals interactio ns
is also necessary to make the ions pairs stable. On the other hand, the major interactio n
between Bis-ANS and protein is the hydrophobic interaction. The binding affinity may
vary due to the different sizes of the dye and the number of binding sites present on the
protein. Both dyes have similar intrinsic fluorescence properties but when compared to the
UV absorption and fluorescence emission, Bis-ANS displays UV-absorption maximum as
well as emission shifted towards longer wavelength. Though the interaction in Bis-ANS is
driven by the hydrophobic interaction it does not bind strongly with the organized
structures. For its strong binding, it requires the molten globule like structures and has
weak reactivity towards amyloid fibrils. Therefore, ANS and Bis-ANS provides differe nt
information in protein aggregation. Bis-ANS provides information on flexibility of the
structure of aggregates i.e. whether it forms loose or tight structures. Tht (Thioflavin T) is
a fluorescent dye that is most commonly used to characterize the amyloid fibrils. The
fluorescent intensity of Tht dye is less depended on the polarity and affected by the
viscosity and rigidity of the environment. The interaction of the Tht to amyloid fibril is
driven by the hydrophobic interactions with the side chains of amino acids. Now it is
evident that Tht not only binds to the fibrils but also to the non-fibrils structure resulting
into the increase in fluorescence.
In chapter 4, Horiba Jobin Yuon spectrofluorometer (Fluoromax-4) was used for
fluorescence measurement. All dyes stocks were prepared in 100% ethanol and were
diluted in respective buffers to prepare working stocks for incubation with samples. UVVis spectrophotometer was used to measure the concentration of each dyes. The extinctio n
coefficient used was ANS ε350 nm = 5,000 M-1cm-1, bis-ANS ε385nm=16,790 M-1cm60

1. Both dyes were used at the final concentration of 10µM and incubated with 10µM of
protein samples on ice for 15 minutes before acquiring emission spectra. The emissio n
spectra were collected from 400-700nm range with excitation at 360nm for bis-ANS and
380nm for ANS dye. Samples were run in triplicates with incubation in dark with dyes.
2.8 Immunofluorescence
Immunofluorescence is the most commonly used technique to detect the localization and
endogenous expression level of protein of interest by using the specific antibodies that is
conjugated

with

the

fluorescent

dye.

Immunofluorescence

is

a

form

of

immunohistochemistry which uses fluorophores to detect the target. This technique can be
used on cultured cells and individual cells, tissue sections. Several factor accounts into its
application ranging from type of cells, nature of antigen, specificity and sensitivity of
antibodies, permeabilization and fixation method, imaging of the cell. The fluoresce nce
detection method involves the use of direct or indirect method

23 . The

direct method uses

of single antibody that is linked to the fluorophore. The antibody recognizes the target
antigen/ molecule and binds specifically to it which can be detected using the fluoresce nce
microscope. This method has advantage over the indirect method because of the direct
conjugation with the fluorophore which minimizes the number of staining step as well as
problem of background signal, antibody cross-reactivity or non-reactivity. However, direct
method is less sensitive compared to the indirect method. The indirect method on the other
hand uses two antibodies primary and secondary. The primary antibody binds to the target
molecule and secondary antibody contains the fluorophore which recognizes the primary
antibody and binds to it. This method requires more steps than direct method.
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In Chapter 3, we applied immunofluorescence technique to detect the cellular localiza tio n
of our TDP-43 protein using N and C-terminal antibodies. Also, in chapter 4, to detect the
effect of Abeta peptides on primary neuronal culture we employed immunofluoresce nce
method in addition to cellular toxicity. The specific details on procedure is described under
respective chapters.
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3.1 Introduction:
Amyotrophic

lateral Sclerosis (ALS) is an adult-onset neurodegenerative disease

characterized by the premature loss of upper and lower motor neurons leading to death of
motor neuron in the brain, brainstem and spinal cord. Patients with ALS have life
expectancy of only 3-5 years after the onset of disease1 . About 10% of the ALS cases are
familial and rest remains to be sporadic2-4 . Frontotemporal Lobar degeneration (FTLD) is
the second common form of cortical dementia observed in patients below the age of 655,6.
FTLD leads to loss of neurons in the frontal and temporal cortex and is characterized by
the alteration in personality, social behavior, and language dysfunction. The hallmark of
ALS and FTLD includes ubiquitin positive abnormal protein aggregates in the brain of
affected patients7,8 . The presence of ubiquitinated aggregates of transactive response DNA
binding protein 43 kDa (TDP-43) in FTLD and ALS patients in 2006 raised a lot of interest
in understanding the role of this protein in the pathogenesis of ALS and FTLD diseases
9,10,11. The

pathogenic mechanism involved in ALS has not been solved yet but in case of

FTLD and ALS patients, TDP-43 is known to be accumulated in the cytoplasmic inclus io n
of affected areas of the spinal cord and brain12 . The common pathological features with
ALS and FTLD include the presence of cytoplasmic inclusions with ubiquitin and TDP-43
positive, α-synuclein and tau negative. The primary cause for the ALS being identified as
the dominant mutation in TDP-43 resulted in further research being directed toward
understanding the role of TDP-43 in neurodegeneration13,14 . In addition to ALS and FTLD,
TDP-43 is also involved in several other diseases like Alzheimer’s, Parkinson’s, Lewy
Body and Huntington15-18 .
66

A 414- amino acid residue protein, TDP-43 is structurally distinguished into N-terminal,
C-terminal and two-RNA binding domains (RRM1 and RRM2)19-27 . Being a protein of
nuclear origin, TDP-43 protein plays a significant role in health and diseases. Under normal
conditions TDP-43 performs a wide variety of functions basically in the regulation of
mRNA pathways which I will discuss in following paragraphs.

Figure 1: Schematic representation of TDP-43 showing different regions.
Biological Functions of TDP-43
TDP-43 is known for its role in protein-protein interaction which occurs through the
glycine rich C-terminal region. TDP-43 is associated with the members of hnRNP family
like hnRNP A2/B1, hnRNP A1, hnRNP C1/C2 and hnRNP A3, interaction of which are
dependent on C-terminal region. TDP-43 plays a wide variety of biological functio ns
mainly in the regulation of RNA pathways as summarized in the figure 317, 19 .
a. TDP-43 as a transcriptional regulator
The conversion of DNA to RNA is regulated by the transcriptional regulator. TDP-43 is
well conserved among invertebrates and mammals and is expressed in almost all tissues.
First identified in 1995, as a transcriptional inactivator of Human immunodeficiency virus
type 1 (HIV-1), TDP-43 role is known in transcription repression. Binding of TDP-43 with
the double stranded HIV TAR DNA repeats takes place through its RRMs domain.
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Presence of polypyrimidine rich region in TAR DNA facilitates its binding with TDP-43
as a result of which recruitment of TATA binding protein to TATA element is inhibited.
TDP-43 also binds with mouse SP-10 gene promoter and is involved in transcriptio n
repression in spermatids18,19, 28-30 .
TDP-43 in splicing regulation
Splicing is the process by which the introns are removed and the exons are joined together
to produce the mature messenger RNA. TDP-43 is known to be involved in splicing
regulation of several gene transcripts such as Cystic fibrosis transmembrane conductance
regulator (CFTR), TARDBP, FUS, SNCA (α-synuclein), HTT (Huntingtin), and APP
(Amyloid precursor protein). The splicing pattern of the targets is known to be altered by
the level of TDP-43, i.e. overexpression or its depletion. The glycine rich C-terminal
domain of TDP-43 is involved in the interaction with different proteins involved in splicing
11, 6, 7 . Being

a member of hnRNP family, TDP-43 is found to interact with various members

of hnRNPs like hnRNP A2/B1, hnRNP A1, hnRNP C1/C2 and hnRNP A3. The C-terminal
region of TDP-43 is involved in binding with hnRNPs and the hnRNPs regulate the
splicing. TDP-43 also regulates survival of motor neuron, apolipoprotein A2 and
serine/arginine–rich splicing factor 211, 16, 18 .

b. TDP-43 in micro-RNA processing
The presence of TDP-43 in Drosha complex (a nuclear RNase type-III protein) together
with FUS/TLS as well as its association with the perichromatin fibers first raised the
possibility of TDP-43 role in miRNA biogenesis.
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Further studies suggested the

dysregulation of several miRNAs upon depletion of TDP-43. An example of this includes
let-7b, miR-9, miR-132, miR-520, miR-663 etc.

11,19, 20 .

TDP-43 is involved

in

dysregulation either by binding with the miRNAs or its precursors molecules. However,
TDP-43 is involved in controlling the stability of Drosha protein during the neuronal
differentiation.
c. Role of cytosolic TDP-43 in regulation of RNA subcellular localization
TDP-43 is a nuclear protein and can shuttle between nucleus and cytoplasm. It performs a
diverse role in nucleus and cytoplasm. In the cytosol, TDP-43 regulates the subcellular
localization of RNA as well as its transport, translation and stress-granule formation. TDP43 role in translation repression is also known by interacting with proteins involved in
translation.
During the condition of stress, the formation of cytoplasmic foci represents TDP-43 as a
component of stress granules. Under the condition of stress TDP-43 translocate into
cytoplasm and colocalizes with stress granules and may play role in mRNA stability as
well as its trafficking. However, how the TDP-43 positive stress granules play role is yet
to be identified16,

29, 30,33.

d. Role of TDP-43 in mRNA stability
Though identified to be highly localized in the nucleus and perform its functional activity,
role of TDP-43 is also identified in the cytoplasm. TDP-43 is involved in the transport,
stability and translation of mRNA in the cytoplasm. The role of TDP-43 in mRNA stability
was first identified in two targets namely human low molecular weight neurofilament and
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the histone deacetylase HDAC6 transcripts. More mRNAs are now known whose stability
is altered by TDP-43. An example of this includes: Add2, VEGFA and GRN, and IL-6 34 .
The maintenance of neuronal activity and synaptic plasticity in the neurons requires the
transport of mRNA into axons and dendrites. In a study reported by Fallini et.al. 2012,
TDP-43 was known to be actively transported along axons in primary motor neurons. Also,
TDP-43 colocalizes with other RNA binding proteins like SMN and FMRP, in RNA
granules

34 .

e. Role of TDP-43 in Genome stability
TDP-43 is important for early mouse embryogenesis, the homozygous disruption of tar
DNA binding gene are embryonically lethal. The expression of TDP-43 is tightly regulated.
It has been observed that the knockdown of TDP-43 leads to death of differentiated neurons
as well as tumor cells. Similarly, the lethality of the second-larvae stage in Drosophila
occurs due to TDP-43 disruption while semi-lethality was reported by some other groups
35 .
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Fig 2: Biological functions of TDP-43. TDP-43 plays a wide variety of biological functio ns
mainly in the regulation of RNA pathways28 . (a) TDP-43 being a component of
heterogenous

ribonucleoprotein

(hnRNPs) participates

in the pre-mRNA splicing

regulation. (b)TDP-43 binds to the 3' untranslated region and affects the mRNA stability
as well as turnover (c) TDP-43 localize with the RNA granules and is involved in mRNA
trafficking as it can shuttle between nucleus and cytoplasm. (d) TDP-43 is part of the
Drosha complex and is involved in processing of miRNAs (e) TDP-43 can act as a
transcriptional repressor by binding to the promoter sequences of single stranded DNA. (f)
TDP-43 stabilizes the mRNA under the condition of stress by colocalizing with the stress
granules. (Figure reprinted from Lee , et.al. Used with permission from the publisher)
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TDP-43 distinguished into different domains, possess specific roles. Compared to other
domains, N-terminal domain function was explored late and was found to be crucial for
regulating its self-interaction. Also, N-terminal region is reported to regulate TDP-43
aggregation. RRM1 and RRM2 domain is involved in binding to RNA/DNA sequence and
protein-protein interaction takes place through Glycine rich C-terminal domain

11,18, 19, 32.

TDP-43 plays an important role in health and disease. Being involved in the pathways of
RNA regulation,

TDP-43 under pathological

conditions

is involved

in several

neurodegenerative diseases.
TDP-43 in neurodegeneration
TDP-43 first identified to be involved in neurodegenerative disease as a ubiquitinated
neuronal cytoplasmic inclusions in FTD and ALS patients is also known to be involved in
several neurodegenerative diseases like Alzheimer’s, Huntington, Parkinson’s Lewy
bodies

37-42.

In 97% cases of ALS, TDP-43 inclusions are known to be positive. The

common pathological features include ubiquitinated and hyperphosphorylated aggregates
in the cytoplasm, devoid of TDP-43 in the nucleus. All of the neurodegenerative diseases
that are associated with deposition of TDP-43 are commonly termed as ‘TDP-43
proteinopathies’ which possesses common pathological features. Intracellular and
extracellular accumulation of protein aggregates comprises the major characteristics of
wide variety of neurodegenerative diseases. Although neurodegenerative diseases like
Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD),
Amyotrophic lateral sclerosis (ALS) have distinct proteins associated with them such as
SOD1 with ALS, Amyloid β with Alzheimer’s etc. There’s a renewed focus on TDP-43 as
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its role and importance in all these diseases have been reported. There lies a common
pathogenic mechanism involved in many neurodegenerative diseases, which involve the
central nervous system amyloidosis because of aggregation and deposition of misfo lded
protein. During this process, the soluble proteins are transformed into the insoluble and
filamentous polymers, which are rich in cross-β-pleated sheet structures. These structures
accumulate in the nuclei or cytosol as a fibrillar amyloid deposits in the affected brain cells
or in extracellular space. For the majority of neurodegenerative diseases, the effective
method of treatment is lacking due to difficulty in identifying the disease-causing toxic
fold of the protein. As TDP-43 is involved in multiple neurodegenerative diseases it has
been target of study by basic and clinical researchers, as well as industry to understand its
role in the disease process.
The cytoplasmic

localization

of TDP-43 is the common

feature observed in

neurodegenerative diseases. Apart from this, the modifications like hyperphosphorylatio n,
ubiquitination and C-terminal truncation is observed in several neurodegenerative diseases.
Most of the mutations in TDP-43 is present in C-terminal domain. The hyperphosphorylated and ubiquitinated C-terminal fragment of TDP-43 comprises the major
component in the neuronal inclusion bodies in case of ALS and FTLD patients.
Experiments carried out in cultured cells showed that the prion -like activity is present in
TDP-43 and is capable of converting the normal cells into the abnormal form 32 . Due to the
importance of C-terminal domain, there is increasing demand to examine the sequence of
this domain. Analysis by PONDR PROGRAM, which predicts the naturally disordered
region, identified that about 80% of the C-terminal region is structurally disordered

41 . The

intrinsically disordered proteins can undergo the transition between order/disorder when
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they bind with their partners even though they lack the secondary and tertiary structures in
their native states. The structure of full- length TDP-43 protein has not been determined by
traditional methods such as NMR or X-ray crystallography. The reported NMR and
crystallography structures are for parts of protein that represent the RRM domains and the
N-terminal region. Recently, a computational composite predicted structure of TDP-43
full- length protein was presented based on NMR structure of RRM (2cqg, aa 81-191),
RRM2 (1wf0, aa 186-273) 2N4P (aa1-77), and 2N2C (aa 307-349) as shown in figure 2.
In 2010, Chen et.al attempted to explore the physical characteristics and conformatio na l
properties of the C-terminal domain by synthesizing four peptide fragments D1 (287-322),
D2 (321-353), D3 (351-383) and D4 (381-414). Their study showed that the D1 formed
the fibers and D2-D4 formed the amorphous aggregates further suggesting that the D1
plays an important role in aggregate formation41 . In a recent study conducted by Shimonaka
et.al. (2016), amino acid sequence of TDP-43 that is necessary for aggregation was
identified. The result showed that the glycine rich region, residues 274-313 is necessary
for the aggregate formation. In addition, it was reported that the region 274-353 is
necessary for the conversion of TDP-43 into the amyloid- like fibrils and the peptide fibrils
had a seeding ability. Several research groups have carried out studies to identify the amino
acid sequences of TDP-43 responsible for the aggregate formation (Figure 4). Although Cterminal domain plays an important role in protein aggregation, N-terminal domain
(residues1-77) has been found to play a role in the recruitment of TDP-43 monomers into
the aggregation process. In a study carried out by Kametani et.al. (2016), novel cleavage
sites in TDP-43 were reported suggesting the N-terminal half have the major cleavage sites
42 . Recently,

more studies have been reported on the role of N-terminal domain of TDP-43
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protein. In a study by Zhang et.al. (2013), the role of residues 1-10 in N-terminus was
explored and was found to play an important role in folding of TDP-43 monomer as well
as formation of TDP-43 inclusion43 .

Figure 3: Schematic representation of TDP-43 structure based on the NMR structure
provided. Homology modeling and loop building technique was used to generate this
schematic of composite TDP-43 structure

44 .

(Figure reprinted from Wobst J.H. et.al.

(2017). Used with permission from the corresponding author)
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Figure 4: TDP-43 protein schematic summarizes aggregation studies carried out on the
protein using truncated constructs of varying lengths41-43,

45-48 .

A– Extreme N-terminus

region is responsible for formation of TDP-43 inclusions. Zhang Y.J. et.al. (2013) Human
Molecular Genetics. B – Truncated RRM2 forms amyloid negative fibrils. Wang Y. T.
et.al. (2013) J. Biol. Chem. C – Residue 274-313 in glycine- rich region is essential for
aggregation. Shimonako S. et.al. (2016) J. Biol. Chem. D – Residue 318-343 as the
amyloidogenic core is essential for TDP-43 aggregation. Jiang L. L. et.al. (2013) J. Biol.
Chem. E – Region in RRM2 (246-255) and C-terminal (311-320) has a propensity to form
aggregates and residue 311-320 plays the crucial role among both. Saini A. and Chauhan,
V. S. (2011) Chembiochem. F – Residue 287-322 formed fibers whereas other residues
taken under study were not amyloid in nature. Chen A. K. et.al. (2010) J. Am.Chem. Soc.
G – Transduction of aggregates prepared from in vitro functional TDP-43 triggered the
intracellular aggregation of TDP-43. Furukawa Y. et.al. (2011) J. Biol. Chem.
Advancement in the field of TDP-43 has led to identification of this particular protein in
several neurodegenerative diseases. However, the exact mechanism of neurotoxicity is not
clear and there are two main hypotheses: 1) supports the toxicity by toxic gain of functio n,
and 2) the other supports the loss of critical function because of dominant negative
mechanism. Both mechanisms of toxicity have been supported by several independent
studies by scientists. In case of a gain-of-toxic function, two possible pathways are
followed, first the overexpression of mutant in gene leads to disease phenotype, in which
expression of normal phenotype (wild type) does not cause the disease. In the second
pathway, one of the normal functions is increased in a mutant gene to greater amount
leading to the toxicity. In this situation, not only the mutant but also overexpression of wild
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type gene will eventually lead to disease phenotype. A loss of function involves gene
knockout or knockdown. A dominant-negative mechanism is the condition where the wildtype allele function is affected by mutant allele, as the mutant allele will not be functio na l
and inhibits the function of wild type. Studies suggests that the overexpression of this
protein leads to toxicity. On the other hand, deletion of TDP-43 has been reported to be
embryonically lethal. Furthermore, the absence of cytoplasmic TDP-43 aggregates was
reported to develop disease in case of TDP-43 mutant transgenic mice suggesting that the
loss of TDP-43 function contributes to its pathogenesis. Also, in the study by Feiguin et.al.,
2009 the in vivo neurodegeneration was observed when the TDP-43 was depleted from
neuron. Considering the aggregates of TDP-43, the answer remains unclear whether these
aggregates have toxic or beneficial role. Studies suggest the direct toxicity of these
aggregates while study carried out in Drosophila model suggests protective role of these
aggregates in early stage of disease. TDP-43 has property of self aggregation and can
sequester other proteins into its aggregates. However, how this process occurs and what
factors play role is yet to be determined. As a consequence of TDP-43 aggregates abnormal
function of protein such as disruption of mRNA transport, altered mRNA splicing, problem
in cellular clearance pathways etc.12, 34, 45, 50. The figure below shows the pathologica l
mechanism involved in neurodegeneration.
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Figure 5: Pathological mechanism involved in TDP-43 neurodegeneration34 . TDP-43 is
involved in several neurodegenerative diseases like ALS, AD, HD etc. Under such
conditions, the normal functions of TDP-43 is altered and cellular clearance mechanism is
also affected. (Figure reprinted from Ratti, A et.al. Used with permission from the
publisher).
The above model underscores the diverse role TDP-43 plays in health as well as disease
process. To better understand how these diverse functions maybe mediated by this protein
we need to better understand its biochemical and biophysical properties. For carrying out
characterization of physicochemical properties of TDP-43 protein we need pure protein
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and preferably from a eukaryotic source. Biochemical and biophysical work reported on
TDP-43 protein so far have been from protein expressed and purified using prokaryotic
source such as bacteria. Furthermore, most studies are on truncated version of protein as
indicated in figure 4. Except for computationally generated full-length structure of TDP43 protein (Figure 3), not much structural information is available on the full- le ngth
protein. Though, a substantial amount of work has been reported on TDP-43 protein,
almost all of them involve the use of prokaryotic expression system. Therefore, to better
understand the biochemical and biophysical properties of full- length TDP-43 protein and
its implication for health and disease we need pure protein from eukaryotic source. Protein
from eukaryotic source will have all-natural posttranslational modifications, that is
expected in an eukaryotic protein and will be better suited to understand the disease
process. TDP-43 protein has six cysteine residues and studies so far have not clarified if
there are any inter-chain or intra-chain disulfide bonds (or not) in the protein. Knowing the
disulfide status of a protein will help to better understand proteins biophysical properties
including role disulfide bonds (or sulfhydryl residues) play in protein aggregation and/or
toxicity. Hence, in this study we first standardized the protocol for purification of TDP-43
full- length protein and C-terminal construct using the eukaryotic expression system. This
will help us characterize biochemical and biophysical properties of full- length protein that
may be different than the properties observed for truncated versions of the protein.
Purification of TDP-43 has been challenging because it aggregates when overexpressed
due to presence of intrinsically disordered region. We also carried out some preliminar y
studies on the effect of reducing agents on TDP-43 full- length protein aggregation and how
it modulates the nature of aggregates.
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3.2 Materials and Methods:
1. Purification of TDP-43 protein:
a) Preparation of expression constructs, production of recombinant baculovirus
The Baculovirus particles were generated as reported previously (Hayward et al., 2002)
with slight modification. Briefly,

the recombinant Baculovirus were generated by

transfecting the recombinant bacmid DNA into sf21 cells using the transfection reagent
Cellfectin II (Invitrogen). The transfection was carried out in a 6-well plate seeded at 8 X
105 cells/well. 1 µg of recombinant DNA and 8 µl of Cellfectin II reagent were mixed with
Grace’s medium, unsupplemented (without antibiotics and serum) separately in equal
volume. Both are combined and incubated for 30 min. at room temperature. The mix was
added dropwise onto the sf21 cells and incubated at 27 °C for 5 hours. The transfectio n
medium was removed and replace with 2 ml of complete growth medium (Grace’s Insect
medium, supplemented + 10% FBS). The cells were incubated at 27 °C for 72 hours or
more until the signs of viral infection was noticed. The cells and media were collected and
centrifuged at 1000g/5 min. The supernatant containing the virus particles was stored at 4
°C and cell pellet at -20 °C.
b)

Cellular localization of recombinant TDP-43 in insect cells

The cellular

localization

of expressed

TDP-43 protein

was confirmed

using

immunohistochemistry. First, the High-five cells were cultured in a 6 well plates containing
glass cover slips and incubated overnight at 27o C. Once the cells were nearly 50%
confluent, infection with baculovirus generated for recombinant TDP-43 was performed
and cells were incubated for 24, 48 and 72 hr at 27o C. Fixation was carried out for 15
minutes at the end of each time point. For this, 3% paraformaldehyde in 0.1M Pipes buffer,
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pH 6.9 was used. Cells were permeabilized by using 0.1% triton-X-100 in pipes buffer for
15 min and rinsed with pipes buffer for 3 times of 5 min each. To prevent non-specific
binding of antibodies, cells were incubated with 1% of BSA in 0.1 M pipes buffer and
washed with pipes buffer three times of 5 min each. Cells were incubated with either antiTDP-43 (C-term) or anti-TDP-43 (N-term) antibodies or without any primary antibodies
(negative control) in 1% BSA in 0.1M pipes buffer for 1 hr at room temperature. Excess
antibodies were removed by rinsing with pipes buffer for 5 min and repeated for 3 times.
The cells were further incubated with anti-rabbit secondary antibodies conjugated with
Alexa Fluor 488 (Invitrogen, Cat# A11034) for 30 min at room temperature. Excess
antibodies were rinsed with pipes buffer for 5 min and repeated for 4 times. Mounting
media with DAPI was used to mount the coverslips on the glass slide. Finally, the images
were acquired using the EVOS fluorescence microscope using DAPI and GFP light cubes.
c) Expression and purification of TDP-43 full length protein in High five cells:
High five cells were grown in Express Five Serum free media (externally suppleme nted
with 20mM L-Glutamine and 1X antibiotic antimycotic) at 270 C with a constant speed of
impellor at 95rpm. The cells in suspension culture were infected with viral stock at a log
phase density of 1.0-1.5 X 106 cells/ml. After 48-72h of infection, the cells were harvested
at the centrifugation speed of 1000g for 10 minutes. A small portion of pellet was tested
for protein expression and remaining was stored at -80o C.
The purification of full length TDP-43 was carried out using the protocol published by
V.Lee et.al 2015 with slight modification51 . The cell pellet was extracted in RIPA buffer
(50mM Tris pH 8.0, 150mM NaCl, 1% Triton X-100, 5mM EDTA, 0.5% sodium
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deoxycholate, 0.1% SDS, 1mM phenylmethylsulfonyl fluoride, and phosphate inhibitors
(2mM imidazole,

1mM NaF,1mM sodium orthovanadate)) and centrifuged at the

centrifugation speed of 19000 rpm (42000g) at 40C for 30 minutes. Then, the insolub le
pellet was re-extracted in RIPA buffer at same speed and the resulting insoluble fraction
was extracted in the urea buffer (30mM Tris pH 8.5, 7M urea, 2M Thiourea and 4%
CHAPS) at the centrifugation speed of 42000g at 250 C. The soluble fraction was then
subjected to the purification by Ni-NTA affinity chromatography. The column was
equilibrated with equilibration buffer (30mM Tris pH 8.5, 7M urea, 2M Thiourea, 4%
CHAPS containing 10mM imidazole). The unbound proteins were washed by increasing
the imidazole concentration to 50mM and decreasing the buffer component by 25%.
Finally, the protein was eluted in 30mM Tris pH 8.5, 300mM NaCl, 500mM Imidazo le.
The eluted fractions containing the TDP-43 protein were identified by SDS-PAGE and
western blot. The fractions were pooled, concentrated, and stored at -800 C.
2. SDS PAGE and Western blot:
Protein estimation was done by using BCA (Bicinchoninic acid) assay. Samples for SDS
PAGE were prepared by incubating the desired concentration of protein with 3X SDS
sample loading buffer for 5mins in a boiling water bath. The proteins were then separated
in 12% SDS polyacrylamide gel by running the gel at 80V for 3 hours in a running buffer
(25 mM Tris (pH 8.3), 192 mM glycine, and 0.1% SDS). The gels after the run were stained
in R-250 stain (0.1% Coomassie Blue R250, 50% methanol, 10% glacial acetic acid)
overnight and destained in fast and slow destaining solution. Finally, the image was
captured using an Epson Scan.
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After the completion of 3 hours of run, the gel was electro blotted into PVDF membrane
for western transfer. The transfer was carried out at 100V for 1 hour. The membrane was
blocked in 5% blocking solution for 1 hour at 40 C shaker and incubated with primary
antibody (1:4000) for overnight. Next day, the membrane was incubated with secondary
antibody for 2 hours in Goat anti-rabbit IgG-HRP (1:10000). Finally, the membrane was
imaged using the Gel Doc System.
3. Reducing and Non-reducing SDS PAGE:
Reduced sample was prepared by adding 5% beta-mercaptoethanol while non-reduced
sample was incubated with 1mM Iodoacetamide for 2 hours at room temperature. The
reaction for non-reducing sample was terminated by adding SDS sample buffer without
reducing agent. All sample was subjected to boil for 5 minutes and loaded (1.5µg/lane) on
gel. The gel was run for 3 hours at 80V in a running buffer (25 mM Tris (pH 8.3), 192 mM
glycine, and 0.1% SDS). The gels after the run were stained in R-250 stain (0.1%
Coomassie Blue R250, 50% methanol, 10% glacial acetic acid) overnight and destained in
fast and slow destaining solution. Finally, the image was captured using an Epson Scan.
3. Field Emission Scanning Electron Microscopy
The morphology of the aggregates was studied using Hitachi S-4700 field-emiss io n
scanning electron microscope (FESEM). For FSEM imaging protein (1µM) was incubated
in buffer (30mM HEPES buffer pH 7.2 + 150mM NaCl) for 0h, 1h, 6h and 48h at 370C
under reducing environment i.e. at different concentration of TCEP (0,1mM and 10mM).
After the incubation, samples were washed using Millipore Amicon Ultra centrifugal filters
(3000 Da – 5000 Da cut off) to remove the impurities. The samples were allowed to dry at
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room temperature after aliquoting on Scanning electron microscope (SEM) stubs. The
samples were coated with platinum on the SEM stubs at a thickness of 10nm using a sputter
coater. Finally, the samples were imaged at the acceleration voltage of 5kV52 .
3.3 Results:
We expressed and purified TDP-43 protein using the eukaryotic baculovirus expression
system. Among the different insect cell lines like Sf21, High-five and Sf9, we choose Highfive cells because of its well-known expression of the secreted protein. As compared to
Sf9, it expresses 5-10-fold higher secreted proteins. As shown in figure 6, we purchased
different constructs of TDP-43 from Addgene. These constructs were 28206 consisting of
full- length gene (1-414 amino acid residues and 1245 bp), 28207 which does not contain
the N-terminal region of TDP-43 and consist of 86-414 amino acid residues and code for
996bp of TDP-43. 29209 is the region without the C-terminal domain and consist of 1-314
amino acid residues and codes for 948bp and lastly 28198 is the region containing glycine
rich domain and C-terminal domain i.e. from 257-414 amino acid residues coding 471bp.
The constructs thus obtained were confirmed by Polymerase Chain reaction (PCR) using
the specific primers that were designed to subclone into insect expression vector. As shown
in Figure 5, we did observe the gene inserts at the designated bp. In this study we choose
to use insect expression vector, pFastBac/HBM-TOPO (Figure 6). This is due to the fact
that it has eukaryotic expression system, Honey bee mellitus secretory signal, polyhedrin
promoter (PPH) and 6XHis-tag at the C-terminal. This vector matched our focus of study,
we aimed to express our protein in eukaryotic system with secreted overexpression and
purify

our protein

through

affinity

chromatography.
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The positive

recombina nt

pFastBac/HBM-TOPO constructs were transformed into DH10Bac E.coli cells for
transposition into the bacmid DNA. The transformation procedure was followed as per the
Invitrogen user manual (Invitrogen, part# A11341) on Bac-to-Bac HBM-TOPO secreted
expression system. Further, the positive bacmids were isolated using PureLink HiPure
Plasmid DNA Miniprep Kit (Invitrogen) for high quality bacmid DNA. The bacmid DNA
concentration was estimated by UV absorbance at 260 nm using Epoch Take3 microvolume plate (Bio-Tek Instruments, Inc.) and stored in aliquots at -20 °C to avoid freezethaw cycles. The recombinant Baculovirus was generated by transfecting the recombina nt
bacmid DNA into sf21 cells using the transfection reagent Cellfectin II (Invitrogen). The
supernatant containing the virus particles was stored at 4 °C and cell pellet at -20 °C. The
outline for generation of recombinant bacmid followed by production of recombina nt
Baculovirus is represented in Figure 6.

Figure 6: Different constructs of TDP-43 and vector used for sub-cloning. The differe nt
constructs of TDP-43 namely 28206 (1-414 amino acid residues), 28207(86-414 amino
acid residues), 29209 (1-314 amino acid residues) 28198 (257-414 amino acid residues)
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were purchased from Addgene and pFastBac/HBM-TOPO insect expression vector was
used for sub-cloning of these constructs.

Figure 7: Verification of TDP-43 constructs obtained from addgene by PCR. Lane M:
Marker, lane 1: TDP43-28206 (insert size 1245 bp), lane 2: TDP43-28207 (996 bp), lane
3: TDP43-28209 (948 bp) and lane 4: TDP43-28198 (471 bp). (The cloning work was
carried out by Dr. Ashutosh Tiwari and Dr. Jagadeesh Janjanam and the figure is placed
with their permission).
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Figure 8: Schematic representation for the production of recombinant Baculovirus (with
TDP-43 genes) using sf-21 insect cells (source Invitrogen user manual, part # A11341).
Cellular localization of recombinant TDP-43 protein in insect cell was confirmed by
immunocytostaining. For this purpose, we used High-five cells and proceeded as described
in material and method section for immunocytostaining. As previously stated, high- five
cells are well known for more secretory protein production when compared to Sf9 and even
Sf21 cells

56 . As

shown in figure 9 and 10, we did not observe any signal for Control cells

i.e. High-five cells without any viral stock under GFP channel using both antibodies
specific to N- and C-terminal. However, our immunocytostaining data for High-five cells
using anti-TDP-43 antibodies specific to N-terminal (Figure 10) or C-terminal (Figure 9)
sequences shows that the protein is stuck in the membrane than being a secreted in a media
which can be seen under GFP channel.
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Figure 9: Immuncytostaining of high-five cells after infecting with TDP-43 viral stock.
The recombinant expression of TDP-43 was detected using anti-TDP-43 antibodies
specific to C-terminal
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Figure 10: Immuncytostaining of high-five cells after infecting with TDP-43 viral stock.
The recombinant expression of TDP-43 was detected using anti-TDP-43 antibodies
specific to N-term antibodies.
Purification of protein was most challenging and we employed different combination of
techniques to purify our protein. Among these methods, we applied different percentage of
ammonium sulfate, detergent, and denaturing agents. Specific details on use of differe nt
purification techniques and data are provided in supporting information for chapter 3. First,
I will discuss the results for purification of full- length TDP-43 protein. Before proceeding
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to the purification step, it is important to check the expression level of protein to verify if
our protein of interest is expressed or not. For that we checked each batch of our harvested
cell pellets before carrying out the purification. This was accomplished by cell lysis
followed by protein estimation by BCA assay and running different concentration of
lysates in gel and carrying out western blot using anti-TDP-43 antibodies. As represented
in figure S1, control/uninfected cell (Φ) and infected cell (I) lysates were loaded at differe nt
concentration (5, 10, 20 and 30 µg/lane) in SDS PAGE and Western blot. As shown in
figure S1, the western blot data showed the presence of protein band (~50 kDa) only in
infected cell lysate but not for control lane at all concentrations loaded. The SDS PAGE
showed the multiple bands at all concentration but represents the identical loading for
control and infected cell lysates. Further, SDS-PAGE confirms the need of further
purification.
Next, we proceeded to enrichment of protein by using ammonium sulfate. As represented
in the flow chart figure S2, different percentage of ammonium sulfate was added to protein.
We used 30% , 50% and 70% saturated ammonium sulfate solutions. As presented in
figures S3-S4, we observed band for TDP-43 protein in Western blot for lysates
supernatant (S) or pellet (P) fractions represented as S0 (total lysate after lysis) ,S30 (lysate
after 30% ammonium sulfate precipitation) and P0 (pellet after cell lysis), and P30 (pellet
after 30% ammonium sulfate precipitation). Only a faint band was observed for P50 and
no band was observed for S50, S70 and P70. Ni-NTA purifications of P30 fraction showed
band for TDP-43 eluted in different fractions but was not a clean single band as observed
by SDS-PAGE (Figure S5-S6). In addition, significant amount of protein was also
observed in bound flow through and wash flow through obtained from column. Analyzing
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the results from ammonium sulfate precipitation, the protein did not completely precipitate
in different percentage of ammonium sulfate solutions as shown by presence of protein in
S0, S30, and P30.
Our next step was solubilizing the protein using detergent. For that purpose, we used SDS.
The SDS PAGE and Western blot data for detergent soluble fraction (Figure S14)
represented the band for TDP-43 full length protein in western blot but not in SDS-PAGE.
The higher amount of protein was observed with increasing concentration but some
additional faint bands were also observed with increasing protein concentration. We saved
the detergent insoluble fraction and ran them on gel loading different volumes (1, 4, 6, 10,
14, 16 and 20ul) represented as DI2, DI4, DI6, DI10, DI14, DI 16, DI20 and ran detergent
soluble 10µg/lane for comparison of band with detergent insoluble fraction (Figure S10).
We observed the thick band for our protein of interest ~50kDa for all volumes loaded in
SDS-PAGE but there were several other bands observed. Also, the thickness of band
observed for DI2 was corresponding with detergent soluble loaded 10µg/lane. We observed
that our protein band is present but contains impurities and most of the protein is in
detergent insoluble fraction.
After several rounds of trials and errors, we came up with the procedure that uses
combination of salt, detergent and denaturant for solubilizing protein and purifying it to
homogeneity. Using urea buffer combination helped us to purify protein with >95% purity
(figure 11). The purity of protein in each step during this procedure is shown in Figure S11.
As shown in figure, the control lysate , infected cell lysate , RIPA re-extracted fraction did
not show any band in western blot. However, a clear band is observed for urea soluble and
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NI-NTA purified fraction. Also, the SDS-PAGE corresponds the purified protein in Gel
and Western blot. A clear depiction of urea soluble and purified protein is shown in figure
11. Since, the same concentration of protein was loaded in gel and western blot i.e. infected
lysate (10µg/lane), urea soluble fraction (5 µg/lane), Purified protein (2 µg/lane), the level
and purity of protein is clearly detected. A significant amount of protein is seen in urea
soluble fraction, but some impurities was observed but after NI-NTA chromatography, the
eluted protein was found to be highly pure.

Figure 11: Reducing SDS PAGE and Western blot showing the purification of TDP-43
full length protein. Lane 1(infected lysate, 10µg/lane), Lane 2 (urea soluble fraction, 5
µg/lane), Lane 3 (Purified protein, 2 µg/lane) was loaded on 12% SDS PAGE. The gels
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were run for 3 hours. For Western blot, the blot was incubated with Anti-TDP-43 (Nterminal region) produced antibody (1:4000) and Goat anti-rabbit IgG-HRP (1:10000).
Aggregation of TDP-43 full- length protein was observed using FESEM. We did not
observe any aggregates for TDP-43 full length protein fresh samples suggesting the protein
is soluble. However, the aggregates were observed after 1 h of incubation for all samples
incubated in presence and absence of TCEP and same phenomenon was observed for 6h
and 48h of incubation (Figure 12). The shape of aggregates were different in presence and
absence of TCEP but all were amorphous in nature. Increasing the concentration of TCEP
from 1mM to 10mM also resulted into amorphous aggregates (Figure S11-S14).

Figure 12: FESEM images of TDP-43 full-length aggregates in presence and absence of
TCEP. TDP-43 protein (1µM) was incubated in presence or absence of TCEP (0,1mM) for
0,1, 6 and 48h at 370 C. Protein aggregates were observed under FESEM. Zoomed in image
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for the area in the box is represented on its side. Scale bar =10µM and 1µM from left to
right.
In order to investigate the status of disulfide bond in TDP-43 full- length protein, we first
ran the protein samples under reduced and non-reduced conditions. Our data showed
almost similar pattern in 12% SDS Gel for TDP-43 full- length protein (Figure 14). Since,
we did not observe any difference in mobility and shape of protein, we need to investigate
further to understand the disulfide status of the protein.

Figure 13: Amino acid sequence of TDP-43 full- length (1-414) protein representing acidic,
basic, aromatic, polar uncharged, non-polar aliphatic groups and cysteine residues. Six
cysteine residues are located in TDP-43 at the positions 39, 50, 173, 175, 198 and 244.
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Figure 14: SDS PAGE showing TDP-43 reduced and non-reduced samples. Reduced
sample (R) was treated with 5% beta-mercaptoethanol and non-reduced sample (NR) was
treated with Iodoacetamide. Protein was loaded 1.5 µg/each lane and run on a 12% SDSPAGE for 3 hours.
Purification of C-terminal construct (28198) was carried out in a way similar to as
described for full- length protein. Like, full- length protein, majority of protein was present
in the insoluble fraction after lysis so we solubilized protein in urea buffer before purifying
on a Ni-NTA chromatography column (Figure S15-S16).
3.4 Discussion :
Expression and purification of protein is routinely employed in lab procedure to study its
biophysical, molecular and physicochemical properties. However, identifying the proper
method of purification yielding pure protein of interest is very challenging. In our study,
we employed different combination of methods to purify TDP-43 protein. Among these
methods, we employed different percentage of ammonium sulfate, detergent, and
chaotropic agents. Several studies on truncated forms of TDP-43 protein have been
reported. However, information on biochemical and biophysical properties of full- le ngth
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protein is limited due to its difficulty in expression and purification. Furthermore, studies
reported are from proteins from prokaryotic source. To investigate the full- length protein
and characterize its physicochemical properties along with other constructs of TDP-43, we
used pFastBac/HBM-TOPO vector for subcloning (Figure 4), a eukaryotic vector.
pFastBac/HBM-TOPO vector has many features including a secreted protein expression
signal (HBM) and a 6X His-tag. This can facilitate protein purification using Ni-NTA
affinity chromatography. However, in our case the purification needed several intermed iate
steps before purification on an affinity column. Confirmation of the constructs were
performed through PCR and subcloning and viral amplification were carried out using the
established protocol from Invitrogen. For production of viral stock, we used Sf21 cells
because they are well suited for transfection, plaque purification, generating high-titer
stocks, plaque formation, and expression of recombinant proteins. After generating the
viral stock, it’s important to test the cellular localization of protein. As shown in figure 3,
we used high-five cells for testing the cellular localization and production of our
recombinant protein. Incubation of cells with either N or C-terminal antibodies resulted in
signal in GFP channel and no signal in control cells. Immunocytostaining confirmed the
cellular expression of our protein upto 72h of post-infection of viral stock. However, we
did not observe the secreted expression of protein. Instead of protein being released in the
media, protein was stuck in the membrane. We employed different methods to purify the
TDP-43 full length protein to get greater than 95% purity. Before applying any purifica tio n
technique, it’s very important to confirm the expression of the protein. For that purpose,
we also tested each batch of our harvested cell pellet for its expression of TDP-43 protein
and confirmed by Western blot. Presence of protein band only in infected cell lysate and
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absence in control lysate confirms our protein expression (Figure S1). After confirming the
expression of protein, the bulk lysis as well as purification procedure was carried out.
We first chose to enrich our protein using ammonium sulfate for precipitation by saltingout. Precipitation of protein does not mean its denaturation, it’s the condition of reduced
solubility which is also related to the enhancement of protein native form stability.
Ammonium sulfate is most commonly used salt in the enrichment of protein because of its
high solubility in water and ability to salt-out some proteins preferentially. Therefore,
initially we also employed the enrichment of TDP-43 protein using saturated solution of
ammonium sulfate. As shown in figures S2-S7, different percentage of saturated
ammonium sulfate solution was used, and protein mostly remained in pellet fraction at 30%
ammonium sulfate concentration or higher. Affinity chromatography of pellet fraction
yielded the bands on western blot but could not resolve the clear bands on the SDS-PAGE.
Detergents are the molecules carrying the amphipathic properties and can disrupt or form
the hydrophobic–hydrophilic interactions among molecules. Detergents are used in
research especially in biological samples for various purposes like cell lysis for the release
of soluble proteins, lipids and membrane proteins solubilization, prevents nonspecific
binding in affinity purification as well as in immunoassay, additives in electrophoresis. We
also used SDS, anionic detergent to solubilize our full- length protein as our protein was
stuck in the membrane. SDS-PAGE and Western blot data showed the protein fraction
present in higher amount in insoluble fraction compared to the soluble fraction. (Figure S8S9). After several trials, we developed a purification strategy for full- length TDP-43
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protein using a combination of salt, denaturant, detergent, and affinity chromatography to
get >95% pure protein.
Urea is the chaotropic agent which is most commonly used in solubilization as well as
denaturation of proteins. Apart from this urea is used for protein renaturation that has been
denatured using 6M guanidine hydrochloride53-55 . Since, most of our protein was present
in pellet fraction after lysis in RIPA buffer, we used combination of buffer containing urea,
thiourea and CHAPS to solubilize our protein present in pellet. Using this method, we were
able to achieve >95% purity which we confirmed by gel and Western blot. (Figure 11)
Protein aggregation is well studied topic. Next, question in the field of TDP-43 is
understanding the nature of aggregated form of TDP-43 protein. Different studies carried
out by different groups reported on the aggregates of TDP-43 protein (Figure 4). Some
studies support the nature of aggregates to be amorphous while other supports the
aggregates to be amyloid in nature56-59 . Since, we do not have clear picture regarding the
disulfide status of the protein, we wanted to understand if full- length TDP-43 protein forms
aggregates under disulfide reducing environment or not. The interesting of all is the studies
reported are on the different truncated constructs of the protein and is carried out using
prokaryotic source. Aggregation of TDP-43 full- length protein carried out in bacteria
shows the amorphous nature. Therefore, we studied the aggregation of TDP-43 by
subjecting it to different concentration of reducing agent and incubation time and observing
the aggregates under microscope. Our finding suggests the TDP-43 forms aggregates under
disulfide reducing environment and the nature of TDP-43 full- length aggregates are
amorphous. Also, our fresh protein did not form any aggregates in absence and presence
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of 1mM TCEP up to 1 h, suggesting our protein is soluble and stable and does not form
aggregate under its normal condition.
TDP-43 has six cysteine residues located at position 38, 49, 172, 174, 197 and 243 (Figure
10). The possibility of formation of disulfide linked TDP-43 dimers and oligomers in vivo
was reported in the study conducted by Zhang et.al. (2011). However, it was suggested that
formation of aggregates does not require such modification. However, the exact disulfide
status of TDP-43 has not been reported yet. It is not clear that how many disulfide bonds
are there in TDP-43 protein. Disulfide bond is present in most of the proteins and it ensures
the correct folding of protein under native conditions. Disulfide bonds occupy 15% of the
human proteome and are present mainly in secreted protein where it makes up to 65%.
Next to peptide bond, the common covalent link between the amino acids in the protein is
the disulfide bond. Disulfide bonds are known to decrease the entropy of the unfolded state
thereby stabilizes the protein thermodynamically. The presence of disulfide bonds are
found in 55% of the pathologic amyloid forming proteins providing the information about
the importance of disulfide bonds in the aggregation kinetics as well as its role in the
toxicity and structure of aggregates. For the proper folding of protein into its native
structures, many proteins require the correct formation of disulfide bonds. Protein
misfolding results when there is abnormal reduction/formation of disulfide bonds.
Disulfide bonds are involved in proteins involved in neurodegeneration. Until date, the role
of disulfide bonds have been studied and found to be important in three proteins involved
in neurodegeneration: prion, SOD1 and Tau. The folding/misfolding pathway can thus be
traced by determining the thiol-disulfide status in the protein. For example, the
folding/misfolding is regulated by thiol-disulfide status in case of SOD1 (Cu, Zn99

superoxide dismutase). The stabilization of matured SOD1 is achieved by the formation of
intramolecular disulfide bonds whereas the reduction of these disulfide bonds leads to the
misfolding and aggregation of SOD1 due to a decrease in conformational stability of a
protein. Therefore, the disulfide bonds play important role in familial form of amyotrophic
lateral sclerosis (fALS)60-63 . In order to understand the disulfide status of TDP-43, we ran
the samples under reduced and non-reduced conditions (Figure 14). The mobility of
proteins under two conditions showed no major variation suggesting us need of further
confirmation.
To compare the characteristics of TDP-43 we next purified C-terminal domain of TDP-43
using the same protocol used for full- length protein (Figure S15-S16). Purifying more of
protein will help to compare the properties of full- length protein with most aggregatio n
prone domain of TDP-43. C-terminal region is the most studied domain of TDP-43 and
much of mutations known are found in this domain. Having this region for comparison will
help us to compare the findings reported in prokaryotic system with our eukaryotic source
and report any variations if present.
3.5 Conclusion:
In summary, this study describes the standardized protocol for expression and purifica tio n
of TDP-43 full- length protein using eukaryotic source. The result shows the purity of
protein >95% as confirmed by gel and Western blot. Further, the nature of aggregates of
full- length proteins were confirmed under reducing environment and were found to be
amorphous in nature. Apart from full-length protein our purification protocol is applicable
to intrinsically disordered portion of this protein, i.e. C-terminal region.
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4.1 Introduction
Protein misfolding and aggregation leads to several neurodegenerative diseases among
which Alzheimer’s disease (AD) is the sixth leading cause of death in U.S. with estimate
of 5.8 million Americans living with the disease in 2019. Alzheimer’s is a progressive
neurodegenerative disease leading to behavioral and cognitive disorder in the elderly1 , and
is characterized by the presence of senile plaques and neurofibrillary tangles. Senile plaque
constitutes mainly of beta amyloid peptide and neurofibrillary tangles is composed of
microtubule associated protein known as Tau 2 . The peptide of Amyloid β vary in length
from 39-43 amino acids. In normal individual, Aβ40 is the major form of Aβ produced and
only 5-15% of total Aβ is comprised of Aβ42. Though Aβ40 is present in higher
concentration in cerebrospinal fluid (CSF) compared to Aβ42, the amyloid plaques from
Aβ42 constitutes the major component in AD brains.
The extracellular amyloid plaques recognized as one of the major hallmark of the disease,
have been reported for variability of toxicity for different structures of Aβ aggregates

3-8.

However, the relationship between different aggregated structures of Aβ peptides and its
associated toxicity is not well understood. This is further underscored by the failure of AD
treatment based on Aβ aggregates as these treatments targeted mature amyloid fibril forms
but failed to target highly transient and dynamic Aβ species that are naturally formed in
the brain

5, 9, 10 .

Post-translational modification is well known for its role in protein folding and
aggregation. Likewise, while considering the in vivo “pool” of Aβ, post-translatio n
modified forms of Aβ are present besides Aβ peptides of different lengths7 . Different post110

translational modifications

(PTMs) such as phosphorylation

isomerization17,18 , and pyroglutamate formation

16,19 , were found

11-13 ,

truncation

14-16

to play role in Aβ peptide

structure and aggregation propensity. In a recent study, protein PTM level were found to
increase roughly two-fold in AD samples compared to normal controls, especially in Aβ
and tau enriched area21 . Among the various post-translational modifications in proteins,
acetylation is one of the major PTM that plays a vital role in health and diseases. Some
major role in health includes DNA repair, protein structure, signaling, and protein selfassembly and is also involved in diseases like cancer and neurodegenerative diseases

21-28.

Interestingly, among all the identified PTM types in AD brains, acetylation only affects ~
10% of the total modified peptides but showed the highest increase level in Aβ- and Taucontaining aggregates

20 .

Acetylation of Tau has already been identified and is proposed

for new therapeutic targets for AD.29-31 However, acetylation on Aβ peptide has not been
investigated in detail. The Aβ peptide has two potential acetylation sites, lysine 16 (K16)
and lysine 28 (K28) (Figure 1A); the effect of K28 acetylation has been investigated,
though K16 residue as an acetylation site was often ignored. Lysine 28 was recognized as
a key player during Aβ fibril formation as it forms a salt bridge with A42 in Aβ42 fibrils
32 , or

with D23 in Aβ40 fibrils

33 , to

stabilize the β-sheet structure.

We notice that a systematic study investigating the impact of acetylation of potential
acetylation sites of Aβ on protein aggregation and the effect of aggregates on biologica l
health has not yet been reported. This is important because many common drugs and
metabolites were recently found to be able to facilitate protein acetylation21,34 . In this study,
synthesized Aβ42 peptides were modified with single acetylation on K16 (K16Ac), K28
(K28Ac), or were double acetylated on both Lysine residues (KKAc) (Figure 1 B–E). The
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fibril formation was simulated via assembly of 9 strands of Aβ42 peptides. The effect of
WT acetylated and 1:1 mixture peptides on cellular heath was measured using cell viability,
cytotoxicity and free radical formation assays. Surprisingly, we found that side-chain
acetylation of K16 can profoundly impair the fibrillization property of Aβ42 peptide and
significantly affects the toxicity, which could account for the modulation of Aβ42
pathogenicity.

Figure 1. (A) Sequence of Aβ42 peptide (PDB entry: 1Z0Q

33 ). Atomic

structures of (B)

WT, (C) K16Ac, (D) K28Ac, and (E) KKAc monomer. The two acetylated positions, K16
and K28, are highlighted in ball and stick.
4.2 Methods
Preparation of amyloid β peptide samples – Peptides: Synthetic wild-type (WT), K16Ac,
K28Ac and KKAc were purchased from Biomatik (Canada). All the peptides were
confirmed for their identity and purity (>95%) by mass spectrometry and RP-HPLC. The
peptides were dissolved as per the methods reported by Roychaudhuri et. al.36 In brief, the
lyophilized peptide was first dissolved in 10% (v/v) of 60 mM NaOH, followed by 45%
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(v/v) MilliQ water. The pH was adjusted by adding 45% (v/v) of 10 mM sodium phosphate
buffer (pH 7.4). Then the centrifugation was carried out at 16,000 × g at 4 °C for 10
minutes. The supernatant fluid thus obtained was filtered through 0.22 μm membrane.
Concentration of peptide stock was determined using ε214 = 75,887 M-1 cm-1 and BCA
Assay. For experiments, 50 µM peptide was mixed with 50 mM phosphate buffer, 300
mM NaCl, pH 7.4 and were incubated at 37 °C with agitation for indicated time. All buffers,
salts and MilliQ water were filtered through 0.22 μm membrane. The peptide stocks were
stored at -800 C.
Fluorescence measurements – All fluorescence measurements were carried out at the final
concentration of 10µM in 10mM phosphate buffer, pH 7.4. Stocks of fluorescent probes 8anilino-1-naphthalene

sulfonic

acid (ANS), and 4,4'-dianilino-1,1'-binaphthyl-5,5'-

disulfonic acid (bis-ANS) were prepared in ethanol and then added to samples to final
concentrations of 10 μM (ANS), and 1 μM (bis-ANS). Emission spectra were collected
using a Horiba Jobin Yvon spectrofluorometer (Fluoromax-4) at room temperature. For
samples with ANS and bis-ANS, spectra were acquired from 400 – 700 nm, with excitatio n
at 380 nm and 360 nm, respectively.
Field emission scanning electron microscopy (FESEM) – Fibrils and aggregates of peptides
were analyzed using a cold field emission high-resolution scanning electron microscope,
Hitachi S-4700 FESEM. After incubation,

fibrils or aggregates were pelleted by

centrifuging at 9,000 × g for 45 min at 25 °C. To wash off salts, the pellets were suspended
in MilliQ water (0.22 μm membrane filtered) and centrifuged at 9,000 × g for 45 min at 25
°C. Washed fibrils or aggregates were applied on SEM stubs and air dried at room
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temperature. The SEM samples were then coated with 10 nm platinum. For FESEM
imaging, 10 kV of acceleration voltage and 5 μA of emission current were used.
Cell viability (MTS) assay – SH-SY5Y human neuroblastoma cells (both from ATCC) were
cultured in Medium 199 and DMEM/F-12 medium, respectively, with 10% FBS and 100
U/ml penicillin-streptomycin at 37 o C in 5% CO2 humidified environment and used within
the first 10 passages. Cells were plated at 2 × 104 cells/well (SH-SY5Y) on 96-well plates
and allowed to grow overnight. The next day, cells were washed with 1X PBS buffer (pH
7.4) twice. Then 100 μl fresh media containing peptide samples were added. Six replicates
were prepared per sample. Media without any peptide were used as controls. After 48 h
incubation, 20 μl of CellTiter 96® AQueous One Solution Cell Proliferation (MTS) Assay
kit (Promega) were added and incubated for 4 h. Absorption at 490 nm were collected using
an ELISA plate reader (BioTek Instruments, Inc.). Blanks containing media and peptide
samples but no cells were similarly prepared and used for background subtraction.
Cytotoxicity (LDH) assay – SH-SY5Y human neuroblastoma cells (from ATCC) were
cultured as described above and plated at 2 × 104 cells/well on 96-well plates and allowed
to grow overnight. The next day, cells were washed with 1X PBS buffer (pH 7.4) twice.
Then 100 μl of fresh media containing peptide samples were added. Six replicates were
prepared per sample. After 48 h incubation, 10 μl of lysis solution (CytoTox 96® NonRadioactive Cytotoxicity Assay (LDH) Assay kit, Promega) was added to maximum LDH
release control wells and incubated for 45 minutes at 37 °C in 5% CO 2 . 50µl of supernatant
from all the wells were transferred into a new plate and to each of those wells 50µl of LDH
reagent was added.

The plate was further incubated in dark for 30 minutes. After
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incubation, 50µl of stop solution was added to each well. Absorption at 490 nm were
collected using a plate reader (BioTek Instruments, Inc.). Appropriate blanks containing
media and peptide samples (without cells) were similarly prepared and used for
background subtraction. Max LDH Control was represented as 100% cytotoxic and all
samples were normalized to Max LDH Control

37 .

Primary hippocampal neuronal cells

were prepared as described in the immunostaining protocol (below). The LDH assay was
carried out for neuronal cells as described for SH-SY5Y cells above with the following
variations. Neuronal cells were plated at 1× 104 cells/well in 96-well plate. And the cells
were incubated with 2 µM of peptides in 100 µL of media for 24 h.
2',7'-dichlorofluorescin diacetate (DCFH-DA) fluorescence assay – SH-SY5Y human
neuroblastoma cells (from ATCC) were cultured and were plated at 2 × 104 cells/well on
96-well plates and allowed to grow overnight. The next day, cells were washed with 1X
PBS buffer (pH 7.4) twice. Then, cells were incubated with 20 µM DCFH-DA for 45
minutes at 37 °C in dark. After incubation, the cells were washed twice with 1X PBS (pH
7.4) and then 100µl of fresh media containing peptide samples were added to DCFH-DA
(Sigma) treated cells in five replicates and incubated for 24 h at 37 °C in 5% CO2
humidified environment. Cells without any treatment and blanks were also incubated under
identical condition. For positive control, cells after DCFH-DA treatment were incubated
with 50 µM of t-butyl-hydroperoxide (tBHP) for 4 h at 37 °C. Finally, the fluoresce nce
intensity was measured using fluorescence plater reader (Fluoroskan Ascent, Thermo
Scientific) at excitation wavelength of 485 nm and emission wavelength of 538 nm. All
data were normalized to tBHP wherein tBHP treated cells were represented as 100% free
radical generating

38 .

DCFH-DA assay for primary hippocampal neuronal cells was same
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as that detailed for SH-SY5Y cells above with the following variations. Neuronal cells
were plated at 1× 104 cells/well in 96-well plate. And the cells were incubated with 2 µM
of peptides in 100 µL of media for 24 h.
Immunostaining of primary hippocampal neuronal cells – Sprague Dawley rats were
purchased from Charles River Laboratories (Wilmington, MA, USA) and used in our
breeding colony to generate1-day-old pups which were euthanized via overdose of
pentobarbital. Hippocampus and cortex from 1-day old rats were dissected, combined
and neuron cells dissociated as detailed previously

39. Cells

were plated in poly-L-Lysine

coated 24 well plates at the seeding density of 5X104 cells/well and incubated at
neurobasal medium containing B27 supplement (Thermo Fisher Scientific) in 370C
incubator. Culture medium was changed every 3 days and the cells were allowed to grow
for 10~14 days prior to their use in experiment. During the experiment, 500 µl of fresh
media containing 2 µM of 7 d Aβ42 peptide aggregates (WT and acetylated) were added
to neuronal cells and incubated for 24h at 370 C incubator. Control cells did not have any
peptides added to them but were incubated similarly. After 24h, the cells were washed
twice with PBS. Then cells were fixed with 4% paraformaldehyde for 10 minutes at room
temperature. Cells were then washed with PBS three times for 5 minutes each. Blocking
solution (5% horse serum and 0.3% Triton X-100 in PBS) was added to each well and
incubated for 1 hour. After one hour, cells were incubated overnight at 40 C in a cocktail
consisting of 1:200 dilution of mouse anti-tau antibody (Invitrogen, catalog# AHB0042)
and 1:100 dilution of rabbit anti-β-tubulin antibody (Cell Signaling Technology,
Catalog# 15115S). Afterwards, cells were washed in PBS thrice for 5 minutes and
incubated overnight at 40 C in a mixture of secondary antibodies (Alexa Fluor 594
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donkey anti-mouse IgG and Alexa Fluor 488 donkey anti-rabbit IgG, both in 1:300
dilution). The sections were mounted in Vectashield (Vector Labs, Burlingame, CA) and
images were taken with a Leica fluorescence microscope (LEICA DM IL LED) at 20X
and were analyzed using Image J software

40 ,41

Statistical analysis – Statistical analysis was performed using one-way ANOVA and posthoc t-test. The p values < 0.05 were considered as significant and are represented *,
p<0.005 represented as ** and p<0.0005 represented as ***.
Computational methods – To construct the acetylated (K16Ac, K28Ac and KKAc)
peptides, we started with the WT Aβ42 monomer as shown in Figure 1B (PDB entry:
1Z0Q). The NH3 +-group of Lysine 16 and Lysine 28 residues of Aβ42 monomer was
modified by substituting with an acetyl-group in the side-chain. Likewise, initia l
configurations of 9-strand aggregates of Aβ42 fibrils (WT and acetylated) were constructed
by aligning the individual Aβ42 monomers parallel to one other, avoiding any close
contacts or atomic clashes during the assembly. The Aβ42 monomers and fibril structures
were initially placed in an periodic orthorhombic box and solvated with water molecules
defined using the TIP3P model 38 . The H-atoms of water molecules were constrained using
the SETTLE algorithm

39 and

counter ions were added to maintain overall charge neutrality

of the system. The details of system size are provided in Supplementary Information, Table
2.
Atomistic MD simulations of WT and acetylated Aβ42 peptides were performed in the
isothermal-isobaric (NPT) ensemble using NAMD program and CHARMM27 force field.
The simulation temperature (310 K) and pressure (101.3 kPa) was maintained using the
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Langevin dynamics and Langevin piston Nose-Hoover method

40 .

The long-range

electrostatic interactions were calculated using the particle mesh Ewald method with a
cutoff of 12.0 Å 41 . For each system, we performed energy minimization for 2000 steps at
a time step of 1.0 fs using the conjugate gradient method, followed by 100 ns of production
run at a time-step of 1 fs. We performed a total of 800 ns runs for all systems and each
simulation run was repeated for reproducibility of the results. Simulation snapshots
corresponding to structural changes, and convergence of MD simulation trajectory was
analyzed using the backbone root-mean-square deviation (RMSD) for the peptides using
VMD 1.9.2. program

42 .

The surface hydrophobic patches for 9 strands of WT and

acetylated (K16Ac, K28Ac, and KKAc) Aβ42 peptides in aqueous solution were analyzed
using the SPDB software.
4.3 Results
Physicochemical characterization of Aβ peptides aggregation
The fibrillization/aggregation properties of WT Aβ, acetylated peptides and 1:1 mixture
ratios was already monitored by ThT fluorescence and reported in Dissertation work of
Yang. M (2016). Based on the findings WT, K28Ac and WT:K28Ac followed the sigmo ida l
fluorescence trend whereas K16Ac and K28Ac showed non-sigmoidal Tht fluoresce nce
trend. Further to verify the aggregates, FESEM was carried out for 7d incubated samples .
In line with the previously reported data for Tht and FESEM, the new batch of peptides
displayed similar morphology for 7d incubated samples (Figure 2). The WT, K28Ac and
WT:KKAc was able to form fibril like structures upon incubation for 7 days while K16Ac,
KKAc and 1:1 mixture of both with WT remained amorphous even after incubation for 7
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days (Figure 2). All peptides of Aβ remained amorphous in nature upto 72h incubatio n
(Supplementary information 1).
Next, we determined the structure flexibility of WT, acetylated and 1:1 mixture of Aβ
peptides by using the structure sensitive probe bis-ANS. We found that K16Ac and KKAc
have flexible structure compared to other peptides. Among all peptides K16Ac showed the
most structure flexibility while KKAc aggregates are more denser compared to K16Ac
(Figure 3). Furthermore, the mixtures of single and double acetylated peptides with WT
Aβ42 peptide (1:1 ratio) formed more rigid amorphous aggregates with fluorescence signal
comparable to WT Aβ42 aggregates than those formed by pure K16Ac peptides (Figure 3).

Figure 2. The morphology of the 7d incubated WT, acetylated and 1:1 mixtures confir med
by SEM. WT, K28Ac and WT:K28Ac forms fibrils while K16Ac, KKAc, WT:K16Ac and
WT:KKAc remains amorphous in nature under 7d incubation. Scale bar = 5 µm, 1 µm and
500 nm from left to right, respectively.
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Figure 3: Structure flexibility of the fresh Aβ42 peptides and their aggregates were
measured by Bis-ANS fluorescence by incubating 10 μM of peptide samples with 1μM of
Bis-ANS and measuring peak intensities at 484 nm. Mixture represents the 1:1 ratio of the
acetylated peptides with WT Aβ42 peptides. Error bars = ± S.D, (n=3) (* represents
significant differences (p < 0.05).
Molecular aggregation dynamics and surface properties of Aβ peptides
To gain atomistic insights into the conformation changes, aggregation dynamics, and map
the folding pathways of Aβ42 peptides

43-49 ,

we performed molecular dynamics (MD)

simulations of WT and acetylated Aβ42 monomers along with 9 strand aggregates of all
four peptides (WT, K16Ac, K28Ac, and KKAc) in aqueous solution using NAMD program
50

and CHARMM27 force field

51 . Note that

aggregation of 9 strands of WT and acetylated

peptides were considered as replica models for simulating the formation of fibril- like
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structures. Supplementary Figure 2 A–D displays the structural changes in WT and
acetylated Aβ42 monomer in aqueous solution at time=0 and100 ns. WT Aβ42 is mostly
α-helical at residues 11–23 and 29–37, which agrees well with previously reported results
based on the discrete MD simulation method

52 .

In our case of atomistic MD study, the

flexible regions are the first 10 amino acids of N-terminus, residues 38–42 of C-terminus
that adopt a random coil structure, and the β-turn region between residues 24–28
(Supplementary Figure 3A). Snapshots of WT and acetylated peptide aggregates at time =
0 and 100 ns elucidate that the nature of fibrillization is distinctive of the modificatio ns :
K16Ac and KKAc assemble into an amorphous structure while K28Ac retains a fibril- like
structure similar to WT peptides (Figure 2). MD simulation snapshots (Supplementar y
Figure 6) of K16Ac at 100 ns affirm the formation of amorphous aggregate as seen in SEM
micrographs (Figure 2). A comparison of the orientation of K16 and K28 residues in
acetylated aggregates suggests that in the former structure, K16Ac residues are somewhat
embedded within the aggregate, stabilized by inter-chain hydrophobic interactions while
in the latter, K28Ac residues project outwards with reduced inter-chain interactio ns
(Supplementary Figure 4). Both MD simulation and experimental results thus find that
K16Ac presents a flexible structure with loss of α-helicity and acetylation significa ntly
impacts aggregation dynamics and impedes fibril formation. Root mean square deviation
(RMSD) analysis was performed for the simulations of each system (Supplementary Figure
9). RMSD of WT and acetylated peptides increases in the first 20 ns and then reaches a
plateau, suggesting an overall stability of the system. A slightly higher RMSD of K16Ac
correlate to the molecular flexibility and observed conformational transition to an
amorphous structure.
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Figure 4. Simulation snapshots depicting the structural changes in aggregation of 9 strands
of WT and acetylated (K16Ac, K28Ac and KKAc) Aβ42 peptides in aqueous solution. For
each structure, the predicted hydrophobic patches (yellow) were mapped on the molecular
surface (violet) using SPDB software. (A) WT, (B) K16Ac, (C) K28 Ac and (D) KKAc
aggregates. The waters molecules are not shown for clarity. (The computational work was
conducted by Professor Ravindra Pandey and Dr. Nabanita Saikia . The figure 3 is added
with their permission).
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Hydrophobic patches on a protein surface identify accessible regions of neighboring apolar
atoms that may play a crucial role in protein folding, structural dynamics, and proteinligand interactions

53 .

Surface hydrophobicity of WT and acetylated peptide aggregates

were analyzed for 100 ns structures (Figure 4). Note that acetylation of the positive ly
charged K16 and K28 lysine residues into hydrophobic moiety destabilizes fibril formatio n
with an overall increase in the surface area (Supplementary Table 1). Interestingly, the
surface area of KKAc is intermediate to K16Ac and K28Ac with relatively scattered
hydrophobic patches on the molecular surface. K16Ac has the highest surface area and
consequently exhibits a greater flexibility to adopt an amorphous structure. WT Aβ42
peptides have one patch above 300 Å2 and 9 patches between 100–300 Å2 (Supplementar y
Table 1). Acetylation leads to loss of the dominant patch above 300 Å2 followed by
decreases in size of the hydrophobic patches but increases the number of patches on the
molecular surface. For acetylated peptides, the hydrophobic patches range between 100–
300 Å2 . These findings are consistent with bis-ANS fluorescence data (Figure 3) that shows
increased fluorescence for 7 d aggregates of K16Ac peptides compared to WT Aβ42
peptides.
Surface hydrophobicity of Aβ peptides
Surface hydrophobicity of the peptides and aggregates were also measured by ANS
fluorescence (Figure 5). All three fresh acetylated peptides showed ANS fluoresce nce
similar to WT Aβ42 peptides. Interestingly, after 3 days of incubation, ANS fluoresce nce
of WT Aβ42 peptides increased significantly compared to acetylated peptides and then
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decreased upon longer incubation of 7 d to levels comparable to fresh WT Aβ42 peptides
(Figure 5). Differences in hydrophobicity among the four peptides were amplified after 7
days of incubation, and was extremely significant for K16Ac peptides that almost doubled
(Figure 5). Seven day incubated K28Ac Aβ42 peptides showed fluorescence signal that
were significant and KKAc aggregates showed signal that were highly significa nt
compared to WT peptides (Figure 5). In addition, for 7 day’s samples incubated as mixture,
the aggregates showed slightly less hydrophobicity compared to pure K16Ac and KKAc
peptides but signals were significant compared to pure WT Aβ42 aggregates (Figure 5).

Figure 5. Hydrophobicity of fresh Aβ42 peptides and their aggregates measured by ANS
fluorescence by incubating 10 μM of peptide samples with 10 μM of ANS and measuring
peak intensities at 485 nm. Mixture represents the 1:1 ratio of the acetylated peptides with
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WT Aβ42 peptides. Error bars = ± S.D. (n = 3). *, **, and *** represents significa nt
differences (* = p < 0.05), (** = p < 0.005), and (*** = p < 0.0005).
Cellular toxicity of Aβ peptides.
In addition to measuring the morphology, surface hydrophobicity and structure flexibility
of Aβ42 WT, acetylated and 1:1 mixture, we investigated the effect of these aggregates on
biological health of the cells. For this purpose, we tested the effect of two differe nt
concentration of peptide samples (2 and 5µM) on SHSY-5Y neuroblastoma cells health
(Supplementary Figure 12 and Figure 6) and 2 µM Aβ42 peptides on primary neuronal
cells from rat (Figure 7). Based on the previous work reported by Yang, M et.al. (2016) on
Tht fluorescence response of these peptides at different time points, we choose to carry out
all cellular experiments at three different time points (Fresh, 72h and 7d). We monitored
the effect of Aβ42 fibrils and aggregates on cell viability of SH-SY5Y neuroblastoma cells
by MTS assay (Figure 6A and Supplementary Figure 11). The data shows that WT and
single acetylated peptides slightly decrease SH-SY5Y cell viability but 7 d aggregates of
KKAc peptides or 1:1 mixture of WT: K16Ac, and WT: K28Ac inhibit cell growth
significantly (Figure 6A). And the 1:1 mixture of WT: KKAc peptides inhibit cell growth
significantly more than KKAc peptides alone (Figure 6A).
Oxidative stress has been implicated in several neurodegenerative diseases includ ing
Alzheimer’s disease

54-60 . Therefore,

we wanted to measure effect of 5 μM of Aβ42 peptides

(fresh as well as aggregates) on generation of reactive oxygen species (ROS) in cells. We
used 2’,7’-dichlorofluorescein diacetate (DCFH-DA) as a fluorescent probe to measure
125

levels of ROS in cells (Figure 6B)

36 .

Compared to untreated cells the cells treated with

WT Aβ42 peptides showed significant increase in ROS production in cells. The 7 d
aggregated acetylated peptides K16Ac, K28Ac, and KKAc peptides showed much higher
production of ROS in cells (Figure 6B). Interestingly, the 1:1 mixture of WT and all
acetylated Aβ42 peptides also showed much higher production of ROS compared to the
pure peptides aggregates with WT:KKAc peptide aggregates showing the highest ROS
production (Figure 6B). To better understand the implication of Aβ42 peptides aggregates
on ROS production and hence cell health, we also measured toxicity of these peptides by
lactate dehydrogenase (LDH) cytotoxicity assay (Figure 6C) 35 . The aggregates from pure
WT Aβ42, K16Ac, and K28Ac peptides and equimolar mixture with WT (1:1) all show
highly significant increase in toxicity for SH-SY5Y cells for 7 d aggregates consistent with
increased ROS production (Figure 6B, C). Interestingly, among the group double
acetylated peptides (KKAc) aggregates showed the highest toxicity (Figure 6C).
Equimolar mixtures (1:1) of WT and KKAc 7 d Aβ42 peptides aggregates showed much
higher increase in ROS production compared to pure KKAc (Figure 6B). However, the
mixtures observed cytotoxicity was comparable to pure KKAc aggregates (Figure 6C).
This maybe because both aggregates (pure KKAc and 1:1 mixture of WT:KKAc) are
extremely toxic and values are close to Max LDH value which is the positive control
(Figure 6C).
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Figure 6. The effect of 5µM fresh Aβ42 peptides and their aggregates on SH-SY5Y
neuroblastoma cells health were measured by (A) MTS assay, (B) DCFH-DA assay, and
(C) LDH assay. The fresh peptides, 72 h, or 7 d aggregates were added to the cells to a final
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concentration of 5 μM. Cells were incubated for 48 h in presence of peptides for MTS and
LDH assay and for 24 h for DCFH-DA assay. For t-butyl-hydroperoxide (tBHP) control
for DCFH-DA assay, cells were incubated with 50 µM of tBHP for 4 h at 37 o C. The
mixtures represent samples containing equimolar (1:1) WT and acetylated peptides. Error
bars = ± S.D. (for A n = 6; for B n = 5; and for C n = 5). *, **, and *** represents significa nt
differences (* = p < 0.05), (** = p < 0.005), and (*** = p < 0.0005).
To further validate results on SH-SY5Y neuroblastoma cells, we carried out toxicity and
ROS studies on primary neuronal cells from rat (Figure 7). Since 5 µM of peptides was
extremely toxic to SH-SY5Y neuroblastoma cells we used a lower concentration of
peptides (2 µM) to evaluate cytotoxicity and ROS production for primary neuronal cells.
We incubated neuronal cells with 2 µM of WT and acetylated Aβ42 peptides for 24 h before
the assay. Compared to the untreated neuronal cells, cells treated with 7 d aggregates of
WT Aβ42 peptides and K28Ac peptides show a highly significant increase in ROS
formation (Figure 7A). Cells treated with 7 d aggregates from K16Ac, KKAc, and
equimolar mixtures (1:1) of WT and acetylated Aβ42 peptides showed much higher
increase in ROS production (Figure 7A). Consistent with increased ROS production, all
neuronal cells treated with 2 µM WT and acetylated Aβ42 peptides and their (1:1) mixtures
showed an extremely significant increase in cytotoxicity as measured by LDH assay
(Figure 7B). The double acetylated Aβ42 peptides (KKAc) showed the highest increase in
cytotoxicity as well as ROS production (Figure 7).
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Figure 7. The effect of 2µM fresh Aβ42 peptides and their aggregates on primary neuronal
cells health were measured by (A) DCFH-DA assay, and (B) LDH assay. The fresh
peptides, 72 h, or 7 d aggregates were added to the cells to a final concentration of 2 μM.
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Cells were incubated for 24 h in presence of peptides for both assays. For t-butylhydroperoxide (tBHP) control for DCFH-DA assay, cells were incubated with 50 µM of
tBHP for 4 h at 37 o C. The mixtures represent samples containing equimolar (1:1) WT and
acetylated peptides. Error bars = ± S.D. (for A n = 5; and for B n = 4). *, **, and ***
represents significant differences (* = p < 0.05), (** = p < 0.005), and (*** = p < 0.0005).
Immunostaining of primary neuronal cells treated with WT and acetylated Aβ42 peptides.
In order to visualize the effect of WT and acetylated Aβ42 peptides on primary neuronal
cells, we carried out immunostaining of cells after treating them with 2 µM of 7 d Aβ42
peptides aggregates for 24 h (Figure 8). We chose 2 µM peptides concentration based on
our ROS and LDH cytotoxicity assay for neuronal cells (Figure 7). We compared the
morphology of neuronal cells treated with Aβ42 peptides for 24 h to control cells (untreated
cells) that were similarly incubated by immunofluorescence microscopy (Figure 8). We
used anti-tubulin antibody (green) to image tubulin protein and anti-Tau antibody (red) to
image Tau protein in cells. The control cells (untreated primary neuronal cells) show a
normal morphology with Tau signal that is diffused and evenly distributed in neurons (both
soma and neurites) (Figure 8). The neuronal cells treated with 2 µM of WT, K16Ac, and
KKAc Aβ42 peptides for 24 h showed a significantly higher immunofluorescence signal
for Tau in soma of neurons compared to neurites (Figure 8, Supplementary Figure 15). Cell
bodies of primary neurons showed the highest Tau signal for cells treated with KKAc
peptides, high Tau signal for cells treated with WT and K16Ac peptides, and a much lower
Tau signal for cells treated with K28Ac peptides (Figure 8). These findings are consistent
with the ROS production and cytotoxicity data reported for these cells (Figure 8).
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Figure 8. Immunostaining of primary neuronal cells. Primary neuronal cells were
incubated with 2 µM of 7 d incubated Aβ42 WT and acetylated peptides for 24 h at 37 0 C.
Control indicates cells that are untreated and incubated under identical conditions with
which Aβ42 treated cells were compared. The cells were fixed and then stained for
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immunofluorescence with antibodies for tubulin (green) and Tau (red). The images were
acquired using Leica DMIL LED at 20X magnification. Scale bar =50 µm.
4.4 Discussion
Scientific literature suggests that formation of highly ordered amyloid fibril or less ordered
oligomer structures could be an outcome of the competition between hydrogen bonding
and hydrophobic interactions, as the higher ordered structures are usually stabilized by high
density of direct inter-chain hydrogen bonds and steric zipper interactions

61,62.

Furthermore, amyloid fibril dynamics could be affected by the chemical nature of the Aβ
peptide through side-chain interactions and/or post-translation modifications

63 . In

theory,

introducing an acetyl moiety to a lysine residue removes a charge and hence can increase
surface hydrophobicity of the peptide. Interestingly, in this study we showed that
acetylation of lysine 16 and 28 on Aβ42 does not affect protein aggregation the same way;
K16 acetylation affects the aggregation morphology as well as kinetics very severely.
We found that the K16Ac peptide is much more hydrophobic with a higher structure
flexibility than WT and other two acetylated peptides (Figures 3, 5). The structural changes
on Aβ42 monomer in aqueous solution (Supplementary Figure 2) agree well with a
previously reported results based on the discrete MD simulation method

52 . Acetylation

of

Aβ42 monomer at K16 leads to one extra β-turn between residues 14-17 (Supplementar y
Figure 3B) but acetylation at K28 retains a structure very similar to WT (Supplementar y
Figure 3C and A). In addition, acetylation of Aβ42 at K16 and K28 residues on KKAC
introduces a pleated region between residues 31-37 with loss in α-helix (Supplementar y
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Figure 3D). In agreement with our MD results, a rapid aggregation kinetics with no lag
time was reported in a simulation study of Aβ16-22 fragment, where the Aβ16-22
oligomers were disordered molten globular structures due to strong hydrophobic
interactions

61 , since

K16 located in the central hydrophobic core, L17-F20, and the 16-20

residues (KLVFF) acts as a docking motif of Aβ fibrillation

33 . This

fact is also supported

by our MD simulations of 9 strands K16Ac aggregates, where the K16Ac residues are
embedded inside the aggregate structure, stabilized by the inter-chain hydrophobic
intercalations (Supplementary Figure 4). Aβ fibril grows in two distinct steps: a rapid and
reversible “dock” phase, followed by a slow but irreversible “lock” phase

64 .

In case of

K16Ac peptide aggregation as observed in the current study, it is possible that the interchain hydrophobic interactions of the 16-20 region are enhanced after removal of the
positive charge on K16 (Figure 9). This may result in initial rapid docking process that
becomes irreversible and as a consequence kinetically inhibits the conformatio na l
reorganization in the locking phase. Even if the formation of amyloid fibrils is
thermodynamically favored, the transition from monomers to amyloid conformations is
kinetically limited

65 .

The other lysine residue, K28, is known to form important salt bridges in Aβ fibrils

30,31.

Removing the positive charge on K28 by acetylation results in K28Ac peptide having
longer lag time than WT Aβ42 during fibril formation. This is consistent with the
stabilizing role of K28 salt bridge on the amyloid fibrils

66 . However,

the K28Ac peptides

were capable of forming amyloid structures upon longer incubation, either as pure K28Ac
peptide sample, or in a heterogeneous equimolar mixture with WT Aβ42 (Figure 2),
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suggesting K28 salt bridge may not play a role in the conformational transition from Aβ42
monomers to mature amyloids. This finding is also supported by a previously study of Nε-amino acetylation on K28 of Aβ25-35 fragment, where the gross structure of Aβ2535_K28Ac fibril were very similar to WT Aβ25-35 fibrils

67 .

In this study we identified two major forms of aggregated structures: amorphous and
fibrillar, from WT, acetylated Aβ42 peptides and their mixtures. The aggregates from these
7 different Aβ42 peptides (WT, K16Ac, K28Ac, KKAc, and 1:1 mixtures of WT:K16Ac,
WT:K28Ac, and WT:KKAc) can be further categorized

based on their unique

physicochemical properties as measured by fluorescent dyes, cell viability,

ROS

production, and their associated cytotoxicity (Table 1). WT Aβ42 peptides 7 d aggregates
show well organized fibrillar structure that has low flexibility, moderate ROS production,
and high toxicity at 5µM concentrations (Figures 2, 3, 6B, C). K28Ac peptides aggregates
form fibrils that are similar to the WT peptides but show high ROS production with high
toxicity (Figures 2, 3; 6B, C). K16Ac peptides form aggregates that are amorphous, highly
hydrophobic, and flexible (Figure 2, 3, 5). In addition, these aggregates also show
cytotoxicity that is slightly higher than WT or K28Ac peptide with high ROS production
(Figure 6B, C). In case of neuronal cells, 7 d aggregates of 2 µM WT Aβ42 peptides and
K28Ac show moderate ROS production but high cytotoxicity (Figure 7). In comparison,
K16Ac peptides show much higher ROS production as well as cytotoxicity (Figure 7).
Interestingly, 7 d aggregates from KKAc peptides that are amorphous in nature show
significantly higher ROS production as well as cytotoxicity for SH-SY5Y as well as
primary neuronal cells (Figures 6B, C, 7). Furthermore, the 1:1 mixtures of WT peptides
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with K16Ac, K28Ac, and KKAc, although have variable structural morphology, all show
very high ROS production and cytotoxicity (Figures 2; 6B, C, 7), with WT: KKAc mixture
showing the highest ROS production as well as cytotoxicity (Figure 6B, C). In addition,
the KKAc peptides (pure or 1:1 mixture with WT Aβ42 peptides) inhibit cell growth
significantly (Figure 6A). The increased oxidative stress has been considered very
important for pathogenesis in Alzheimer’s disease as it can lead to oxidation of proteins,
lipid peroxidation, free radical generation, mitochondrial dysfunction, and synaptic
dysfunction

68 . And

neurons are particular sensitive to ROS, which serves as source of

oxidative stresses and results in damages in the brain

60,69,70.

Table 1. Comparison of unique physicochemical properties of WT and acetylated Aβ42
peptides and their mixtures for 7 d aggregates.

Aβ42
peptides

WT

Flexibilit
y

Structure
type

Hydroph
obicity

(SEM)

(ANS)

(BisANS)

Fibril

+

+

Cytotoxi
city

ROS
production

(LDH)

(DCF-HDA)

No
significant
inhibition

+++

++

+++

+++

Cell viability
(MTS)

K16Ac

Amorphou
s

++++

+++

No
significant
inhibition

K28Ac

Fibril

++

+

No
significant
inhibition

+++

+++

KKAc

Amorphou
s

++

Significant
Inhibition
++

++++

++++

+++
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WT +
K16Ac
(1:1)
WT + K28
Ac (1:1)
WT +
KKAc
(1:1)

Amorphou
s

++

+

Significant
Inhibition +

+++

+++

Fibril

++

+

Significant
Inhibition +

+++

+++

Amorphou
s

++

+

Significant
Inhibition
+++

++++

++++

Number of + indicates proportional levels: (+) = low; (++) = moderate; (+++) = high;
(++++) = highest among the group.
To visualize the effect of aggregated peptides we treated neuronal cells from rat with 2 µM
of 7 d Aβ42 peptides aggregates for 24 h (Figure 8). The neuronal cells treated with Aβ42
peptides for 24 h, all show a significantly higher immunofluorescence signal for Tau in
soma of neurons compared to neurites (Figure 8, Supplementary Figure 15). This is
consistent with other literature reports where a direct relationship between amyloid β
oligomers leading to altered Tau protein biochemistry that may result in Tau that maybe
fragmented, soluble, with/without requiring hyperphosphorylation and maybe toxic71-75
1278.full;. Therefore, to better understand the oligomeric nature of 7 d Aβ42 peptides
aggregates we analyzed by SDS-PAGE (Supplementary Figure 16). The 7 d peptides
samples were run on a 15% SDS-gel and electrophoretically separated under fully
denaturing conditions. These peptides largely separated in two groups, monomers and large
higher molecular weight species with some oligomeric species seen for different Aβ42
peptides as smear (Supplementary Figure 16). Although these 7 d Aβ42 peptides aggregates
136

have distinct structural morphology as seen by SEM (Figure 2), on SDS-PAGE these
largely show presence of monomeric and high molecular weight SDS-resistant species with
some low molecular weight oligomeric species (Supplementary Figure 16). It is possible
that cytotoxic effect of these peptides maybe mediated due to aberrant hydrophobic
interaction directly or through Tau76,77 71,73,78-80 .
Consistent with ROS production and cytotoxicity data of primary neuronal cells (Figure
7), immunostaining data showed significantly higher immunofluorescence signal for Tau
in soma of neurons compared to neurites with the highest Tau signal for cells treated with
KKAc peptides (Figure 8, Supplementary Figure 15). This is also consistent with other
animal/cell model studies where increased cross talk between Aβ and Tau has been reported
with Aβ exerting its toxicity via Tau that maybe fragmented, become oligome r ic,
with/without hyperphosphorylation and impact synaptotoxicity

74,75,81-84.

Our data shows

that the Aβ42 peptides aggregates lead to increased Tau signal in soma of neuronal cells
compared to control cells (Figure 8).
Although both K16Ac and KKAc aggregates are amorphous, the K16Ac aggregates are
bead-like structures that are slightly more hydrophobic and flexible compared to KKAc
(Figures 2, 3; 5). Both of these peptides 7 d aggregates show high toxicity but the difference
in ROS production of these two peptides may be related to their subtle structure variatio ns
(Table 1)78 . This is consistent with recently reported literature findings where the toxicity
of misfolded proteins was determined by both size and surface hydrophobicity of the
molecule23 . As large assemblies have lower surface hydrophobicity/volume ratios, they
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have lower diffusional mobility and lower potential to interact with cell membrane and
receptors23 .
An alternative hypothesis suggests that the cytotoxicity may be related to the aggregatio n
process that is dynamic, rather than a single structural species 9,88 . Minor shifts in the Aβ40:
Aβ42 ratio was demonstrated to be enough to modulate neurotoxicity

89 .

The non-toxic

K16N mutation of Aβ42 exhibits severe toxicity when mixed with WT peptides91 . Here in
this study, the aggregates formed from heterogeneous mixtures of WT and acetylated
peptides all showed increased ROS production and toxicity compared to homogeneo us
samples of WT and K28Ac (Figures 6B, C, 7). Therefore, in addition to the structural
characteristics, the dynamic interactions of different species contribute significantly to
aggregation related toxicity.

Figure 8. Suggested schematic model for WT and acetylation modified Aβ42 peptides
aggregation and cytotoxicity. WT Aβ42 and K28Ac peptides show a lag and log phase of
aggregation kinetics and form ordered aggregates with large surface hydrophobic patches
(yellow) that can assemble as amyloid fibrils and have moderate toxicity. Peptides
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acetylated at K16 (K16Ac or double acetylated KKAc) show rapid aggregation kinetics
and form disordered, amorphous, and flexible aggregates that have higher surface
hydrophobicity and high toxicity.
4.5 Conclusion
In this study, we focused on understanding how acetylation of Aβ42 peptides (K16Ac,
K28Ac, and KKAc) impacts its physicochemical properties and modulates its toxicity. For
comparison WT Aβ42 and 1:1 mixture of acetylated peptides with WT were also studied.
As, acetylation plays an important role in protein folding and aggregation, understanding
the effect of acetylation on Aβ42 peptides biophysical properties and biological health is
critical to understanding its role in the disease process. Our study shows that although the
structural morphology of peptides (WT, K16Ac, and KKAc) are different, all show
increased cytotoxicity and ROS production. Compared to WT and K28Ac, all other
peptides (K16Ac, KKAc, and 1:1 mixture of acetylated Aβ with WT peptides) showed
much higher increase in ROS production as well as cytotoxicity. Furthermore, the increased
Tau signal in soma of neurons compared to control cells when treated with Aβ42 peptides
aggregates suggests a dynamic interaction between Tau and Aβ42 peptides . Overall, the
data suggests that in addition to the structural characteristics, the dynamic interactions of
different Aβ species may contribute significantly to toxicity directly or through cross-talk
with other proteins such as Tau.
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Chapter 5: Summary and Future Perspective
Protein folding, misfolding, and aggregation are at the core of proteinopathies and have
been studied

extensively.

How protein aggregates

morphology

and its unique

physicochemical properties are linked to cellular toxicity is still a subject of intense debate.
There are substantial number of published studies that have focused on fibrillar structure
of proteins, with very few studies exploring the role of amorphous protein aggregate
structures in the disease process. In this dissertation, we focused on two proteins that are
very important from a neurodegenerative perspective: 1) Role of acetylation of amyloid β
42 on cytotoxicity and 2) Expression, purification, and characterization of Tar-DNA
binding protein 43 (TDP-43) from a eukaryotic source. Both of these studies are very
important as role of amyloid β in Alzheimer’s toxicity has long been known but still the
toxic form/fold of Aβ is not well understood. Moreover, role posttranslational modifica tio n
such as acetylation may play in the disease process is still not very well understood and is
a topic of intense debate. For the TDP43 project, the importance of this protein has been
shown for several neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s
disease and the literature is filled with biochemical and biophysical characterization from
prokaryotic sources with very little work done using proteins from eukaryotic source.
Therefore, in this dissertation I tried to shed light on the role, acetylation of Aβ42 (K16Ac,
K28Ac, and KKAc) have on amyloid β toxicity, and also expressed and purified TDP43
protein from insect cells (eukaryotic source) and studied their basic biochemical and
biophysical properties.
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We chose to investigate the effect acetylation of Aβ peptide have on modulating cellular
toxicity, as these have major implication for pathogenesis in Alzheimer’s disease. Analys is
of physicochemical properties of acetylated peptides showed that amorphous structures
play a critical role in proteins physicochemical properties and its associated toxicity. This
work underscores the importance of posttranslational modification such as acetylation of
Aβ peptides on toxicity as well as aggregate morphology (e.g. K16Ac has amorphous
structure) which will lead to better drug designs in future.
Next, we standardized the procedure for purification of TDP-43 protein, now known to be
involved in several neurodegenerative diseases like ALS, FTLD, Alzheimer’s, Lewy body,
and Huntington. Even though, several elegant research studies have been conducted on this
protein using prokaryotic proteins, a method for purifying full- length protein using a
eukaryotic expression system is lacking. Furthermore, purification of full- length protein is
challenging as its overexpression leads to aggregation. And for the same reasons, detailed
biochemical and biophysical studies on full- length protein from eukaryotic source and its
associated toxicity are lacking. We have standardized the procedure for purifying fulllength TDP-43 protein using a eukaryotic expression system that is rigorous but
reproducible. Furthermore, we investigated the morphology of TDP-43 protein aggregates
under disulfide reducing and non-reducing conditions and found these form amorphous
structures. This opens-up possibility of future studies on exploring the role sulfhydryl status
of the protein plays in the toxicity of these proteins and hence the disease process.
TDP-43 has six sulfhydryl residues (Cys) which opens up the possibility of disulfide bond
formation that maybe inter-chain or intra-chain. Our initial experiment on TDP-43 full155

length protein using mal-PEG (5KDa) shows some shift in the band of proteins suggesting
susceptibility of TDP-43 to disulfide reducing agent. How these Cys residues may play a
role in aggregation and cellular toxicity needs to be explored further keeping in view the
redox status of cells and how this equilibrium can shift under cellular stress.
There has been a renewed interest in determining the toxic fold of a protein to better
understand its role in protein misfolding, aggregation, and its toxicity. This is where having
aggregates that are well characterized from a eukaryotic source for TDP-43 protein will be
of great interest to researchers trying to understand role of TDP-43 protein in the disease
process. This is because a protein from eukaryotic source will have all natural
posttranslational modification that are expected in the mature protein. While, studies on
TDP-43 proteins from bacterial source have contributed significantly to scientific
literature, it may still miss out some key findings that may be linked to its natural
posttranslational modifications. In addition, a methodical study exploring morphology and
physicochemical properties of TDP-43 full- length aggregates under reducing and nonreducing cellular environment are lacking. Hence, we made an attempt to study the nature
of aggregates of TDP-43 at physiological temperature in presence and absence of reducing
agent like TCEP. Our results show that TDP-43 full length protein forms amorphous
aggregates. These aggregates need to be further explored to investigate their associated
toxicity using neuronal cell lines for biological relevance. These can be some of the same
assays as outlined in amyloid β toxicity chapter such as MTS, DCF-HDA, and LDH assay.
The future studies can explore two areas of research that are intricately related to my PhD
work: 1) Role of posttranslational modification such as acetylation, phosphorylation, in the
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disease process (stems from Aβ acetylation study), 2) Do TDP-43 protein from a eukaryotic
source may have some unique characteristics that the prokaryotic protein does not have.
Future studies on these can help better understand the toxic fold/nature of proteins and can
help shed light on the pathogenesis in the disease process. Eventually, these studies may
lead to development of better and more effective drugs.
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Appendix A Supporting Information for Chapter 3

Figure S1: Reducing SDS PAGE and Western blot showing the expression of TDP-43 full
length protein. M-Marker, Φ (Uninfected lysate), I (Infected lysate). Uninfected or infected
lysate was loaded 5 , 10 , 20 and 30 µg/lane represented as Φ5, Φ10, Φ20, Φ30 on 12%
SDS PAGE. The gels were run for 3 hours. For Western blot, the blot was incubated with
Anti-TDP-43 (N-terminal region) produced antibody (1:4000) and Goat anti-rabbit IgGHRP (1:10000).
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Ammonium sulfate precipitation:
Ammonium sulfate precipitation is one of the common method employed in purifica tio n
of a protein. It is based on the principle of salting out. Different percentage of saturated
ammonium sulfate solution was used for protein extraction. The schematic representation
for ammonium sulfate precipitation is shown below in figure S2. In brief, the cell pellets
were first lysed in lysis buffer and centrifuged at 20,000g for 1 hour at 40 C. The resultant
supernatant was then subjected to slow addition of ammonium sulfate to make it 30%
saturated. The saturated solution was subjected to centrifugation at 20,000g for 1 hour at
40 C. The supernatant obtained in this step was again subjected to ammonium sulfate to get
30% saturated solution. The resultant solution was then centrifuged at same speed, time
and temperature. The supernatant thus obtained from this step was again subjected to
ammonium sulfate to get 50% saturated solution. Then, after 70% saturated solution was
subjected to centrifugation at 20,000g for 1 hour at 40 C. The supernatant and pellet
obtained in each step was saved and tested in western blot. The procedure for SDS PAGE
and Western blot was followed similarly as explained in material and methods in Chapter
3. As shown in figure S3, the protein bands were observed in Supernatant obtained after
cell lysis and 30% ammonium sulfate precipitation represented by S0 and S30 respectively.
However, no clear bands were observed in supernatant obtained after 50 and 70% (S50 and
S70) ammonium sulfate precipitation. Similarly, the total pellet (P0) and pellet obtained
after 30% ammonium sulfate precipitation (P30) showed the significant amount of protein
and to some extent in pellet obtained after 50% ammonium sulfate precipitation (P50). But
no band was observed in pellet obtained after 70% ammonium sulfate precipitation (P70).
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Based on finding from western blot we decided to run the fractions S0, S30 and P30 in
SDS PAGE and Western blot . We used BCA assay to estimate the protein concentratio n
and ran 10µg/lane of each fraction for gel and western blot (Figure S4). As shown in figure
S4, we observed the protein bands at our desired molecular weight (~50kDa) in all three
samples but while comparing SDS PAGE we did not observe the concentrated band for
protein at 50KDa instead a smear/multiple bands were observed in all three samples
suggesting of protein mixtures.
Ammonium sulfate precipitation of lysates:
Pellets stored at -800 C

Resuspend in Lysis buffer (work on ice)

Homogenize using bead beater for 12 cycles

Centrifuge the lysates at 20,000g/maximum possible speed for 1 hour at 40 C

Save 200µl of
supernatant at
-200 C

Add (NH4 )2 SO4 to the
supernatant slowly to
make 30% saturated
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Dissolve pellet
in
20mM
phosphate
buffer and save
at -200 C

Centrifuge at 20,000g for 30 minutes at 40 C

Save 500µl of
supernatant at -200 C

Dissolve pellet
in
20mM
phosphate
buffer and save
at -200 C

Add (NH4 )2 SO4 to the
supernatant slowly to
make 50% saturated
saturatedsaturated

Centrifuge at 20,000g for 30 minutes at 40 C

Dissolve pellet in 20mM
phosphate buffer and save
at -200 C

Save 500µl of
supernatant at -200 C
Add (NH4 )2 SO4 to
the supernatant
slowly to make 70%
saturated

Centrifuge at 20,000g for 30 minutes at 40 C

Dissolve pellet in 20mM
phosphate buffer and
save at -200 C

Save 500µl of
supernatant at -200 C
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Note:
To each 500µl of supernatant saved after 30%, 50% and 70% saturation with (NH4 )2 SO4
carry out following protocol:
500 µl of supernatant

Dilute by 50% in autoclaved double distilled water

Concentrate using 5k cutoff Centricon

Add buffer

Concentrate using 5k centricon and make the volume around 200µl to 250µl. (Save at 200 C)

Perform Protein estimation of each fractions

Run the SDS- PAGE

Western blot
Figure S2: Schematic representation of Scheme for Ammonium Sulfate Precipitation
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Figure S3: Western blot of supernatant and pellet fractions obtained after differe nt
percentage of ammonium sulfate precipitation. The notation in the figure represents as
follows: M-Marker, S0- Supernatant obtained after cell lysis, S30, S50 and S70Supernatant obtained after 30, 50 and 70% ammonium sulfate precipitation and P0-pellet
obtained after cell lysis, P30, P50 and P70-Pellet obtained after 30, 50 and 70% ammonium
sulfate precipitation. The blot was incubated with primary antibody N-terminal TDP-43
(1:4000) and secondary antibody, Goat anti-rabbit IgG-HRP (1:10000)
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Figure S4: SDS Page and Western blot of S0, S30 and P30 fractions.
Next, we decided to proceed the NI-NTA purification using the pellet obtained after 30%
ammonium sulfate precipitation (P30). The pellet obtained was dissolved in phosphate
buffer and stored at -20o C. Then, on the day of purification, the pellet was diluted in
equilibration buffer (20mM sodium phosphate, 300mM NaCl (PBS) containing 10mM
imidazole, pH 7.4) and loaded on the packed Ni-NTA column. The bound flow through
was collected after loading the dissolved pellet on the column. The column was washed
with wash buffer (PBS with 25mM imidazole, pH 7.4) for 3-5 column volume and wash
flow through was collected to remove the unbound proteins. Finally, the elution fractions
were collected in microcentrifuge tubes using elution buffer (PBS containing 0.5M
imidazole, pH 7.4). After the column purification Western blot of elution fractions were
performed to determine the elution fractions containing the protein (Figure S5-S6). Figure
S5 represents the Ni-NTA carried out with only small portion of pellet. As shown in figure
S6, the elution fractions from tube number 1 to13 shows the presence of TDP-43 protein
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in good amount. However, a good amount of protein was obtained in bound flow through
and wash flow through.

Fig S5: Western blot result of P30 after Ni-NTA column (Carried out with larger
portion of pellet)
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Fig S6: SDS PAGE and Western blot results of Pellet and supernatant fractions of
total lysates after 20 and 50 % ammonium sulfate precipitation.
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Fig S7: Western blot results of P20 after Ni-NTA column. (TDP-43 full length)

SDS PAGE and Western blot results of detergent soluble fractions from total pellet
(P0).
After ammonium sulfate precipitation, we next tried to dissolve our protein using detergent
(0.5% SDS). For this purpose, to the pellet obtained after cell lysis phosphate buffer was
added and then 0.5% SDS was added. The pellet was allowed to incubate at 40 C for
overnight in a shaker. Next day, the soluble fraction was obtained by centrifugation and
protein estimation of detergent soluble fraction was carried out by BCA assay. The
insoluble fraction was dissolved in 20mM phosphate buffer and stored at -200 C. SDS
PAGE and western blot for detergent soluble and insoluble fractions were carried out using
same primary and secondary antibody used for N-terminal TDP-43. SDS-PAGE and
Western blot of soluble fraction was carried out at different concentrations (1, 2 , 5 and
10µg/lane). Applying this procedure, we could see the bands for TDP-43 with increasing
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concentration as loaded but some additional bands were observed at higher exposure of
blot in western blot imaging which is suggestive of some degraded products. Further, while
running SDS PAGE multiple bands were observed in 2, 5 and 10µg/lane loaded lanes
suggestive of protein mixtures. Also, no darker bands were observed towards our expected
molecular weight .
The schematic representation of procedure is shown below:
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Figure S8: Reducing SDS PAGE and Western blot showing the TDP-43 protein level in
detergent soluble fraction. Detergent soluble fraction (DS) was loaded at different volumes
1µg/lane, 2µg/lane, 5µg/lane and 10µg/lane represented as DS1, DS2, DS5 and DS10.

Figure S9: Reducing SDS PAGE showing the TDP-43 protein level in detergent insolub le
fraction. Detergent insoluble fraction (DI) was loaded at different volumes 1, 4, 6, 10, 14,
16 and 20ul, represented as DI2, DI4, DI6, DI10, DI14, DI 16, DI20 and detergent soluble
fraction loaded 10µg/lane represented as DS10.
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Figure S10: SDS-PAGE and Western blot showing the purification steps of TDP-43 full
length protein. Lane 1(Control lysate, 10µg/lane), Lane 2 (Infected lysate, 10µg/la ne),
Lane 3 (lysate re-extracted in RIPA buffer, 10µg/lane), Lane 4 (urea soluble fraction,
5µg/lane) and Lane 5 (Purified protein, 3µg/lane) was loaded on 12% SDS PAGE and run
for 3 hours. For Western blot, all samples were loaded 1/10th of the gel and incubated with
Anti-TDP-43 (N-terminal region) produced antibody (1:4000) and Goat anti-rabbit IgGHRP (1:10000).
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Figure S11: FESEM images of TDP-43 full- length aggregates in presence and absence of
TCEP. TDP-43 protein (1µM) was incubated in presence or absence of TCEP (0, 1 and
10mM) for 0h. Protein aggregates were observed under FESEM. Scale bar =10µm, 5µm,
and 1µm from left to right respectively.
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Figure S12: FESEM images of TDP-43 full- length aggregates in presence and absence of
TCEP. TDP-43 protein (1µM) was incubated in presence or absence of TCEP (0, 1 and
10mM) for 1h at 370 C. Protein aggregates were observed under FESEM. Scale bar =10µm,
5µm, and 1µm from left to right respectively.
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Figure S13: FESEM images of TDP-43 full- length aggregates in presence and absence of
TCEP. TDP-43 protein (1µM) was incubated in presence or absence of TCEP (0, 1 and
10mM) for 6h at 370 C. Protein aggregates were observed under FESEM. Scale bar =10µm,
5µm, and 1µm from left to right respectively.
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Figure S14: FESEM images of TDP-43 full- length aggregates in presence and absence of
TCEP. TDP-43 protein (1µM) was incubated in presence or absence of TCEP (0, 1 and
10mM) for 48h at 370 C. Protein aggregates were observed under FESEM. Scale bar
=10µm, 5µm, and 1µm from left to right respectively.
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Figure S15: Ni-NTA purification of TDP-43 C-terminal construct. Different elution
fraction after Ni-NTA purification was run on the 15% gel and western blot was developed
for it using primary and secondary antibody.
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Figure S16: Purification

TDP-43 C-terminal construct. TDP-43 construct 28198

containing glycine rich and c-terminal region was subjected to purification as shown in
schematic diagram on left and the urea soluble fraction (1) and concentrated Ni-NTA
purified sample (2) was loaded on the gel to maximum volume possible. 15% reducing gel
was run for SDS-PAGE and Western blot. For western blot, Anti-TDP-43 (C-terminal
region) produced antibody (1:1000) was used as primary antibody and Goat anti-rabbit IgG
–HRP (1:10000) was used as secondary antibody.
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Appendix B Supporting Information for chapter 4

Supplementary Figure 1. SEM images of the WT and acetylated Aβ42 aggregates after
72 h of incubation. Scale bars are 5 μm, 1 μm, and 500 nm from right to left respectively.
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Supplementary Figure 2. Simulation snapshots representing the structural changes in WT
and acetylated Aβ42 monomer at 100 ns in aqueous solution. (A) WT, (B) K16Ac, (C)
K28Ac and (D) KKAc. The waters molecules are not shown for clarity. The inset figure
highlights the α-helix, β-turn, and random coil regions in WT Aβ42 monomer.
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Supplementary Figure 3. The α-helix, β-turn, and random coil regions in Aβ42 monomer.
(A) WT, (B) K16Ac, (C) K28Ac and (D) KKAc.
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Supplementary Figure 4. Orientation of (A) K16Ac residues in 9 strands of K16Ac
peptides, and (B) K28 residues in 9 strands of K28Ac aggregates at 100 ns.
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Supplementary Figure 5. Simulation snapshots depicting the structural changes in
aggregation of 9 strands of WT Aβ42 peptides for 100 ns of dynamics. The waters
molecules are not shown for clarity.
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Supplementary Figure 6. Simulation snapshots depicting the structural changes in
aggregation of 9 strands of K16Ac peptides for 100 ns of dynamics. The waters molecules
are not shown for clarity.
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Supplementary Figure 7. Simulation snapshots depicting the structural changes in
aggregation of 9 strands of KKAc peptides for 100 ns of dynamics. The waters molecules
are not shown for clarity.
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Supplementary Figure 8. Simulation snapshots depicting the structural changes in
aggregation of 9 strands of K28Ac peptides for 100 ns of dynamics. The waters molecules
are not shown for clarity.
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Supplementary Figure 9. (A) Root mean-square deviation (RMSD) in 9 strands of WT,
K16Ac, K28Ac, and KKAc Aβ42 peptides in aqueous solution.
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Supplementary Figure 10. Hydrophobicity of fresh Aβ42 peptides and their aggregates
measured by ANS fluorescence by incubating 10 μM of peptide samples with 10 μM of
ANS and measuring peak intensities at 485 nm. Mixture represents the 1:1 ratio of the
acetylated peptides with WT Aβ42 peptides. Error bars = ± S.D. (n = 3). *, **, and ***
represents significant differences (* = p < 0.05), (** = p < 0.005), and (*** = p < 0.0005).
(+,#,* represents statistics for Fresh, 72h and 7d data respectively and significa nt
differences are set identical for all time points).
Note: Statistical analysis (one-way ANOVA) for 7d sample is included at the end of the
document. For Fresh and 72h sample statistical analysis as separate file is included.
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Supplementary Figure 11. Structure flexibility of the fibrils or aggregates was measured
by bis-ANS fluorescence by incubating 10 μM of peptide samples with 1 μM of bis-ANS
and measuring peak intensities at 484 nm. Error bars = ± S.D. (n = 3). +,#,* represents
statistics for Fresh, 72h and 7d data respectively and significant difference are set identica l
for all time points. +,* represents significant differences (p < 0.05).
Note: Statistical analysis (one-way ANOVA) for 7d sample is included at the end of the
document. For Fresh and 72h sample statistical analysis as separate file is included.
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A

The effects of 2 µM of WT and acetylated fresh Aβ42 peptides and their aggregates on
SH-SY5Y neuroblastoma cells health measured by MTS and DCF-HDA assay. Refer
next page for more details.
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C

Supplementary Figure 12. The effect of 2µM of WT and acetylated fresh Aβ42 peptides
and their aggregates on SH-SY5Y neuroblastoma cells health were measured by (A) MTS
assay, (B) DCFH-DA assay, and (C) LDH assay. The fresh peptides, 72 h, or 7 d aggregates
were added to the cells to a final concentration of 2 μM. Cells were incubated for 48 h in
presence of peptides for MTS and LDH assay and for 24 h for DCFH-DA assay. For tbutyl-hydroperoxide (tBHP) control for DCFH-DA assay, cells were incubated with 50 µM
of tBHP for 4 h at 37 o C. The mixtures represent samples containing equimolar (1:1) WT
and acetylated peptides. Error bars = ± S.D. (for A n = 6; for B n = 5; and for C n = 6). *,
**, and *** represents significant differences (* = p < 0.05), (** = p < 0.005), and (*** =
p < 0.0005). (+,#,* represents statistics for Fresh, 72h and 7d data respectively and
significant differences are set identical for all time points).
Note: Statistical analysis (one-way ANOVA) for 7d sample is included at the end of the
document. For Fresh and 72h sample statistical analysis as separate file is included.
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The effects of 5 µM of WT and acetylated fresh Aβ42 peptides and their aggregates on
SH-SY5Y neuroblastoma cells health measured by MTS and DCF-HDA assay. Refer
next page for more details.
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C

Supplementary Figure 13. The effect of 5 μM of WT and acetylated fresh Aβ42 peptides
and their aggregates on SH-SY5Y neuroblastoma cells health were measured by (A) MTS
assay, (B) DCFH-DA assay, and (C) LDH assay. The fresh peptides, 72 h, or 7 d aggregates
were added to the cells to a final concentration of 5 μM. Cells were incubated for 48 h in
presence of peptides for MTS and LDH assay and for 24 h for DCFH-DA assay. For tbutyl-hydroperoxide (tBHP) control for DCFH-DA assay, cells were incubated with 50 µM
of tBHP for 4 h at 37 o C. The mixtures represent samples containing equimolar (1:1) WT
and acetylated peptides. Error bars = ± S.D. (for A n = 6; for B n = 5; and for C n = 5). *,
**, and *** represents significant differences (* = p < 0.05), (** = p < 0.005), and (*** =
p < 0.0005). (+,#,* represents statistics for Fresh, 72h and 7d data respectively and
significant difference are set identical for all time points).
Note: Statistical analysis (one-way ANOVA) for 7d sample is included at the end of the
document. For Fresh and 72h sample statistical analysis as separate file is included.
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Supplementary Figure 14. The effect of 2 μM of WT and acetylated fresh Aβ42 peptides
and their aggregates on primary neuronal cells health were measured by (A) DCFH-DA
assay, and (B) LDH assay. The fresh peptides, 72 h, or 7 d aggregates were added to the
cells to a final concentration of 2 μM. Cells were incubated for 24 h in presence of peptides
for both assays. For t-butyl-hydroperoxide (tBHP) control for DCFH-DA assay, cells were
incubated with 50 µM of tBHP for 4 h at 37 o C. The mixtures represent samples containing
equimolar (1:1) WT and acetylated peptides. Error bars = ± S.D. (for A n = 5; for B n = 4).
*, **, and *** represents significant differences (* = p < 0.05), (** = p < 0.005), and (***
= p < 0.0005). (+, #, * represents statistics for Fresh, 72h and 7d data respectively and
significant difference are set identical for all time points).
Note: Statistical analysis (one-way ANOVA) for 7d sample is included at the end of the
document.
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Supplementary Figure 15. Immunostaining of primary neuronal cells from rat brain.
Primary neuronal cells were incubated with 2 µM of 7 d incubated Aβ42 WT and acetylated
peptides for 24 h at 37 0 C. Control indicates cells that are untreated and incubated under
identical conditions with which Aβ42 treated cells were compared. The cells were fixed
and then stained for immunofluorescence with antibodies for tubulin (green) and Tau (red).
The images were acquired using Leica DMIL LED at 20X magnification. Scale bar =50
µm (A). Zoomed in images of (A) are represented in (B) and are shown in boxes in panel
A. Scale bar for panel B=20 µm.
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Silver staining of Aβ WT and acetylated peptides
For silver staining 15% homemade SDS-PAGE was used and followed the manufacture r’s
instructions (ThermoScientific). In brief, the Aβ 7d incubated samples were mixed with 3X
sample loading buffer and boiled for 3-5 minutes. All samples were loaded at the final
concentration of 2µg/lane and ran for 3 hours at 80V. After the run, the gel was rinsed with
MilliQ water for 5 minutes with two repeats. All steps were carried out in shaker with
gentle agitation. The gel was fixed with fixing solution (30% Ethanol: 10% acetic acid) for
15 minutes and repeated for another 15 minutes followed by two washes in 10% Ethanol
at the interval of 5 minutes. Next, the gel was washed twice in MilliQ water for 5 minutes
and sensitized for 1 minutes with Silver stain sensitizer working solution. The gel was then
washed twice with MilliQ water for 1 minutes and incubated in Silver stain working
solution for 30 minutes. After the incubation, the gel was washed twice for 20 seconds and
the gel was developed by adding the Developer working solution. Once the desired band
intensity were observed the stop solution (5% Acetic acid) was added. The gel was further
incubated for 10 minutes in stop solution and the image was captured using Epson scanner.
The gel was quantified using the Image J software and the plot was plotted for the ratio of
High molecular weight vs monomer.
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Supplementary Figure 16. Silver staining of 7d incubated WT, acetylated, and mixture
of Aβ42 peptides. Samples were mixed with 3X sample loading buffer and boiled for 3-5
minutes. All samples were loaded 2µg/lane in 15% gel and ran for 3 hours at 80V. The gel
was then subjected to silver staining as per manufacturer’s instructions. * and ** represents
monomer and high molecular weight respectively. (←) represents the oligomeric species
of varying molecular weight (A). The gel was quantified using the Image J software and
the data was plotted as ratio of high molecular weight vs monomer (B).
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Supplementary Figure 17. Full-size gel image of silver staining of 7d incubated WT,
acetylated, and mixture of Aβ42 peptides. B- blank, M-Marker, * represents monomer and
** represents high molecular weight. (←) represents the oligomeric species of varying
molecular weight.
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was taken from the PDB entry 1Z0Q. For
MD simulations of WT and acetylated
(K16Ac, K28Ac, and KKAc) Aβ42
monomer, the peptide was first placed in a
periodic box having dimension of 61.90 ×
60.00 × 60.00 Å3 . The simulation box was
uniformly solvated with water molecules
with explicit waters defined using the
TIP3P water model. Counter ions were
added to the system to maintain charge
neutralization. The solvated peptide
system (WT and acetylated) was subjected
to 200 steps of the energy minimization at
a time step of 1 fs followed by 100 ns of
production run.

Supplementary Table 1. Calculated
surface area and hydrophobic patch values
of WT and acetylated (K16Ac, K28 Ac
and KKAc) aggregates obtained using
SPDB software.
Hydrophobic patch
2
values below 100 Å are not reported.
Parameters

WT

K16Ac

K28Ac

KKAc

Surface area
(Å2)

19199

20209

19703

19582

579

219

248

223

278

208

200

196

243

193

199

143

220

173

179

133

189

151

153

130

181

143

140

121

164

136

138

121

118

122

125

120

109

120

110

115

105

117

105

111

-

104

101

-

-

-

101

-

Hydrophobic
patch area
(Å2)

To
simulate
the
assembly
and
fibrillization process of 9 strands of WT
and acetylated Aβ42 peptide aggregates in
aqueous solution, initial structure was
taken to be the 9 monomer strands aligned.
The peptides were then placed in the
periodic box having dimension of 85.00 ×
80.00 × 85.00 Å3 and solvated with water
molecules with the TIP3P water model.
The total number of atoms and number of
water molecules for all systems are
provided in Table S2. Counterions were
added to maintain charge neutralization in
the system. The solvated peptides (WT
and acetylated) was subjected to 200 steps
of the energy minimization at a time step
of 1 fs followed by 100 ns of production
run.

Simulation systems.
Initial structural configuration of WT
Aβ42 monomer with sequence

All simulations were performed at 310 K
temperature and 101.3 kPa pressure in the
NPT ensemble using NAMD program and
CHARMM27
force field.
The

DAEFRHDSGYEVHHQKLVFFAEDV
GSNKGAIIGLMVGGVVIA
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peptides were computed using VMD
program. Surface hydrophobic patches of
WT
and
acetylated
peptides
corresponding to the structures at 100 ns,
were mapped on the molecular surface for
the 4 systems using the SPDB program.

experiments were performed at 310 K.
Data were saved every 20 ps intervals for
analysis of the structural changes for 100
ns of MD trajectory. Convergence of the
simulations was further confirmed using
the root mean-square deviation (RMSD)
analysis, implemented in VMD 1.9.2.
suite of program. In addition, electrostatic
potential isosurface for WT and acetylated
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Supplementary Table 2. Number of water molecules and total number of atoms in WT
and acetylated (K16Ac, K28Ac, and KKAc) Aβ42 monomer and peptide aggregates for
MD simulations in aqueous solution.

WT

K16Ac

K28Ac

KKAc

# total atoms

20868

21728

20873

20779

Aβ42

# water

20238

21093

20238

20139

monomer

molecules
627

631

631

635

3

4

4

5

# Aβ42
monomer
#
counterions

# total atoms
9 strands of # water
Aβ42
peptides

WT

K16Ac

K28Ac

KKAc

58893

49486

58770

58824

53222

43776

53055

53064

5643

5679

5679

5715

27

31

36

45

molecules
# Aβ42
monomer
#
counterions
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Statistical Analysis of 7d samples
One-way ANOVA was used for the statistics calculation of Fluorescence experime nts
(ANS, Bis-ANS) and toxicity assays (MTS, LDH, and DCF-HDA) carried out in SH-SY5Y
and primary neuronal cells. Statistics for all 7 days data are provided below.
A. Statistical Analysis of ANS data. All acetylated and 1:1 mixture of Aβ42 7d data were
compared with WT of 7d. p<0.05 was considered as significant and represented as *,
p<0.005 represented as ** and p<0.0005 represented as *** (Refer to figure 5 in
chapter 4)
WT vs K16Ac- 7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

WT

3

54710
0

18236.666
7

858433.333
3

K16Ac

3

96450

32150

701633.333
3

SS

df

MS

F

ANOVA
Source of
Variation
Between
Groups

2.9E+08

1

29037126

Within Groups

3120133

4

780033.33

Total

2.93E+0
8

5

200

P-value

F crit

372.254946 4.25336E4
05 7.70864

WT vs K28Ac-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

WT

3

54710

18236.67

858433.3

K28Ac

3

67330

22443.33

5549200

SS

df

MS

F

ANOVA
Source of
Variation

P-value

F crit

Between
Groups

26544067

1 26544067 8.285139 0.045086 7.708647

Within Groups

12815267

4

Total

39359333

5

3203817

WT vs KKAc-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

WT

3

54710 18236.67 858433.3

KKAc

3

86130

28710

6242533

SS

df

MS

F

ANOVA
Source of
Variation
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P-value

F crit

Between
Groups

1.65E+08

1 1.65E+08 46.34188 0.002433 7.708647

Within Groups

14201933

4

Total

1.79E+08

5

3550483

WT vs WT:K16Ac-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

WT

3 54710

18236.67 858433.3

WT:K16Ac

3 70640

23546.67

3206233

MS

F

ANOVA
Source of
Variation
Between
Groups
Within Groups
Total

SS
42294150

df

P-value

F crit

1 42294150 20.81064 0.010324 7.708647

8129333

4

50423483

5

2032333

WT vs WT: K28Ac-7d
Anova: Single Factor
SUMMARY
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Groups

Count

Sum

Average

Variance

WT

3 54710 18236.6667

858433.3333

WT:K28Ac

3 72040 24013.3333

6580800

ANOVA
Source of
Variation

SS

Between
Groups

5005481

1

Within
Groups

1487846

4 3719616.6

Total

6493328

5

df

MS

F

50054816

P-value

F crit

13.4569825 0.02142173 7.70864

WT vs WT: KKAc- 7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

WT

3

54710

18236.67

858433.3

WT:KKAc

3

67060

22353.33

3204100

ANOVA
Source of
Variation
Between
Groups

SS
25420417

df

MS

F

P-value

F crit

1 25420417 12.51456 0.024065 7.708647
203

Within Groups
Total

8125067

4

33545483

5

2031267

B. Statistical Analysis of Bis-ANS data. All acetylated and 1:1 mixtures of Aβ42 7d data
were compared with WT of 7d. p<0.05 was considered as significant and represented
as *, p<0.005 represented as ** and p<0.0005 represented as *** (Refer to figure 3 in
chapter 4)
WT vs K16Ac-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

WT

3

363680

121226.666

1.2E+08

K16Ac

3

445230

148410

1.59E+0
8

SS

df

MS

F

P-value

F crit

Between
Groups

1108400417

1

1108400417

7.95500
8

0.04780
6

7.70864
7

Within
Groups

557334666.
7

4

139333666.
7

Total

1665735083

ANOVA
Source of
Variation

5

WT vs K28Ac- 7d
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Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

WT

3 363680

121226.7

1.2E+08

K28Ac

3 336100

112033.3 56194433

ANOVA
Source of
Variation

SS

df

MS

Between
Groups

1.27E+08

1

Within Groups

3.52E+08

4 88074233

Total

4.79E+08

5

F

1.27E+08

P-value

1.439423 0.296435 7.708647

WT vs KKAc- 7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

WT

3

363680

121226.6667

1.2E+08

KKAc

3

408830

136276.6667

1539064

Anova: Single Factor
ANOVA

Source
of

SS

df

MS

F
205

F crit

P-value

F crit

Variatio
n
Betwee
n
Groups

33975375
0

1

Within
Groups

24298619
5.3

60746548.
4
83

Total

58273994
5.3

5

33975375
0

5.59297
2

0.07724
5

7.70864
7

WT vs WT:K16Ac- 7d
SUMMARY
Groups

Count

WT

Sum
3

WT:K16
Ac

3

Average

363680
365120

Variance

121226.7

1.2E+08

121706.7

1.33E+0
8

ANOVA
Source
of
Variatio
n

SS

df

MS

Betwee
n
Groups

345600

1

345600

Within
Groups

5.05E+08

4

1.26E+08

Total

5.06E+08

5
206

F
0.00273
6

P-value

F crit

0.960792

7.70864
7

WT vs WT:K28Ac
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance
1.2E+08

WT

3 363680

121226.7

WT:K28Ac

3 386920

128973.3 2.07E+08

ANOVA
Source of
Variation

SS

df

MS

Between
Groups

90016267

1 90016267

Within Groups

6.53E+08

4

Total

7.43E+08

5

F

1.63E+08

Anova: Single Factor
SUMMARY
Count

Sum

Average

Variance

WT

3 363680

121226.7

1.2E+08

WT:KKAc

3 382380

127460

1.1E+08

ANOVA
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F crit

0.55121 0.499055 7.708647

WT vs WT:KKAc-7d

Groups

P-value

Source of
Variation

SS

df

MS

F

P-value

F crit

Between
Groups

58281667

1 58281667 0.507399 0.515612 7.708647

Within Groups

4.59E+08

4

Total

5.18E+08

5

1.15E+08

C. Statistical Analysis of MTS (5µM) data carried out in SH-SY5Y cells. WT,
acetylated and 1:1 mixtures of Aβ42 7d data were compared with untreated cells
which was used as control. p<0.05 was considered as significant and represented as
*, p<0.005 represented as ** and p<0.0005 represented as *** (Refer to figure 6 in
chapter 4)
Untreated vs WT-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

Untreated

6 0.279

0.0465 0.000212

WT

6 0.187 0.031167 0.000163

ANOVA
Source of
Variation

SS

Between
Groups

0.000705

Within Groups

0.001878

df

MS

F

P-value

F crit

1 0.000705 3.756435 0.081329 4.964603
10 0.000188
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Total

0.002583

11

Untreated vs K16Ac-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Untreated

6 0.279

K16Ac

6 0.203 0.033833

Variance

0.0465 0.000212
2.02E-05

ANOVA
Source of
Variation

SS

df

MS

Between
Groups

0.000481

Within Groups

0.001162

10 0.000116

Total

0.001643

11

F

Anova: Single Factor
SUMMARY
Count

F crit

1 0.000481 4.143472 0.06916 4.964603

Untreated vs K28Ac-7d

Groups

P-value

Sum

Average

Untreated

6 0.279

K28Ac

6 0.199 0.033167

Variance

0.0465 0.000212
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2.58E-05

ANOVA
Source of
Variation
Between
Groups
Within Groups
Total

SS

df

0.000533
0.00119
0.001723

MS

F

P-value

F crit

1 0.000533 4.483048 0.060295 4.964603
10 0.000119
11

Untreated vs KKAc-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

Untreated

6 0.279

0.0465 0.000212

KKAc

6 0.122 0.020333 0.000494

ANOVA
Source of
Variation

SS

df

MS

Between
Groups

0.002054

1 0.002054

Within Groups

0.003531

10 0.000353

Total

0.005585

11
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F

P-value

F crit

5.81756 0.036561 4.964603

Untreated vs WT:K16Ac-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

Untreated

6

0.279

0.0465

0.00021
2

WT:K16Ac

6

0.17333
3

0.02888
9

0.00011
3

df

MS

F

P-value

F crit

5.71889

0.03786

4.96460

ANOVA
Source of
Variation

SS

Between
Groups

0.00093

1

0.00093

Within Groups

0.00162

10

0.00016

Total

0.00255

11

Untreated vs WT:K28Ac-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Untreated

6 0.279

WT:K28Ac

6 0.164 0.027333

Variance

0.0465 0.000212

ANOVA
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2.24E-05

Source of
Variation

SS

df

MS

Between
Groups

0.001102

1 0.001102

Within Groups

0.001173

10 0.000117

Total

0.002275

11

F

P-value

F crit

9.39676 0.011934 4.964603

Untreated vs KKAc-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Untreated

6 0.279

WT:KKAc

6

Average

Variance

0.0465 0.000212

0.1 0.016667

4.28E-05

ANOVA
Source of
Variation
Between
Groups

SS
0.00267

df

MS
1

F

P-value

F crit

0.00267 20.94457 0.001016 4.964603

Within Groups

0.001275

10 0.000127

Total

0.003945

11

D. Statistical Analysis of LDH (5µM) data carried out in SH-SY5Y cells. WT,
acetylated and 1:1 mixtures of Aβ42 7d data were compared with untreated cells
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which was used as control. p<0.05 was considered as significant and represented as
*, p<0.005 represented as ** and p<0.0005 represented as *** (Refer to figure 6 in
chapter 4)
Untreated vs WT-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

Untreated

6

0.183

0.0305

0.00171

WT

6

0.819

0.1365

9.35E-05

df

MS

F

P-value

F crit

37.37719

0.000113623

4.964603

ANOVA
Source of
Variation

SS

Between Groups

0.033708

1

0.033708

Within Groups

0.009018

10

0.000902

Total

0.042726

11

Untreated vs K16Ac-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

Untreated

6

0.183

0.0305

0.00171

K16Ac

6

1.104

0.184

0.00195
6

ANOVA
Source of
Variation

SS

df

MS

F
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P-value

F crit

Between
Groups

0.07068
7

1

0.07068
7

Within Groups

0.01833

10

0.00183
3

Total

0.08901
7

11

38.5630
7

0.0001

4.96460
3

Untreated vs K28Ac-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

Untreated

6

0.183

0.0305

0.00171016

K28Ac

6

0.971

0.16183

0.00204896

ANOVA
Source of
Variation

SS

df

MS

F

Between
Groups

0.05174

1

0.05174

Within Groups

0.01879

10

0.00188

Total

0.07054

11

P-value

27.5304591

Untreated vs KKAc-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

Untreated

6

0.183

0.0305

0.00171

KKAc

6

1.617

0.2695

0.000489

ANOVA
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0.00037
5

F crit
4.96460274

Source of
Variation

SS

df

MS

Between
Groups

0.171363

1

0.171363

Within Groups

0.010996

10

0.0011

Total

0.182359

11

F
155.8365

P-value
2.0133E07

F crit
4.96460
3

Untreated vs WT:K16Ac7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

Untreated

6

0.183

0.0305

0.00171

WT:K16Ac

6

1.141

0.190167

0.002583

MS

F

P-value

F crit

35.62914

0.000137691

4.964603

ANOVA
Source of
Variation

SS

Between Groups

df

0.07648

1

0.07648

Within Groups

0.021466

10

0.002147

Total

0.097946

11

Untreated vs WT:K28Ac7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

215

Variance

Untreated

6

0.183

0.0305

0.00171

WT:K28Ac

6

1.117

0.186167

0.002071

MS

F

P-value

F crit

38.44807

0.000101

4.964603

ANOVA
Source of
Variation

SS

Between Groups

0.072696

1

0.072696

Within Groups

0.018908

10

0.001891

Total

0.091604

11

df

Untreated vs WT:KKAc7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

Untreated

6

0.183

0.0305

0.00171

WT:KKAc

6

1.637

0.272833

0.0025

ANOVA
Source of
Variation

SS

Between Groups

0.176176

Within Groups
Total

df

MS

F

P-value

F crit

1

0.176176

83.69289

3.5714E-06

4.964603

0.02105

10

0.002105

0.197227

11

E. Statistical Analysis of DCFH-DA (5µM) data carried out in SHSY-5Y cells. WT,
acetylated and 1:1 mixtures of Aβ42 7d data were compared with untreated cells
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which was used as control. p<0.05 was considered as significant and represented as
*, p<0.005 represented as ** and p<0.0005 represented as *** (Refer to figure 6 in
chapter 4)
Untreated vs WT-7d
Anova: Single Factor
SUMMARY
Groups

Count

Untreated
WT

Sum

Average

Variance

5

0.4361

0.08722

0.00058
4

5

1.08523
3

0.21704
7

0.00336
2

df

MS

F

ANOVA
Source of
Variation
Between
Groups

SS
0.04213

1

0.04213
0.00197

Within
Groups

0.01578

8

Total

0.05792

9

21.3556

P-value
0.00170748
7

Untreated vs K16Ac-7d
Anova: Single Factor
SUMMARY
Groups
Untreated

Count

Sum
5 0.4361

Average

Variance

0.08722 0.000584477
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F crit
5.31765507

K16Ac

5 2.2993

0.45986 0.000222993

ANOVA
Source of
Variation
Between
Groups
Within
Groups
Total

SS

df

MS

F

P-value

0.347151

1

0.347151424 859.8497133

0.00323

8

0.000403735

0.350381

9

F crit

1.98174E09 5.317655

Untreated vs K28Ac-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum
0.4361

Average

Variance

Untreated

5

0.08722 0.000584

K28AC

5 2.550633 0.510127 0.005405

ANOVA
Source of
Variation

SS

df

MS

F

P-value

F crit

Between
Groups

0.447125

1

1.86708E0.447125 149.3156
06 5.317655

Within Groups

0.023956

8

0.002994

Total

0.471081
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Untreated vs KKAc-7d
Anova: Single Factor
SUMMARY
Groups

Count

Untreated
KKAc

Sum

Average

Variance

5

0.4361

0.08722

0.00058447
7

5

3.28833
3

0.65766
7

0.0013063

df

MS

ANOVA
Source of
Variation

SS

Between
Groups

0.81352
3

1

0.81352

Within
Groups

0.00756

8

0.00094

Total

0.82108

9

F

1.97565E
860.517658
-09

Untreated vs WT:K16Ac-7d
Anova: Single Factor
SUMMARY
Groups
Untreated
WT:K16Ac

Count

P-value

Sum

Average

Variance

5

0.4361

0.08722

0.00058447

5

2.78883
3

0.55776
7
219

0.0011343

F crit
5.31765507
2

ANOVA
Source of
Variation

SS

df

MS

F
644.103817
7

Between
Groups

0.55353

1

0.55353

Within Groups

0.00687

8

0.00085

Total

0.56041

9

P-value

F crit

6.22434E09 5.31765

Untreated vs WT:K28Ac-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

Untreated

5

0.4361

0.08722 0.00058447

WT:K28Ac

5

2.53896

0.50779 0.00385373

ANOVA
Source of
Variation

SS

df

MS

F

Between
Groups

0.44220

1

0.44220 199.271698

Within Groups

0.01775

8

0.00221

Total

0.45995

9
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P-value

F crit

6.16418E07

5.31765

Untreated vs WT:KKAc-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

0.4361

Variance

Untreated

5

0.08722 0.000584

WT:KKAc

5 5.187167 1.037433 0.004266

ANOVA
Source of
Variation

SS

df

MS

F

Between
Groups

2.257263

1 2.257263 930.6428

Within Groups

0.019404

8 0.002425

Total

2.276667

9

F.

P-value

F crit

1.44778E09 5.317655

Statistical Analysis of LDH (2µM) data carried out in primary neuronal cells. WT,
acetylated and 1:1 mixtures of Aβ42 7d data were compared with untreated cells which
was used as control. p<0.05 was considered as significant and represented as *,
p<0.005 represented as ** and p<0.0005 represented as *** (Refer to figure 7 in
chapter 4)

Untreated vs WT -7d

Anova: Single Factor
SUMMARY

221

Groups

Count

Sum

Average

Variance

Untreated

4

1.200667

0.300167

0.001145

WT

4

3.538667

0.884667

0.002106

df

MS

F

ANOVA
Source of
Variation

SS

Between Groups

0.683281

1

0.683281

Within Groups

0.009753

6

0.001626

Total

0.693034

7

420.351

P-value
8.75603E07

F crit
5.987378

Untreated vs K16Ac-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

Untreated

4

1.200667

0.300167

0.001145

K16Ac

4

6.187667

1.546917

0.004958

df

MS

F
1018.726

ANOVA
Source of
Variation

SS

Between Groups

3.108771

1

3.108771

0.01831

6

0.003052

3.127081

7

Within Groups
Total

222

P-value
6.28689E08

F crit
5.987378

Untreated vs K28Ac7d

Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

Untreated

4

1.200667

0.300166667

0.001145

K28Ac

4

4.781

1.19525

0.000308

df

MS

F

P-value

F crit

2206.205

6.24123E09

5.987377607

ANOVA
Source of
Variation

SS

Between
Groups

1.602348

1

1.602348347

Within
Groups

0.004358

6

0.000726292

Total

1.606706

7

Untreated vs KKAc-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

Untreated

4

1.200667

0.300167

0.001145

KKAc

4

8.228667

2.057167

0.004659

df

MS

ANOVA
Source of
Variation

SS

F

223

P-value

F crit

Between
Groups

6.174098

Within
Groups

0.017412

6

6.19151

7

Total

1

6.174098

2127.532047

6.95769E09

5.987377607

0.002902

Untreated vs WT: K16Ac-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

Untreated

4

1.200667

0.300167

0.001145

WT:K16Ac

4

6.220667

1.555167

0.004269667

df

MS

F

P-value

F crit

1163.524994

4.22778E08

5.987377607

ANOVA
Source of
Variation

SS

Between
Groups

3.15005

1

3.15005

Within Groups

0.016244

6

0.002707

Total

3.166294

7

Untreated vs
WT:K28Ac-7d
Anova: Single Factor
SUMMARY
Groups
Untreated

Count
4

Sum

Average

Variance

1.200667

0.300167

0.001145

224

WT:K28Ac

4

6.021667

1.505417

0.003206

SS

df

MS

F

P-value

Between
Groups

2.905255

1

2.905255

1335.366

2.80151E08

Within
Groups

0.013054

6

0.002176

Total

2.918309

7

ANOVA
Source of
Variation

F crit
5.987378

Untreated vs
WT:KKAc-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

Variance

Untreated

4

1.200666667

0.300167

0.001145

WT:KKAc

4

6.841666667

1.710417

0.00518825

df

MS

ANOVA
Source of
Variation
Between
Groups
Within
Groups
Total

SS
3.97761

1

3.97761

0.019

6

0.003167

3.99661

7

225

F

P-value

F crit

1256.103936

3.36352E08

5.987378

G. Statistics Analysis of DCFH-DA (2µM) data carried out in primary neuronal cells.
WT, acetylated and 1:1 mixtures of Aβ42 7d data were compared with untreated cells
which was used as control. p<0.05 was considered as significant and represented as
*, p<0.005 represented as ** and p<0.0005 represented as *** (Refer to figure 7 in
chapter 4)
Untreated vs WT- 7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

0.3787

Variance

Untreated

5

0.07574 0.000917

WT

5 0.964567 0.192913 0.002527

ANOVA
Source of
Variation

SS

df

MS

F

P-value

F crit

Between
Groups

0.034324

1 0.034324 19.93725 0.002097 5.317655

Within Groups

0.013773

8 0.001722

Total

0.048097

9

Untreated vs K16Ac-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average
226

Variance

Untreated

5

0.3787

0.07574

0.00091

K16Ac

5

1.44263

0.28852

0.00499

df

MS

F

ANOVA
Source of
Variation

SS

Between
Groups

0.11319

1

0.11319

Within Groups

0.02366

8

0.00295

Total

0.13685

9

P-value

F crit

38.2676 0.000263396 5.317655

Untreated vs K28Ac-7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

0.3787

Variance

Untreated

5

0.07574 0.000917

K28AC

5 1.068567 0.213713 0.003781

ANOVA
Source of
Variation

SS

df

MS

F

P-value

F crit

Between
Groups

0.047592

1 0.047592 20.26017 0.001999 5.317655

Within Groups

0.018792

8 0.002349

227

Total

0.066384

9

Untreated vs KKAc -7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Average

0.3787

Variance

Untreated

5

0.07574 0.000917

KKAc

5 2.192133 0.438427 0.004799

ANOVA
Source of
Variation

SS

df

MS

F

Between
Groups

0.328854

1 0.328854 115.0654

Within Groups

0.022864

8 0.002858

Total

0.351718

9

Untreated vs WT: K16Ac -7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum
0.3787

Average

Variance

Untreated

5

0.07574 0.000917

WT:K16Ac

5 1.604033 0.320807 0.000374

ANOVA
228

P-value

F crit

5.01524E06 5.317655

Source of
Variation

SS

df

MS

F

Between
Groups

0.150144

1 0.150144 232.7355

Within Groups

0.005161

8 0.000645

Total

0.155305

9

P-value

F crit

3.37998E07 5.317655

Untreated vs K28Ac -7d
Anova: Single Factor
SUMMARY
Groups

Count

Sum

Untreated

5

WT:K28Ac

5

Average

Variance

0.07574

0.000917

1.52106 0.304213

0.000622

0.3787

ANOVA
Source of
Variation
Between
Groups

SS

df

MS

0.1305

1

0.1305

Within Groups

0.00615

8

0.00076

Total

0.13665

9

Untreated vs WT: KKAc -7d
Anova: Single Factor
229

F
169.638

P-value

F crit

1.14564E06

5.317655

SUMMARY
Groups

Count

Sum

Average

Untreated

5 0.3787

WT: KKAc

5 2.2765

Variance

0.07574 0.000916608
0.4553

0.004404

ANOVA
Source of
Variation

SS

df

MS

F

Between
Groups

0.36016

1

0.36016 135.3847094

Within Groups

0.02128

8

0.00266

Total

0.38144

9
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P-value

F crit

2.71104E06 5.317655
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Permission for figure 2 in Chapter 1
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Permission for figure 3 in Chapter 1
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Permission for figure 4 in Chapter 1
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Permission for figure 3 in Chapter 2
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Permission for figure 2 in Chapter 3
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Permission for figure 4 in Chapter 3

237

Permission for figure 5 in Chapter 3
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Permission for figure 4 and modeling figure in supporting information in chapter 4
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